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Executive summary 
1  Introduction 
• In England, adult smoking prevalence in 2016 was 15.5% and while it has fallen 
considerably over the last few decades, smoking remains the leading preventable 
cause of illness and premature death and one of the largest causes of health 
inequalities.  
• This report has been commissioned to summarise evidence to underpin policy and 
regulation of e-cigarettes/vaping devices.  
• It is the fourth in a series of reports commissioned by Public Health England (PHE) 
on e-cigarettes. In particular, this report updates the 2015 PHE report on e-
cigarettes.  
• Since the previous report, heated tobacco products, so-called ‘heat-not-burn’ 
tobacco products, have come onto the market in the UK and the report will provide 
evidence on this new product type as well as on e-cigarettes.  
 
2 Methods 
• The methods and sources of data used in the remaining chapters of the report focus 
on evidence produced since the previous report in 2015.  
• The evidence falls into three main categories: 1) peer-reviewed literature and 
2) surveys and 3) other reports and database sourced by and made available to 
PHE, King’s College London and other partner organisations since the publication of 
the 2015 report: 
 
1) Peer-reviewed literature 
o Searches of the published, peer reviewed literature on e-cigarette 
published between 1 January 2015 and 18 August 2017.  
o A separate literature search was conducted for heat-not-burn products. 
This was not included in the 2015 report so literature was searched 
from 1 January 2010 to 13 July 2017.  
2) The use of survey data 
o For youth, these included: ASH Smoke-free Great Britain – Youth 
survey; Wales Schools Health Research Network; Scottish Schools 
Adolescent Lifestyle and Substance Use Survey; Smoking, Drinking 
and Drugs Survey; Youth Tobacco Policy Survey.  
o For adults, these included: ASH Smoke-free Great Britain - Adult 
survey; Eurobarometer; International Tobacco Control Policy 
Evaluation Survey; Internet cohort Great Britain survey; Opinions and 
lifestyle survey; Smoking Toolkit Study.  
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3) Other reports and databases 
o Data from NHS Digital (derived from local authorities) were assessed for 
Stop Smoking Service information. 
o Publicly available data from the National Poison Information Service were 
used for information on poisonings. 
o UK Fire and Rescue Incident Recording System (as reported by the 
Home Office) data was used for information on fires due to e-cigarettes.  
o Freedom of information requests were also sent to the UK regional fire 
and rescue services for information on fires caused by e-cigarettes and 
mobile phones. 
o A freedom of information request was sent to burns units, but for many, 
the cost of accessing the data would have been excessive. No data was 
included in this report. 
o The Medicines and Healthcare products Regulatory Agency provided us 
with details for spontaneous suspected adverse reaction reports for e-
cigarettes along with details of suspected adverse drug reactions for 
nicotine replacement therapy products.  
o The ECig Intelligence Global Database was used to explore average price 
of various categories of e-cigarette.  
 
3  Policy 
Key findings 
• As with tobacco products, in most parts of the UK, there is a minimum age of sale of 
18 for e-cigarettes and e-cigarettes cannot be purchased on behalf of someone 
under the age of 18. 
• The revised European Union Tobacco Products Directive is now fully operational in 
England, transposed into UK law through the UK Tobacco and Related Products 
Regulations 2016, and covers e-cigarettes that do not contain nicotine when sold 
(eg disposable EC and 0% nicotine e-liquids) and products that do not have a 
medicinal licence. These regulations include a notification process to the Medicines 
Healthcare products Regulatory Agency (MHRA), minimum standards for safety and 
quality of e-cigarette products, standards for information provision (including a 
nicotine health warning) and advertising restrictions and updated standards. The 
Advertising Standards Authority has carried out a consultation on health claims; the 
results are awaited. A system to report side-effects and safety concerns related to 
e-cigarettes has been implemented. 
• Over 32,000 e-cigarette and nicotine containing e-liquid products have been notified 
which suggests a level of compliance with the regulations, and that the notification 
process is not too onerous.  
• There are some signs that ways are being found to avoid the law, for example 
particularly on size of bottles, but evidence is limited.  
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• Alongside products regulated in line with the EU Tobacco Products Directive, 
manufacturers can also apply for medicinal licensing from the Medicines Healthcare 
products Regulatory Agency. However, no licensed e-cigarette has yet been 
marketed.  
• Other e-cigarette related developments include consensus statements from a 
number of organisations and guidance on the use of e-cigarettes in public places 
and on their use in research. 
• Non-nicotine e-cigarettes are governed by general product safety regulations (unlike 
combustible tobacco products). 
• There is a separate notification process for heated tobacco products (to PHE) and 
results from a consultation on the tax treatment of these products are forthcoming. 
At the time of writing, two products had been notified.  
• A new Tobacco Control Plan for England was published in July 2017. 
 
Implications 
Research 
• There is a need for continued research on the impact of regulations on smoking 
rates and patterns, use of e-cigarettes by adults and young people, product design 
and quality, and adverse effects of e-cigarettes.  
• Research should specifically assess the impact of the EU Tobacco Products 
Directive on production (with a specific focus on independent manufacturers who 
were the first to enter this field), innovation of products, and e-cigarette users and 
smokers. 
 
Policy 
• Regulations need to balance the risks of e-cigarettes with their potential benefits – 
and achieve key aims of reducing smoking and continuing to avoid uptake of e-
cigarettes by non-smokers. This requires keeping them under regular review and 
evaluating their impact. 
• Regulations for heated tobacco products should be made as least a stringent as for 
e-cigarettes.  
• It remains a viable and important goal to facilitate regulation of some e-cigarettes as 
medicines via the Medicines Healthcare products Regulatory Agency. A review is 
needed of how to achieve this, possibly including more focus on post marketing 
surveillance and the provision of licences for short-term rather than extended use. 
• Restrictions on communicating relative risks of e-cigarettes in comparison with 
combustible tobacco should be reconsidered. In any future review of the EU 
Tobacco Products Directive, consideration should be given to the wording of the 
health warning on nicotine per se given public misperceptions of its harmfulness.  
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• There appears to be no evidence justifying an urgent change regarding non-nicotine 
e-cigarettes or e-liquids which are currently outwith the scope of the EU Tobacco 
Products Directive.  
 
4  Nicotine 
Key findings 
• The addictiveness of nicotine depends on the delivery system. 
• It is possible that the addictiveness of tobacco cigarettes may be enhanced by 
compounds in the smoke other than nicotine. 
• As e-cigarettes have evolved, their nicotine delivery has improved. This could mean 
that their addiction potential has increased, but this may also make them more 
attractive to smokers as a replacement for smoking. It is not yet clear how addictive 
e-cigarettes are, or could be, relative to tobacco cigarettes.  
• While nicotine has effects on physiological systems that could theoretically lead to 
health harms, at systemic concentrations experienced by smokers and e-cigarette 
users, long-term use of nicotine by ‘snus’ (a low nitrosamine form of smokeless 
tobacco) users has not been found to increase the risk of serious health problems in 
adults, and use of nicotine replacement therapy by pregnant smokers has not been 
found to increase risk to the foetus. 
• Adolescent nicotine use (separate from smoking) needs more research. 
• The long-term impact of nicotine from e-cigarettes on lung tissue is not yet known 
and may be different from its impact systemically. 
 
Implications 
Research 
• More research on nicotine in comparison to tobacco cigarette smoking is needed, 
and the popularity of e-cigarettes enables such research, albeit in the context of the 
other components in e-cigarette and e-cigarette aerosol.  
• Further research is needed on the similarities and differences in addictiveness of e-
cigarettes and tobacco cigarettes and the potential harms associated with inhaled 
nicotine.  
 
Policy and practice 
• Widespread misperceptions about the relative risks of nicotine and tobacco (see 
Chapter 10) need to be addressed and corrected. 
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• Clear messages, based on current evidence about nicotine, its relationship with 
harms, and its addictiveness, compared with smoking, are necessary and could 
have a marked impact on public health. 
• Policies on tobacco and e-cigarettes should have at their core the recognition that 
nicotine use per se presents minimal risk of serious harm to physical health and that 
its addictiveness depends on how it is administered.  
people  
5 Use of e-cigarettes among young people 
Key findings 
• E-cigarettes cannot be legally sold to young people under the age of 18 in most 
parts of the UK. Purchasing does occur including from sources rarely used for 
tobacco, such as online suppliers.  
• Despite some experimentation with these devices among never smokers, e-
cigarettes are attracting very few young people who have never smoked into regular 
use. 
• E-cigarettes do not appear to be undermining the long-term decline in cigarette 
smoking in the UK among young people.  
• Never smokers in the UK who try e-cigarettes are more likely to have tried smoking 
subsequently than those who have not tried e-cigarettes. A causal link has not been 
established and neither has progression to regular smoking. The ‘common liability’ 
hypothesis seems a plausible explanation for the relationship between e-cigarettes 
and smoking implementation.  
 
Implications 
• Trends in e-cigarette use and smoking among youth should continue to be 
monitored using standardised definitions of use. This should include the use of 
nicotine in e-cigarettes and checks on the understanding of survey questions. 
• Patterns of e-cigarette purchasing by young people should be closely monitored, 
particularly internet sales. Age of sale regulations are in place for e-cigarettes and 
cigarettes and should be strongly enforced. 
• Research is needed on trajectories of use – not just from e-cigarette 
experimentation to smoking, but also from smoking to e-cigarette use among young 
people.  
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6  Use of e-cigarettes in adults 
Key findings 
Prevalence 
• In GB, prevalence of e-cigarette use in adults has plateaued at approximately 6% of 
the adult population.  
• E-cigarette use among never smokers in GB remains very rare at less than 1%, 
similar to the level of use of nicotine replacement therapy. Among never smokers 
who have ever used e-cigarettes, a minority have used nicotine-containing liquids 
and the vast majority not progressed to regular use.  
• Prevalence of e-cigarette use and trial among smokers has plateaued while use and 
trial among ex-smokers continue to increase. 
• Socioeconomic differences in e-cigarette use by smokers and recent ex-smokers 
have become smaller with no clear gradient in prevalence by occupational grade. 
• Prevalence of dual use (use and smoking) is similar for e-cigarette users and users 
of nicotine replacement therapy. 
 
Characteristics of use 
• Most e-cigarette trial does not become regular use. 
• Most current e-cigarette users use daily and have used e-cigarettes for more than 
six months. 
• Models with refillable tanks for liquids are the most widely used type. 
• Since May 2017, nicotine concentration in liquids has been limited to a maximum of 
20mg/mL. In March 2017, around 6% of e-cigarette users reported using higher 
nicotine concentrations; substantial proportions had difficulties reporting these 
figures so more may have been affected by the limit. 
• The most popular groups of flavours among current e-cigarette users are fruit 
(29%), tobacco (27%) and menthol/mint (25%). 
• Specialist vape shops (physical premises rather than online) are the most popular 
place of purchase (>40%). 
• The most common reason for e-cigarette use continues to be in order to stop 
smoking, and smokers who use e-cigarettes on average have higher motivation to 
stop smoking than other smokers.  
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International 
• Data can be outdated by the time of publication.  
• Prevalence of current use in GB is at the higher end for countries in the EU where 
the average is 2% for current e-cigarette use. Prevalence estimates for current e-
cigarette use in the US are around 4% to 6%, which is similar to GB.  
• Across international surveys, a consistently low prevalence (<1%) of e-cigarette use 
has been reported among never-smokers; one exception is one Spanish survey at 
1.2%.  
• Prevalence figures found for smokers and ex-smokers vary more widely across 
surveys in different countries (4% to 22% among smokers and 0.1% to 5% among 
ex-smokers). 
 
Implications  
Research 
• As recommended in the 2015 PHE report, trends in e-cigarette use among adults 
should continue to be monitored using standardised definitions of use. Measures 
should include frequency and type of device used including different types of tank 
models. 
• E-cigarette use among ex-smokers needs monitoring and further evidence to 
understand when and why they take up e-cigarette use and whether this is 
associated with an increase or decrease of relapse to smoking.  
• More research is needed into different patterns of e-cigarette use while smoking and 
their effect on subsequent smoking behaviour to understand how best to move dual 
users to stop smoking. 
• More research is needed on the impact of e-cigarettes on health and economic 
inequalities associated with smoking; in particular on use of e-cigarettes in 
disadvantaged groups with high smoking prevalence and smoking-related morbidity 
and mortality, such as those with mental health problems or offenders. Data that 
have been gathered from the Adult Psychiatric Morbidity Survey should be released 
for analysis. 
 
Policy 
• As recommended in 2015 and as per existing NICE guidance, all smokers should 
be supported to stop smoking completely, including ‘dual users’ who smoke and use 
e-cigarettes. 
• Access to e-cigarettes should be improved for smokers in disadvantaged groups.  
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7  The effect of e-cigarette use on smoking cessation and reduction 
Key findings 
• In the first half of 2017, quit success rates in England were at their highest rates so 
far observed and for the first time, parity across different socioeconomic groups was 
observed. It is plausible that e-cigarettes have contributed to this.  
• Recent estimates of additional quitters resulting annually from the availability of e-
cigarettes, using the same dataset but two different methods, resulted in similar 
figures within the range of 16,000-22,000. Varying the assumptions, and updating 
these estimates for 2016, resulted in an upper bound estimate of around 57,000 
additional quitters annually resulting from e-cigarettes (lower bound around 22,000). 
While caution is needed with these figures, the evidence suggests that e-cigarettes 
have contributed tens of thousands of additional quitters in England.  
• E-cigarette use, alone or in combination with licensed medication and behavioural 
support from a Stop Smoking Service, appear to be helpful in the short term. 
However, fewer smokers use an e-cigarette as part of a quit attempt with a Stop 
Smoking Service compared with licensed medication.  
• We identified 14 systematic reviews of e-cigarettes for smoking cessation and /or 
reduction published since our last report, seven of which included a meta-analysis. 
The authors of the systematic reviews arrived at the same conclusion that further 
randomised controlled trials of e-cigarettes are needed. However, the reviews that 
included a meta-analysis produced different results; two found a positive effect on 
cessation for e-cigarette use, four found an inconclusive effect for cessation and 
one found a negative effect.  
 
Implications  
Research  
• An important focus of future research is longer-term relapse trajectories of people 
who use e-cigarettes for quitting compared with other stop smoking treatments and 
also assess whether the uptake of e-cigarettes after quitting can prevent relapse 
back to smoking. 
• Funders should consider that although randomised controlled trials (RCTs) may 
yield higher internal validity this is at the cost of lower generalisability. Future robust 
observational studies and RCTs should consider allowing for user experimentation 
(eg trial and error of different types of e-cigarette products), as well as the inclusion 
of study outcomes that are relevant and meaningful for e-cigarette users.  
• Funders should commission research about the effect of e-cigarettes on smoking 
cessation in vulnerable populations (eg people who smoke who have a mental 
illness, substance misuse disorder, homeless or prison populations). 
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Policy and practice 
• Stop smoking practitioners and health professionals should provide behavioural 
support to smokers who want to use an e-cigarette to help them quit smoking.  
• Stop smoking service practitioners and health professionals supporting smokers to 
quit should receive education and training in use of e-cigarettes in quit attempts.  
• Local authorities should continue to fund and provide Stop Smoking Services in 
accordance with the evidence base. 
 
8  Poisonings, fires and explosions 
Key findings 
Poisonings  
• There are recorded cases of poisoning from e-liquid in the UK. These have 
predominantly involved accidental ingestion with fewer incidences of other routes 
(eg ocular or dermal) of exposure.  
• Intentional poisoning using e-liquids has been reported in self-harm and suicide 
attempts.  
• Toxic effects from e-cigarette poisoning are usually short in duration and of minimal 
severity; severe cases and fatalities, while very rare, have been recorded.  
• E-cigarette poisonings reported to medical centres most commonly occur in children 
under five years old. Toxic effects for this age group are usually short in duration 
and non-severe. Fatalities, while very rare, have also been recorded in this age 
group.  
• Incidents of poisoning in children are often preventable and have involved liquids 
stored non-securely, in unmarked containers or in containers without safety caps.  
 
Fires 
• E-cigarette fires are recorded at the discretion of individual fire rescue services in 
the UK. Information provided to us through a Freedom of Information request 
suggest that, where recorded, they occur in low numbers and are vastly outweighed 
by fires caused by smokers’ materials. There were no fatalities from fires caused by 
e-cigarettes in the reporting period. 
• E-cigarettes and/or their batteries are recorded as the cause of fires by UK fire 
rescue services. The root cause of e-cigarette fires is likely to be through a 
malfunctioning lithium-ion battery.  
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Explosions 
• Exploding e-cigarettes can cause severe burns and injuries that require intensive 
and prolonged medical treatment especially when they explode in users’ hands, 
pockets or mouths. 
• Incidents are very rare. The cause is uncertain but appears to be related to 
malfunctioning lithium-ion batteries.  
 
Implications 
Research 
• Research is required on the prevalence of e-liquid poisoning, fires and explosions 
caused by e-cigarettes in England. This will require some synthesis of existing 
datasets.  
• Research on presence and effectiveness of safety features and instructions should 
be part of a future review of the EU Tobacco Products Directive. 
  
Policy and practice 
• Monitoring of fires caused by e-cigarettes should be recorded by Fire Rescue 
Services in a mandatory way (similar to “cooking appliances”, “smokers’ materials” 
and “other electrical appliances”) and should not continue to rely on free text entry. 
• E-cigarettes can trigger fire/smoke detectors and therefore consumers should be 
advised to move away from detectors when using them. 
• It is too early to assess the impact of the EU Tobacco Products Directive in reducing 
poisonings, fires or explosions, or whether further regulations are needed. 
Therefore, continued monitoring is required to assess effectiveness of EU Tobacco 
Product Directive regulations (such as childproof containers), in reducing accidental 
ingestion of e-liquid.  
• Regulations should require that labelling on e-liquid bottles advises customers to 
store products away from similar looking medicines such as eye drops, ear drops 
and children’s medicine. 
• Regulations should require that labelling reinforces advice on the safe storage and 
transportation of batteries used by e-cigarettes. For example, advice should be 
given that e-cigarettes should not be carried in pockets with coins, keys or other 
metallic objects, and that the correct charger should always be used.  
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9  Health risks of e-cigarettes 
Key findings  
• One assessment of the published data on emissions from cigarettes and e-
cigarettes calculated the lifetime cancer risks. It concluded that the cancer potencies 
of e-cigarettes were largely under 0.5% of the risk of smoking. 
• Comparative risks of cardiovascular disease and lung disease have not been 
quantified but are likely to be also substantially below the risks of smoking. Among 
e-cigarette users, two studies of biomarker data for acrolein, a potent respiratory 
irritant, found levels consistent with non-smoking levels. 
• There have been some studies with adolescents suggesting respiratory symptoms 
among e-cigarette experimenters. However, small scale or uncontrolled switching 
studies from smoking to vaping have demonstrated some respiratory improvements.  
• E-cigarettes can release aldehydes if e-liquids are overheated, but the overheating 
generates an aversive taste. 
• To date, there is no clear evidence that specific flavourings pose health risks but 
there are suggestions that inhalation of some could be a source of preventable 
risks. 
• To date, the levels of metals identified in e-cigarette aerosol do not give rise to any 
significant safety concerns, but metal emissions, however small, are unnecessary. 
• Biomarkers of exposure assessed to date are consistent with significant reductions 
in harmful constituents and for a few biomarkers assessed in this chapter, similar 
levels to smokers abstaining from smoking or non-smokers were observed.  
• One study showed no reductions across a range of biomarkers for dual users (either 
for nicotine replacement therapy or e-cigarette dual users).  
• To date, there have been no identified health risks of passive vaping to bystanders. 
• Reporting of some academic studies has been misleading. 
 
Implications 
Research 
• More research is needed with human users about biomarkers of exposure, risk and 
harm and health effects over time.  
• More research with biomarkers across the range of different combinations of dual 
use is needed. 
• Adverse effects of passive vaping should be monitored.  
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Policy 
• Policy makers and regulators should ensure that e-cigarettes are manufactured in a 
way that minimises harm. An advantage of e-cigarettes is that particular 
constituents can be removed or minimised in a way that is not feasible with tobacco 
cigarettes.  
• Regulations should therefore be flexible to ensure any emerging evidence of 
constituent harmfulness can be acted upon, such that products are modified to 
remove any components shown to pose avoidable risks.  
• Consumers and health professionals should be encouraged to use the Yellow Card 
Scheme for reporting adverse reactions to e-cigarette use. 
• Vaping poses only a small fraction of the risks of smoking and switching completely 
from smoking to vaping conveys substantial health benefits over continued smoking. 
Based on current knowledge, stating that vaping is at least 95% less harmful than 
smoking remains a good way to communicate the large difference in relative risk 
unambiguously so that more smokers are encouraged to make the switch from 
smoking to vaping. It should be noted that this does not mean e-cigarettes are safe. 
• The lack of difference in biomarkers between dual users and smokers found so far 
underlines the need to encourage and support dual users to stop smoking 
altogether.  
 
10 Perceptions of relative harms of nicotine, e-cigarettes and smoking  
 
Key findings 
• Perceived relative harm of e-cigarettes compared with cigarettes has continued to 
increase; less than half of adults in Great Britain think e-cigarettes are less harmful 
than smoking. 
• Nicotine replacement therapy is subject to similar misperceptions and only just over 
half of adults in GB think that nicotine replacement therapy is any less harmful than 
smoking.  
• Adult smokers are poorly informed about relative risks of different products.  
o Only half of smokers believe that e-cigarettes are less harmful than smoking and 
this decreases to one third among smokers who have never tried e-cigarettes. 
o In contrast to evidence to date, it appears that a majority of smokers and ex-
smokers does not think that complete replacement of cigarettes with e-cigarettes 
would lead to major health benefits.  
o Only half of all adult smokers believe that nicotine replacement therapy is any 
less harmful than smoking.  
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• As the common factor for cigarettes, nicotine replacement therapy and (most) e-
cigarettes is nicotine, these misperceptions may be linked to the perception of 
nicotine.  
o When adults in GB are asked what proportion of the health harms of smoking is 
due to nicotine, the accurate response (most health harms are not caused by 
nicotine) is the least common response consistently chosen by 8-9%. Smokers’ 
knowledge around nicotine is similarly poor.  
o Four in ten smokers and ex-smokers incorrectly think nicotine in cigarettes is the 
cause of most of the smoking-related cancer.  
o Misperceptions around nicotine and cancer are greater in more disadvantaged 
groups. 
• It is unclear to what extent the perception of addictiveness underpins the perception 
of harm.  
• Among youth in GB, perceived harm of e-cigarettes relative to cigarettes has also 
increased over time and nicotine knowledge is similarly poor (7% correctly 
responded that none or a small portion of the harms of smoking is due to nicotine).  
• Where available, international data show similar misperceptions around nicotine and 
relative harmfulness of e-cigarettes and smoking as in England. International data 
also support the trends of increased harm perception of e-cigarettes with the 
exception of one survey in youth in the US. 
 
Implications  
Research 
• Future research should aim to assess causes and effects of misperceptions of the 
relative harmfulness of e-cigarettes and nicotine replacement therapy compared 
with cigarettes, including to what extent the perception of addictiveness contributes 
to these misperceptions.  
 
Policy 
• Misperceptions of nicotine and different nicotine-containing products need to be 
addressed. These have deteriorated further since the PHE report in 2015 which 
called for clear and accurate information on relative harms. 
o Misperceptions of the relative harms of nicotine replacement therapy and e-
cigarettes compared with cigarettes need to be addressed, particularly among 
smokers who would benefit from switching to nicotine replacement therapy or e-
cigarettes.  
o Knowledge about the role of nicotine in the development of cancers and other 
diseases caused by smoking needs improvement. 
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11 Pricing 
Key findings  
• Price varies considerably between products, and there appear to be differences 
between online and bricks and mortar shop prices, with closed system products 
tending to be cheaper online, and open system kits cheaper in bricks and mortar 
shops.  
• Generally, average maximum and minimum prices seem to have remained relatively 
stable from August 2015 to July 2017 for all product categories.  
• There appear to have been no major and consistent changes in price over the first 
year since implementation of the EU Tobacco Products Directive. 
 
Implications  
• Current available data provide minimum, maximum and average prices, but do not 
provide detail on nicotine levels, brands and flavours that would be helpful to our 
understanding of market developments. 
• Currently e-cigarette products are available in a wide range of prices and therefore 
affordable to various types of e-cigarette users. Any changes in pricing need to 
ensure that e-cigarettes are affordable to smokers to avoid discouraging smokers 
from switching away from smoked tobacco which would be counter-productive in 
public health terms. There should therefore be a competitive advantage for the 
prices of e-cigarettes compared to combustible tobacco products. 
 
12  Heated tobacco products 
Key findings 
• In mid 2017 heated tobacco products were commercially available in 27 countries 
and further country launches were planned. Three tobacco manufacturers were 
promoting heated tobacco products: ‘IQOS’ was promoted by Philip Morris 
International, ‘glo’ by British American Tobacco, and ‘Ploom TECH' by Japan 
Tobacco International. 
• Out of 20 studies that were included in this review, 12 were funded by 
manufacturing companies so there is a lack of independent research.  
• There is a variety of heated tobacco products, including some that deliver via both 
vapour and combustion.  
• Most studies published at the time of the search for this review evaluated IQOS, 
none evaluated glo or Ploom TECH. An updated version of the review including 
later publications is in preparation to be published separately. 
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• In Great Britain, in 2017, awareness and ever use of heated tobacco products were 
very rare. 
• Nicotine in mainstream aerosol from heated tobacco products reached 70%–84% of 
the nicotine detected in smoke from reference cigarettes. 
• The tested heated tobacco products delivered more nicotine in aerosol than a 
cigalike e-cigarette and less nicotine than a tank style e-cigarette. 
• Pharmacokinetics and delivery of nicotine after single use of a heated tobacco 
product were generally comparable with smoking a cigarette. However, studies that 
compared ad libitum use of heated tobacco products with smoking cigarettes 
consistently reported lower nicotine levels in heated tobacco product users 
compared with smokers. 
o Probably to compensate, smokers who were switched to using heated tobacco 
products adjusted their puffing behaviour. 
• Heated tobacco product use reduced urges to smoke, but smokers consistently 
reported heated tobacco product use to be less rewarding compared with smoking a 
cigarette. 
• Compared with cigarette smoke, heated tobacco products are likely to expose users 
and bystanders to lower levels of particulate matter and harmful and potentially 
harmful compounds. The extent of the reduction found varies between studies.  
• The limited evidence on environmental emissions from use of heated tobacco 
products suggests that harmful exposure from heated tobacco products is higher 
than from e-cigarettes, but further evidence is needed to be able to compare 
products. 
• Japan, where e-cigarettes are not available, has the most diverse heated tobacco 
product market with three tobacco manufacturers participating. Past 30 day use for 
the most frequently used product increased from 0.3% in 2015 to 3.7% in 2017, 
suggesting rapid penetration of heated tobacco products. 
 
Implications 
Research 
• There is a need for more research that is independent of commercial interests.  
• Different types of heated tobacco products will have different characteristics and 
effects, presenting a challenge for research. 
• Research is needed on relative risks of heated tobacco products to users and those 
around them compared with cigarettes and e-cigarettes.  
• Evidence is needed on appeal of heated tobacco products to smokers and non-
smokers, particularly among youth. 
• Effects on smoking need to be researched, this includes whether they replace or 
complement cigarettes. Due to co-branding of some products with cigarettes and 
the more similar sensory profile, findings may be different than for e-cigaretttes.  
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• Future studies, whether funded by manufacturers or independently, should ensure 
conduct of studies in line with established guidelines such as definitions of 
abstinence from smoking, using intention-to-treat analysis and registering trial 
protocols prior to the start of participant recruitment. 
• The appropriateness of different methods for measuring emissions and their 
translation from cigarettes to heated tobacco products should be evaluated to be 
able to recommend a gold standard. 
• Prevalence and market share should be monitored, particularly in markets targeted 
by manufacturers.  
o In line with recommendations for e-cigarette use, measures should go beyond 
lifetime use or past 30 day use to assess current use; uptake and use should be 
assessed by smoking status.  
o Monitoring should include transitions between smoking, e-cigarette use and 
heated tobacco product use.  
 
Policy 
• The available evidence suggests that heated tobacco products may be considerably 
less harmful than tobacco cigarettes and more harmful than e-cigarettes. 
• With a diverse and mature e-cigarette market in the UK, it is currently not clear 
whether heated tobacco products provide any advantage as an additional potential 
harm reduction product.  
• Depending on emerging evidence on their relative risk compared to combustible 
tobacco and e-cigarettes, regulatory levers such as taxation and accessibility 
restrictions should be applied to favour the least harmful options alongside 
continued efforts to encourage and support complete cessation of tobacco use.  
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1  Introduction 
In England, smoking prevalence has fallen considerably over the last few decades, but 
smoking remains the leading preventable cause of illness and premature death and 
one of the largest causes of health inequalities. The decline has continued in the last 
few years: adult smoking prevalence in England declined from 19.9% in 2010 to 15.5% 
in 2016 (1). In 2017, the Department of Health and Social Care for England has 
published a new Tobacco Control Plan aiming to achieve a ‘smokefree generation’ with 
smoking prevalence eventually at 5% or below (2). Four ambitions were outlined, which 
highlighted the importance of reducing smoking in young people, in more 
disadvantaged groups including those with mental health problems and reducing 
smoking in pregnancy; the fourth ambition recognised the role that less harmful 
alternatives could play. The Tobacco Control Plan indicated that PHE would update 
their evidence report on e-cigarettes (EC) and other novel nicotine delivery systems 
annually until the end of Parliament in 2022. This report is the first of those updates.  
 
EC comprise a battery-powered heating element that is designed to vaporise a solution 
made of propylene glycol and/or glycerine, water and frequently flavouring and nicotine. 
This vapour (or rather aerosol) is then inhaled. There are many different types of EC; 
they can be classified into three basic types: (1) one-time, disposable products (often 
referred to as cigalikes); (2) reusable, rechargeable kits that are designed to be refilled 
with liquid by the user (often referred to as tanks) and (3) reusable, rechargeable kits 
that allow users to customise their product such as by regulating the power delivery 
from the batteries to the heating element (sometimes these are included with other tank 
models). In contrast to EC, heated tobacco products in general apply heat to tobacco 
instead of liquids (although there are hybrid products). Typically, heated tobacco 
products are rechargeable and include a holder, and tobacco sticks, plugs or capsules 
to be heated with an electronically controlled heating element.  
 
Objective of the report 
This report has been commissioned to summarise evidence to underpin policy and 
regulation of EC and novel nicotine delivery systems. It is the fourth in a series of 
reports commissioned by PHE on EC (3, 4). In particular, this report updates the 2015 
PHE report on EC (5). Since the previous report, heated tobacco products, so-called 
‘heat-not-burn’ tobacco products have come onto the market in the UK and the report 
will summarise evidence on this new product type as well as on EC.  
 
Structure of the report 
Following this introduction, Chapter 2 describes the methods used for the chapters 
presenting the most recent evidence on EC and heated tobacco products. Chapter 3 
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provides a summary of the current regulations for EC and heated tobacco products in 
the UK and Chapter 4 summarises evidence on the role of nicotine in tobacco and EC 
use, its addictiveness and safety profile. Chapter 5 summarises evidence on use 
among young people and Chapter 6 summarises evidence on use among adults. 
Chapter 7 considers the evidence for EC in smoking cessation. Chapter 8 summarises 
the available evidence on the risks of fires, poisonings and explosions related to EC 
and Chapter 9 discusses health risks to users and bystanders. Chapter 10 provides 
evidence on the relative harm perceptions of different nicotine-containing products. 
Chapter 11 describes trends in indicative pricing of EC. Finally, Chapter 12 assesses 
the evidence on heated tobacco products. This report is focused on England, and 
draws on surveys from England, Great Britain and the United Kingdom. A brief 
overview is also given, where appropriate, of the international situation.  
 
Acronyms and abbreviations used in this report 
A&E = Accident and Emergency 
ASA = Advertising Standards Authority 
ASH = Action on Smoking and Health 
ASH-A = ASH Smoke-free Great Britain-Adult survey 
ASH-Y = ASH Smoke-free Great Britain-Youth survey 
AOR = Adjusted Odds Ratio 
BAT = British American Tobacco 
CHTP = Carbon Heated Tobacco Product 
CI = Confidence Interval 
CO = Carbon Monoxide 
CPD = Cigarettes Per Day  
CVD = Cardiovascular Disease  
EC = E-cigarette/E-cigarettes 
ENDS = Electronic Nicotine Devices/Electronic Nicotine Delivery Systems 
EU TPD = The Revised European Union Tobacco Products Directive 
EU = European Union 
FDA = Food and Drug Administration (US) 
FOI = Freedom of Information 
FOI-B = Freedom of information request made to UK burns treatment centres 
FOI-F = Freedom of information request made to UK fire rescue services 
GB = Great Britain 
GBP = Pounds Sterling 
GPs = General Practitioners 
HCI = Health Canada Intense 
HPHC = Harmful and Potentially Harmful Compounds 
ICGBS = Internet cohort Great Britain survey  
ISO = International Organization for Standardization 
ITC = International Tobacco Control 
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IV = Intra Venous 
KCL = King’s College London 
MHRA = Medicines and Healthcare products Regulatory Agency 
NYTS = National Youth Tobacco Survey (US) 
NHS = National Health Service (UK) 
NICE= National Institute for Health and Care Excellence 
NPIS = National Poisons Information Service 
NRT = Nicotine Replacement Therapy 
ONS = Office for National Statistics 
OR = Odds Ratio 
OTC = Over the Counter 
PATH = Population Assessment of Tobacco and Health (US) 
PG = Propylene Glycol 
PHE = Public Health England 
PMI = Philip Morris International 
RCP = Royal College of Physicians 
RCTs = Randomised Controlled Trials 
SALSUS = Scottish Schools Adolescent Lifestyle and Substance Use Survey 
SD = Standard Deviation 
SDD = Smoking, Drinking and Drugs Survey  
SHRN = Wales Schools Health Research Network survey 
STS = Smoking Toolkit Study  
WHO = World Health Organization 
YTPS = Youth Tobacco Policy Survey   
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2  Methods 
Introduction 
This chapter describes the methods and sources of data used in the report and focuses 
on evidence produced since the previous report in 2015. The evidence falls into three 
main categories:  
 
• peer-reviewed literature reviews: Searches of the published, peer reviewed 
literature on EC produced between 1 January 2015 and 18 August 2017. A separate 
literature search was conducted for heated tobacco products (often referred to as 
heat-not-burn). This was not included in the 2015 report so literature was searched 
from 1 January 2010 to 13 July 2017.  
• survey data 
• other reports and databases sourced by and made available to PHE, King’s College 
London (KCL) and other partner organisations since the publication of the 2015 
report 
 
A summary of methods for each topic is given at the beginning of each chapter, but 
details of the literature reviews and sources of surveys and other data are given here. 
 
Literature reviews  
A full systematic review was not possible given the timeframe within which the report 
was commissioned and needed to be delivered, and the wide scope of the topics 
covered. However, a systematic review was carried out for heated tobacco products – 
see below for the search strategies and methods used, and chapter 12. For the 
remainder of the report topics covering EC, we carried out one literature search using 
systematic review methods, and we included key material on EC relevant to the topics 
studied, such as new syntheses of evidence, new evidence or data from research 
studies or detailed case studies. In addition, studies published since the search were 
included where they were pertinent to the topics we were studying and provided new 
relevant information. 
 
EC literature 
The literature search was based on the search developed and used in the 2015 PHE 
report (5) to ensure consistency between the two reports. However two terms within the 
search were updated. The terms “ENDS” and “Vap*” were both combined with the term 
“nicotine” because of their use in non-nicotine fields. The final search term was: 
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(("2015/01/01"[Date - Publication]: "3000"[Date -Publication])) AND (((((((e-cigarette) 
OR Electronic cigarettes) OR e-cig*) OR electronic cig*) OR (ENDS AND Nicotine)) OR 
electronic nicotine delivery systems) OR electronic nicotine delivery system) OR 
((Nicotine) AND (Vaping* OR Vape* OR Vaporiz* OR Vaporis* OR Vapouris*)). The 
term "(2015/01/01"[Date - Publication]: "3000"[Date -Publication])” limits the search to 
all literature published after 1 January 2015 to the day of the search.  
 
The final search was completed on 18 August 2017 and covered the following 
databases: Pubmed, Embase, PsychInfo, MEDLINE, Web of Science and CINAHL. 
This search yielded 10,810 results which were screened initially by title and abstract 
and then by full text. The full screening process is shown in Figure 1. Literature was 
included where it reported on EC, published new evidence or data from research 
studies, presented a new synthesis of existing evidence, detailed case studies relevant 
to EC, analysed policy and was published in English. Literature was excluded where 
they did not present new data, were editorial or opinion based in nature (ie did not 
contain new data), syntheses or research findings, were not peer-reviewed or were 
published before 1 January 2015. Additional literature known to the authors was 
included where it was able to provide context. 
 
In addition to literature identified by this screening process, high profile studies that 
were published since the search were included where they provided new relevant 
information or generated particular media interest. Some studies published before 2015 
were also included where they provided relevant background or context.  
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Figure 1: PRISMA Flowchart of the EC literature search 
 
 
 
Heated tobacco products literature review 
A separate literature search was conducted for evidence on heated tobacco products. 
  
Search strategy and selection of studies 
MEDLINE, EMBASE, PsychInfo, ProQuest, Scopus, and Web of Science databases 
were searched on 13 July 2017. The search included terms relating to general heated 
tobacco product names (‘heat not burn’, ‘tobacco heating system’) and brand names 
(‘IQOS’, ‘Ploom’, ‘Heets’), and were limited to studies published from 2010. Endnote X7 
was used to record publications at all stages of the review.  
 
The final search term was as follows:  
 
(("2010/01/01"[Date - Publication]: "3000"[Date -Publication])) AND ((Heat not burn) OR 
(tobacco heating system) OR (heat* adj3 tobacco) OR (IQOS) OR (Ploom) OR (Heets)) 
 
One reviewer (ES) screened all titles and abstracts of initially included studies, and two 
reviewers (ES and LBr) independently screened full text papers; Cohen’s kappa was 
calculated as a measure of agreement. Articles were screened in if they were studies of 
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heated tobacco products, studies of emissions or human studies, studies that 
presented new data or evidence and were research papers. Articles were excluded if 
the subject was not heated tobacco, not peer reviewed (eg conference abstracts, 
commentaries, editorials), published before 1 January 2010, were animal or in vitro 
studies, if focused on products that are no longer available such as Premier or Eclipse. 
The full screening process is shown in Chapter 12. 
 
Data extraction 
Data was extracted to a pre-defined table by one reviewer (ES) and checked by a 
second reviewer (LBr). 
 
Data synthesis 
Data from studies on heated tobacco product emissions and on use of heated tobacco 
products by humans were synthesised separately. Key findings were summarised in a 
narrative synthesis, and quantitative results were compared between studies where 
comparison was possible. 
 
Surveys 
In the introduction of each chapter in this report we detail the specific datasets used in 
that chapter. Data from several surveys were used, their details are listed in Table 1. 
Where possible, references are made to peer-reviewed publications that have used the 
data.  
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Table 1: Surveys used in this report 
 
Name and 
acronym 
Commissioned & 
conducted by 
Geographic 
coverage, 
sample 
Representativeness  Design Time-frame 
included 
Example 
publications 
Youth surveys       
ASH Smoke-free 
Great Britain-Youth 
survey (ASH-Y) 
ASH, YouGov plc GB, aged 11-18, 
annual n>2,000 
Recruited via a panel, 
weighted to be 
representative of all GB 11-
18 year olds 
Online, repeated 
cross-sectional 
2016 and 2017 (6, 7) (8) 
Wales Schools 
Health Research 
Network survey 
(SHRN) 
Partnership led by 
Cardiff University; 
with Welsh 
Government, Public 
Health Wales, 
Cancer Research 
UK and 113 
secondary schools 
Wales secondary 
school pupils, 
n=32,479 
Network schools represent 
about half of all secondary 
schools, representation in 
all local authority areas. 87 
participating schools; where 
full participation was not 
possible two randomly 
selected mixed ability 
classes 
Online, school-
based, repeated 
cross-sectional 
2015 (6) (9) (10) 
Scottish Schools 
Adolescent Lifestyle 
and Substance Use 
Survey (SALSUS) 
Scottish 
Government, Ipsos 
MORI Scotland 
Scotland, second-
year (n=13,607) 
and fourth-year 
(n=11,697) 
secondary school 
pupils 
Sample weighted to be in 
line with the pupil census at 
national level 
School-based, 
online and on paper 
in exam conditions, 
repeated cross-
sectional  
2015/16  (6) (10) 
 
Smoking, Drinking 
and Drugs Survey 
(SDD) 
NHS Digital, Ipsos 
MORI 
England, school 
pupils aged 11-
15, 2016 
n=12,051 
Sample weighted to be in 
line with the pupil census at 
national level 
Completed on 
paper in exam 
conditions, 
repeated cross-
sectional 
2016 (11)  
Youth Tobacco 
Policy Survey 
(YTPS) 
Stirling University, 
FACTS 
International 
(Ashford, UK), 
UK, aged 11-16, 
n=1,213 
Random location sampling 
in 92 electoral wards, 
stratified to cover 
geographic areas and 
socio-demographic 
backgrounds 
Face-to-face 
household 
interviews, 
repeated cross-
sectional 
2016 (6) 
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Name and 
acronym 
Commissioned & 
conducted by 
Geographic 
coverage, 
sample 
Representativeness  Design Time-frame 
included 
Example 
publications 
Adult surveys       
ASH Smoke-free 
Great Britain-Adult 
survey (ASH-A) 
ASH, YouGov plc GB, aged 18+, 
annual n>12,000 
Recruited from a panel 
according to quotas; 
responses weighted to be 
representative 
Online, repeated 
cross-sectional 
Annually 2010 
to 2017 
(12-14) 
Eurobarometer European 
Commission, TNS 
EU, aged 15+, 
n=27,901 
Multi-stage random 
probability sampling in each 
country, responses 
weighted 
Face-to-face 
interviews, 
repeated cross-
sectional 
2017 (15) 
 
ITC Policy 
Evaluation Survey 
(ITC) 
A variety of 
funders, see 
http://www.itcproject.o
rg/sponsors  
29 country 
cohorts typically 
smokers and ex-
smokers aged 18 
years and over. 
N~ 2000 per 
country per 
survey.  
Typically random sampling 
within stratified population 
quota. Weighted data 
Telephone, online, 
longitudinal 
Surveys 2002-
2016  
(16) 
For more detail 
about the methods 
of this survey see 
http://www.itcproject
.org/methods  
Internet cohort Great 
Britain survey 
(ICGBS) 
KCL, Ipsos MORI  GB, smokers and 
ex-smokers, aged 
18+, 2012: 
N=5,000, 2013: 
N=2,182, 2014: 
N=1,519, 2016: 
N=3,431 (incl 
n=2,403 new 
recruits) 
Recruited from a panel 
using quotas on age, sex 
and region 
Online, longitudinal 2012, 2013, 
2014, 2016 
(17-21) 
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Name and 
acronym 
Commissioned & 
conducted by 
Geographic 
coverage, 
sample 
Representativeness  Design Time-frame 
included 
Example 
publications 
Opinion and lifestyle 
survey (ONS) 
ONS GB, aged 16+, 
n=7,713 
Two stage, stratified 
random probability sample, 
responses weighted 
Household face-to-
face interviews, 
repeated cross-
sectional 
2016 (22) 
For more detail 
about the methods 
of this survey see 
https://www.ons.gov
.uk/peoplepopulatio
nandcommunity/he
althandsocialcare/h
ealthandlifeexpecta
ncies/bulletins/adult
smokinghabitsingre
atbritain/2016, 
Smoking Toolkit 
Study (STS) 
University College 
London, Ipsos 
MORI 
England, aged 
16+, n~1800 per 
month 
Recruited to be nationally 
representative to the 
population of England 
according to census data 
Household face-to-
face interviews, 
repeated cross-
sectional 
Monthly 2011-
2017 
(23) 
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Other reports and databases 
The following section details sources of data used in the present report. These include 
data sources that were available, or otherwise sought by PHE, KCL and other partners. 
The methods used to create each individual dataset are summarised here as well as 
methods used to source the data where relevant.  
 
NHS Digital; formerly Health and Social Care Information Centre (HSCIC) 
PHE monitors the delivery of Stop Smoking Services in England. Data are collected from 
local authorities by NHS Digital (formerly the HSCIC), an internal NHS Information 
technology provider. The data include information on the number of patients setting a quit 
date; the number who successfully quit and key measures of the service including 
intervention type, intervention setting and type of pharmacotherapy received. Since 2014, 
Stop Smoking Services have been asked to record if an EC was used in a quit attempt. A 
successful quitter is defined as a person who reports they have not smoked in the past two 
weeks, when assessed 4 weeks after their designated quit date. Clients who self-report as 
having quit at the 4-week follow up are required to have their CO levels monitored as a 
validation of their quit attempt; self-reported quit rates and CO validated rates are reported 
separately by NHS Digital. We report data from April 2015 to March 2017.  
 
National Poisons Information Service (NPIS) 
Data from publicly available reports by NPIS were used. The NPIS advises hospitals, 
emergency services and members of the public on the treatment of poisoned patients 
by providing up-to-date advice and information by telephone and online. NPIS records 
the numbers of enquiries, treatments and outcomes for different types of poisoning and 
publishes annual activity reports. Activity between 2015 and 2017 were used here. 
 
For more detail about the methods of this survey see (24) 
 
Fire Service data 
Fire statistics are published by the UK government Home Office (25) using data 
collected from the UK Fire and Rescue Incident Recording System. An entry on to the 
system is made after each incident attended and covers the causes of fires (or other 
incidents), contributing factors, injuries and fatalities, locations and outcomes. The 
Incident Recording System uses pre-determined categories which includes the 
category “smokers’ materials” but does not specify EC materials. There is however a 
free text box in which extra data can be entered where the cause of fire is not 
adequately represented by existing categories. Data from April 2015 to March 2017 
was used here.  
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Freedom of Information data – Fire services (FOI-F) 
Fifty-two regional UK fire services were identified and a Freedom of Information (FOI) 
request was sent to each asking for data on fires caused by EC (including their 
batteries and chargers) as well as fires caused by mobile phones (including their 
batteries and chargers) for context. It was not possible to send an FOI to one service 
because their regulations specified that you must be a local resident to do so. The data 
was requested for each year from 2015 to 2017. Data for 2017 were requested during 
August 2017 and the data available up to that point were provided, accordingly the cut 
off dates for 2017 data varied between services. Data was collected and analysed 
specifically for the current report. Responses came from fire services who were able to 
search the free text box in the incident recording system described above (see “Fire 
Service Data”).  
 
All Fire and Rescue Services were asked for the following information:  
 
The number of recorded fires and false alarms related to ECs and mobile phones for 
2015, 2016 and 2017. (False Alarms are incidents where the Fire Rescue Service 
attends a location believing there to be an incident, but on arrival, discovers that no 
such incident exists or existed.) 
 
The number of injuries and fatalities related fires caused by EC or mobile phones for 
2015, 2016 and 2017. 
 
FOI Burns units (FOI-B) 
Twenty-five adult, and four children’s UK burns services were identified and a FOI 
request was sent to each asking for data on burns caused by EC as well as burns 
caused by mobile phones for each year from 2015 to 2017. Data was collected and 
analysed specifically for the current report. For many burns services the data was only 
recorded in case notes and therefore the cost of accessing these data exceeded the 
limit set by the FOI Act.  
 
MHRA Yellow Card Scheme 
The Yellow Card Scheme, run by the MHRA, is the system for recording suspected 
adverse reactions to medicines and medical devices in the UK. On 20 May 2016 the 
Yellow Card Scheme launched an online reporting form tailored to collecting cases of 
suspected adverse reactions and physical safety concerns associated with EC. The 
Yellow Card Scheme was established in 1964 and is an important way in which the 
MHRA collects information to monitor the safety of medicines in the UK; medicines 
safety information from other UK and international data sources supplements data 
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collected by the Yellow Card Scheme. Any suspected adverse drug reaction to a 
medicine can be reported by a health professional, or member of the public and 
manufacturers have a legal obligation to report reactions. Inclusion of a report in the 
Yellow Card Scheme database does not necessarily mean that the reactions reported 
were caused by a medicine or an EC, only that the person reporting the event had a 
suspicion it may have, or it had a close temporal relationship to the administration of 
the medicine or EC. The MHRA provided us with anonymised details for spontaneous 
suspected adverse reaction reports for EC along with details of suspected adverse 
drug reactions for NRT products. We report spontaneous adverse drug reactions for 
the period 1 January 2015 to 20 October 2017.  
 
ECigIntelligence data 
ECigIntelligence is an independent resource that tracks market intelligence for the EC 
sector. The available data from the ECigIntelligence Global Database from August 
2015 to July 2017 describe average prices of various categories of EC. Since the 
number of products available is substantial, ECigIntelligence data typically present 
average lowest prices, thus reflecting the floor price of the products involved though 
towards the end of study period offers prices for some of the most expensive 
clearomiser/tank. The categories are: 
 
• Closed system products: EC with pre-filled clearomisers or cartomisers 
o Cheapest closed system kit- products with varying content but include at least 
one of the following- a USB charger, one cartomiser/capsule/ clearomiser 
(prefilled and containing nicotine) or one battery (non-reusable kit); 
o Cheapest pre-filled clearomiser- the refillables of the closed system kit are pre-
filled cartridges, capsules or clearomisers; 
o Cheapest disposable EC - must contain nicotine, generally come in a cigalike 
form 
• Open system products: EC that allows a user to choose their preferred e-liquid to 
refill their hardware device 
o Cheapest basic open system kit- products with varying content but include at 
least one of the following- a USB charger, one cartomiser/capsule/ clearomiser 
(prefilled and containing nicotine) or one battery. This kit should allow user to 
use any e-liquid without any modifications. 
o Cheapest clearomiser- the clearomiser is ready to use and include outer casing, 
an atomiser and a mouthpiece. 
o Cheapest e-liquid- lowest prices e-liquid bottle containing at least 10mL, and the 
price per mL is calculated  
o Variable wattage/ voltage kits 
o Most expensive clearomiser 
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Price data was provided in US dollars and converted to British pounds using monthly 
exchange rates obtained from Bank of England website (26). For most categories, the 
majority of data was derived from online sales, though towards the end of the study 
period data from retailers such as vape shops were included in the analysis. Average, 
minimum, maximum and median prices were provided; we used average price to 
explore the trends and maximum and minimum values to illustrate the price range. 
  
38 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
3  Policy 
Introduction 
Since the 2015 PHE report (5), several new regulations for EC have been 
implemented. These include age of sale regulations and the Revised European Union 
Tobacco Products Directive (EU TPD) (27) translated into UK law through the UK 
Tobacco and Related Products Regulations 2016 (see below). The national competent 
authority for these regulations is the MHRA acting for the Secretary of State for Health. 
The MHRA has implemented a notification scheme for EC and e-liquids (EC refill 
containers) and a system for notification of side-effects and safety concerns from EC 
under the TPD. Other TPD regulations cover minimum standards for safety and quality, 
advertising, labelling and packaging. E-liquid products that do not contain nicotine 
when sold (eg disposable EC and 0% nicotine e-liquids) are not deemed to fall within 
the scope of the TPD in the UK regulations and therefore do not have to meet its 
requirements, but are regulated under General Product Safety Regulations (28). The 
General Product Safety Regulations impose requirements concerning the safety of 
products intended for consumer use, and require producers only to place safe products 
on the market (it is worth noting that combustible tobacco products are exempt from 
this). Another regulatory option for EC is for manufacturers to apply for a medicines 
licence through the MHRA. Additionally, the Department of Health and Social Care in 
England has published a new Tobacco Control for England plan (2) and heated 
tobacco products (a new type of product often called heat-not-burn) have appeared on 
the market. Although we heralded some of these in our previous report, we describe 
relevant new regulations in detail in this chapter, roughly in order of date of 
implementation. 
 
Age of sale of EC 
New legislation came into force in England and Wales on 1 October 2015 and in 
Scotland on 1 April 2017 (29), introducing a minimum age of sale of 18 for EC and 
prohibiting the purchase of these products on behalf of someone under the age of 18. 
This mirrors the law for the age of sale for tobacco cigarettes.  
 
The data in Chapter 5 suggest that among those who use these products, similar 
proportions (approximately one third) of 11-15 year olds purchase EC as do purchase 
cigarettes. A smaller proportion of young people purchase EC than purchase 
cigarettes, from newsagents, but this may reflect the lower prevalence of EC available 
for purchase in newsagents. Around a quarter of 11-15 year olds reported buying EC 
from EC shops, and large proportions reported being given or buying their EC or 
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cigarettes from other people. Clearly there is scope to improve enforcement of age of 
sale laws for EC and cigarettes. 
 
European Union Tobacco Products Directive (EU TPD)  
Article 20 of the revised EU TPD (27) introduced new regulations for nicotine-
containing EC. The EU TPD was adopted in 2014 and translated into UK law through 
the UK Tobacco and Related Products Regulations 2016 (30) (Parts 6 and 7) which 
came into force on 20 May 2016, although some provisions were phased in during the 
period leading up to 20 May 20171. The advertising component of the EU TPD was 
implemented in May 2016 and superseded the previous voluntary agreement on 
advertising which was revised and a further consultation closed in October 2017 (see 
below).  
 
Under the TPD, the Secretary of State can require EC producers to withdraw their 
products from the market if they believe that they could present a serious risk to human 
health. The Secretary of State is obliged to review the regulations and publish a report 
within five years of coming into force and within every five years afterwards. 
 
In our last report we described the challenge by Totally Wicked, a privately-owned 
business selling EC devices and e-liquids, against one Article of the EU TPD, on the 
basis that it represented disproportionate and inappropriate regulation. The challenge 
was supported by nearly 100,000 EC users from across the European Union (EU) who 
signed a petition that was delivered to the Department of Health and Social Care in 
England. On 4 May 2016 the European Court (31) rejected the challenge ruling in 
agreement with the European Commission and upholding the EU TPD. 
 
Notification process 
Producers of EC and nicotine containing e-liquids are required to notify the MHRA and 
submit relevant information (a producer is defined as anyone who manufactures or 
imports these products or who re-brands any product as their own). Producers of all EC 
and e-liquids that were on the market before 20 May 2016 had until 20 November 2016 
to submit a notification to the MHRA. Producers of new EC and/or e-liquid products 
must submit a notification six months before they intend to put their product on the UK 
market. Submissions must be updated when products are modified or withdrawn. 
Relevant information required must be submitted electronically (by type of submission 
required); Table 2 summarises the key components. 
 
1 For an overview of consumer product regulations for EC please see https://www.gov.uk/guidance/e-cigarettes-regulations-
for-consumer-products ,updated 29 November 2017 
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Table 2: Details of notification requirements for EC 
 
Information required 
 
Guidance and notes 
Name and contact details of manufacturer, importer or a 
responsible person within an EU Member State 
 
Product type  EC guidance Chapter 2 (32) 
A list of all ingredients contained in, and emissions 
resulting from the use of the product by brand and variant 
name including quantities 
EC guidance Chapter 3 for emissions 
(33)  
EC guidance Chapter 6 for ingredients 
(34) 
Toxicological data regarding the product’s ingredients 
(including in heated form) and emissions, referring in 
particular to their effects on the health of consumers when 
inhaled and taking into account, among other things, any 
addictive effect (see also prohibited additives below) 
EC guidance Chapter 6 for ingredients 
(34) 
Nicotine dose and consistency of dose uptake  EC guidance Chapter 4 (35) 
Uptake when consumed under normal or reasonably 
foreseeable conditions 
 
A description of the components of the product including, 
where applicable, the opening and refill mechanism of the 
EC or refill container 
 
A description of the production process and a declaration 
that the production process ensures conformity with the 
requirements 
 
A declaration that the producer bears full responsibility for 
the quality and safety of the product when supplied and 
used under normal or reasonable foreseeable conditions 
 
Annual submissions (on or before 20 May) including sales 
volume by brand/type in the UK, preferences of consumer 
groups (published or unpublished data), mode of sale of 
products, executive summaries of market surveys  
EC guidance chapter 1 (36) 
Annual reporting guide (37) 
The Secretary of State is required to 
monitor this information particularly in 
relation to their use acting as a “gateway 
to nicotine addiction and ultimately 
traditional tobacco consumption among 
young people and non-smokers” 
 
The fee (38) for notifying each product is £150. A fee of £60 is also payable on 1 April 
annually for each product remaining on the market. These fees are to cover the 
MHRA’s costs of administering the notification scheme and also the requirement to 
oversee the publication of the notification information on a website (although trade 
secrets are treated in a confidential manner). The MHRA has given a commitment to 
review the level of fees in the light of the number of notifications received in the first 
year, so it is likely these will be reduced.  
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Notifications registered with the MHRA 
As of 31/10/2017, almost 400 different producers had submitted information about 
32,407 different e-liquids (90% of notifications) or devices (10% of notifications). A 
recent rise in the number of nicotine shots notified has been observed (39). Nicotine 
shots are 10mL bottles of high strength nicotine e-liquid which are flavourless, and 
which comply with the EU TPD regulations. Nicotine shots can then be added to much 
larger bottles of flavoured nicotine free e-liquids (which are not covered by the EU TPD, 
but would be prohibited if they contained nicotine) to make the desired nicotine content. 
These larger bottles are deliberately made to leave space for the nicotine shots to be 
added (referred to as “short-fills”). This practice is sometimes referred to as ‘Shake and 
Vape’. A survey carried out by ECigIntelligence of industry associations and New 
Nicotine Alliance members estimated that approximately 20% of the total EC product 
market was outside of the EU TPD and notification process (the percentage of EC user 
respondents claiming to use non-EU TPD products was multiplied by the percentage of 
the market estimated to be represented by enthusiast advanced tank users; 
ECigIntelligence consumer survey 2017 (39) and personal correspondence). This 
survey also estimated that the reduction in price between a 10mL EU compliant bottle 
and a 60mL short fill and 10mL shot was on average 30% (ECigIntelligence consumer 
survey 2017 (39)).  
 
Minimum standards for safety and quality 
Minimum standards for the safety and quality of all nicotine containing EC and e-liquids 
came into effect 20 May 2016, with a transition period until 20 May 2017. These 
included: 
 
• child-resistant and tamper evident packaging 
• protection against breakage and leakage  
• a mechanism for ensuring re-filling without leakage 
• prohibition of certain additives such as colourings, caffeine and taurine (these are 
listed under Article 16 of the Tobacco and Related Products Regulations, 2016 and 
pertain to tobacco products but are extended to EC) 
 
Additional restrictions have been placed on the size of the tank and strength of nicotine 
in e-liquid, summarised in Table 3. 
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Table 3: Restrictions on tanks and nicotine strength 
 
Component  Maximum allowed  
Tank capacity  2mL 
E-liquid refill container capacity 10mL 
Nicotine strength of e-liquid  20mg/mL  
 
Information provision 
From 20 May 2017, all EC/liquids had to comply with requirements to have a health 
warning and provision of other information on the pack or on the device/bottle if there 
was no outer packaging (40, 41). 
 
Health warning 
This must be prominent in black text on a white background covering 30% of the area 
on the front and back of the unit packet and any container pack: 
 
“This product contains nicotine which is a highly addictive substance” 
 
Other labelling requirements  
On the pack: 
 
• list of ingredients in liquid where they are used in quantities of 0.1% or more 
• nicotine content and delivery per dose 
• batch number 
• recommendation to keep the product out of reach of children 
 
Unless included on the pack, the following information was required on an 
accompanying leaflet: 
 
• instructions for use and storage, including instructions for refilling where appropriate 
and the MHRA advise the information should include appropriate advice on product 
storage, particularly on how to ensure the battery does not malfunction 
• contra-indications, warnings for specific risk groups and possible adverse effects, 
addictiveness and toxicity 
• contact details of producer including a contact within the EU 
 
There are requirements on product presentation such as not to encourage 
consumption. Offers and discounts and product safety/health claims are prohibited (see 
below).  
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Advertising 
The EU TPD prohibited cross-border advertising of nicotine-containing EC which 
covered broadcast television and radio, newspapers, magazines, periodicals, online 
media and some other forms of electronic media. This superseded a voluntary code 
which had been in place prior to EU TPD implementation. In 2017, the Committee of 
Advertising Practice (CAP) introduced a new rule in its Code, to reflect the prohibitions 
in the revised EU TPD and Tobacco and Related Products Regulations 2016. These 
outlined the channels that are and are not allowed,Table 4 (42). The guidance indicates 
that indirect effects are also prohibited (such as non-nicotine EC should not have the 
indirect effect of cross-promoting a nicotine-containing EC). 
 
Table 4: Advertising regulations (other than broadcast media which is all prohibited) 
 
Prohibited  Allowed* 
Newspapers Outdoor advertising, including digital outdoor 
advertising 
Magazines Posters on public transport (not leaving the UK) 
Periodicals Cinema 
Commercial email Direct copy hard mail 
Commercial text messaging (for this and the 
prior item, unless specifically opted in, should 
be given to opt-out with every communication) 
Leaflets 
Marketers online activities eg website/social 
media (except factual information, see guidance 
as this is a complex area) 
Private, bespoke correspondence between a 
marketer and a consumer 
Online (display) ads in paid-for space Media which are targeted exclusively to the 
trade 
Paid-for search listings; preferential listings on 
price comparison sites; viral advertisements 
Advertisements for businesses in non-broadcast 
media 
Paid social media placements, advertisement 
features and contextually targeted branded 
content 
Sponsorship of events which isn’t across 
borders 
In-game advertisements  
Commercial classified ads  
Advertisements which are pushed electronically 
to devices 
 
Advertisements distributed through web widgets  
Promotional marketing online  
Affiliate links  
In-app advertising  
Product placement   
* must still comply with relevant CAP rules about content and placement 
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A further CAP Code 22 (43) indicates restrictions to protect those under 18 from EC, 
such as ensuring marketing communications for EC are socially responsible, clear they 
are for EC rather than tobacco cigarettes, etc. 
 
In autumn 2017, CAP and BCAP (the UK Code of Broadcast Advertising) carried out a 
consultation on changes to their Codes to remove the current prohibition on health 
claims being made for EC and to guide advertisements for health campaigns which 
refer to EC (44). The outcome might mean that advertisers could make claims about 
the health benefits of EC in comparison to tobacco, although the likelihood is that such 
claims would need to be linked to evidence for the exact product under consideration, 
rather than to the generic category (eg EC).  
 
Retailers 
Retailers of EC had until 20 May 2017 to sell existing stock of products that did not 
comply with EU TPD labelling and product composition requirements. Guidance for 
retailers on EC is available (45). The Independent British Vape Trade Association 
(IBVTA)(46) reported that there were around 2,000 independent vape stores on the 
high streets in the UK, compared with over 50,000 convenience stores and around 
10,000 supermarkets in the UK, the vast majority of which are likely to sell tobacco. 
While tobacco outlets may also sell EC, it’s likely that the independent vape stores sell 
a greater variety of EC models (including those thought to be more effective, the tank 
models) than the tobacco outlets.  
 
Reporting of side-effects and safety concerns 
In May 2016, the MHRA extended its Yellow Card reporting system to include reporting 
on EC and e-liquids. Consumers and healthcare professionals can report both side-
effects and product safety concerns to the MHRA. Report received are summarised in 
Chapter 9. Alternatively, issues about defective/non-compliant EC can be raised with 
local Trading Standards offices. However, a recent report from the National Audit Office 
(47) indicated concern about capacity of local Trading Standard offices which had lost 
56% of full time equivalent staff since 2009, with 20% of services having had reduced 
funding by over 60% since 2011 (47). Trading Standards therefore may not have the 
capacity to deal with EC issues, or enforce relevant regulations.  
 
Medicines licensing process through the MHRA 
As indicated above, EC producers can also apply for a medicines licence for their 
products from the MHRA (48). Nicotine–containing products that make claims for 
cutting down, quitting or reducing the harms of smoking are considered to be medicinal 
products and regulated by the MHRA. Licences can be for the General Sales List, 
Pharmacy Medicines or Prescription Only Medicines. Licensed EC are exempt from the 
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EU TPD and Classification, Labelling and Packaging regulations, and subject to the 
requirements of medicinal regulation instead. Licensing is important as this may allow 
health professionals to prescribe EC which could make them more accessible to more 
disadvantaged smokers, and also enable them to be supplied with advice and support 
about their use (see Chapter 7). 
 
In the 2015 PHE report (5), we described how Voke (a non-EC nicotine inhaler product) 
had been granted a medicines licence and that a British American Tobacco (BAT) 
electronic product (e-Voke) was going through the medical licensing process. In 
November 2015, general sales list marketing authorisations were indeed given for 
10mg and 15mg e-Voke to Nicovations (formerly Nicoventures, both fully-owned BAT 
subsidiaries) for marketing as an aid to help people to stop smoking (49). E-Voke uses 
cartridges containing pharmaceutical grade nicotine. Medicines licensing meant that 
the product could be prescribed by medical practitioners. However, neither Voke nor e-
Voke have been brought to market and in January 2017, BAT announced that it was 
dropping Voke to prioritise its vapour and tobacco heating products. Kind consumer, 
the original developer, has taken back ownership of Voke, but it has not yet been 
brought to market. There is therefore no EC product that has received a medical 
licence currently available on the market or on prescription.  
 
In February 2017 the MHRA updated its guidance on the licensing process. This 
indicated that manufacturers would be expected to comply with relevant standards. The 
British Standards Institute had published a British Standards Institute-endorsed Publicly 
Available Specification (PAS) (50) for EC produced by key stakeholders. The standard 
covers, inter alia: purity of e-liquid ingredients, potential contaminants from device 
materials and potential emissions from device operation; a test solution-liquid, and an 
outline for the toxicological and chemical analysis of emissions; safety of batteries and 
chargers. The French national standards authority AFNOR has also produced a 
standard (51). European and international standards are in the process of being 
developed by the European Committee for Standardisation (CEN) and the International 
Organization for Standardization (ISO) respectively. For medicinal EC and nicotine 
containing products, the MHRA stated that additional requirements, additional to 
published standards, might also be needed to meet safety, quality and efficacy criteria 
under medicines regulations. It is likely that efficacy standards are clear, as 
manufacturers need to be able to demonstrate that nicotine delivery is comparable with 
licensed nicotine replacement therapies. However, demonstrating long-term safety may 
be more difficult for newer products. This might suggest that, in the first instance, 
licences could be granted for short-term use as was the case with NRT licences 
initially, before the harm reduction licence was added in 2010 (52).  
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Other policy-related developments 
General product safety regulations 
These regulations exist for all consumer products and non-nicotine EC are required to 
comply with these regulations (28). As noted above, combustible tobacco products are 
exempt from these regulations.  
 
Classification, labelling and packaging regulations  
EC must comply with the EU TPD but also with classification, labelling and packaging 
regulations (53) which are European regulations based on a United Nations system. 
Classification, labelling and packaging regulations apply to chemicals in EC as it does 
to other chemicals placed on the market, irrespective of whether they contain nicotine 
or not. Labelling and packaging requirements therefore pertain to any chemicals in EC. 
 
Consensus statements 
Following the publication of the 2015 PHE report, an emerging public health consensus 
was published on EC between PHE and 12 other organisations (54). This consensus 
statement emphasized the opportunity that EC provide by helping smokers to quit, but 
that combining EC (the most popular method) with most effective (stop smoking 
services) would optimise that opportunity. A recent publication by the British Medical 
Association on EC (55) is in line with this consensus.  
 
In September 2017, NHS Scotland published a consensus statement on EC (56) 
created in collaboration with, NHS and public health bodies, Royal Colleges, charities 
and universities. One of its two key messages addressed smokers, urging them to try 
stopping smoking whether or not they use EC and advising them of the help available. 
The other key message urged health professionals to advise smokers about the 
different ways they can quit and the evidence base and not to turn anyone away 
because they choose to use EC.  
 
Guidance on the use of EC in public places 
In 2015, Action on Smoking and Health (ASH) and the Chartered Institute of 
Environmental Health published a briefing on ‘five questions’ concerning the 
implementation of controls on vaping in work and public places (57). Following on from 
this, PHE carried out a consultation and survey on five principles for policy and practice 
(58). In July 2016, PHE published advice for organisations to support policy making in 
relation to the use of EC in public places and workplaces (59). The advice is based 
around the five principles, covering the need to make a clear distinction between 
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vaping and tobacco cigarette smoking, ensuring policies are informed by the evidence 
on risks to bystanders, identifying and managing risks of uptake by children and young 
people, supporting smokers to stop smoking and stay stopped, and supporting 
compliance with the smokefree law and policies. The advice, published together with a 
brief five-point guide, is non-prescriptive in recognition of the fact that settings differ and 
there is no ‘one-size-fits-all solution’.  
 
MHRA guidance on EC in research 
The MHRA has produced an algorithm, guidance and examples on the use of EC in 
clinical trials (60). As EC are not medicinal they are not considered as investigational 
medicinal product (IMP) in health or clinical research. A clinical trial authorisation (CTA) 
would only be required in most circumstances if the research uses a licensed nicotine 
product as a comparator. Accessing this guidance should be made easier for 
researchers.  
 
Heated tobacco product (heat-not-burn) regulations 
In heated tobacco products, processed tobacco is heated instead of being combusted. 
Part 4 and Part 5 of the UK Tobacco and Related Products Regulations 2016 detail the 
notification process for novel tobacco products such as heated tobacco products (30). 
Notification must be done electronically to PHE which is an executive agency 
sponsored by the Department of Health and Social Care and the UK’s competent 
authority for overseeing and publishing the notifications for tobacco products as well as 
herbal products for smoking. Notification of novel tobacco products must be done at 
least six months before the producer intends to supply the product. Fees apply for the 
notification process, for the annual reports and testing, and for any modifications.  
 
Notification should include the following information:  
 
a) detailed description (including components, mechanisms by which any 
emission/vapour is generated, and means by which nicotine is absorbed by the 
consumer) 
b) instructions for use 
c) ingredients (by weight and quantity and including reasons for inclusion, status of 
each ingredient, classification, any available toxicological data in burnt or unburnt 
form as appropriate, referring in particular to the effect of the ingredient on health 
including addictive effects) 
d) emissions (including information about the product’s tar, nicotine and CO and 
other emissions by brand and variant name)  
e) available studies on the toxicity, addictiveness and attractiveness of the product 
in particular with regard to ingredients and emissions  
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f) any available studies, executive summaries or market research, in relation to the 
product on the preferences of consumer groups, including young people and 
current smokers  
g) any other available information (including risks and benefits, expected effects on 
cessation of tobacco consumption, expected effects on tobacco consumption 
initiation, and the predicted perception of the product by consumers and potential 
consumers).  
 
A recent HM Treasury consultation (61) on the tax treatment of heated tobacco 
products in the UK classified heated tobacco products into three main types: 
 
• Type 1 - processed tobacco heated directly to produce vapour 
• Type 2 - tobacco designed to be heated in a vaporiser 
• Type 3 - devices that produce vapour from non-tobacco sources, where the vapour 
is then passed over processed tobacco in order to flavour the vapour 
 
Type 2 products include vaporisers often used for cannabis which have been sold for 
some time in the UK but we are not aware of any such products being marketed by the 
tobacco industry in the UK or elsewhere. The Treasury are currently analysing the 
responses to their consultation. 
 
It should be noted that the Treasury made clear that this category of tobacco product 
did not include EC, stating that EC do not contain tobacco and are therefore not liable 
for tobacco duty. 
 
Two products have been notified to PHE, one Type 1 (IQOS, produced by Philip Morris 
International) and one Type 3 product (iFuse, produced by British American Tobacco) 
and are currently available on the market in the UK (see Chapter 12).  
  
Towards a Smokefree Generation. A Tobacco Control Plan for England  
The new Tobacco Control Plan for England (2) sets out the commitments of the 
Department of Health and Social Care, PHE and MHRA (Table 5) to support smokers 
to quit and adopt the use of less harmful nicotine products.  
 
Over the next five years the ambition is to: 
 
• reduce the prevalence in: 
o 15 year olds who regularly smoke to 3% or less 
o adults in England from 15.5% to 12% or less 
o pregnancy to 6% or less  
• reduce the inequality gap in smoking prevalence between those in routine and 
manual occupations and the general population 
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• improve data collected on smoking and mental health to help support people with 
mental health conditions to quit smoking and make all mental health inpatient 
services sites smokefree by 2018  
• help people to quit smoking by permitting innovative technologies that minimise the 
risk of harm and maximise the availability of safer alternatives to smoking 
 
Table 5: Organisational commitment to support smokers to quit and adopt the use of 
less harmful nicotine products 
 
Organisation  Commitment  
PHE  • Update their evidence report on EC and other novel nicotine delivery 
systems annually until the end of the Parliament in 2022.  
• Include within quit smoking campaigns messages about the relative safety 
of EC.  
• Continue to provide smokers and the public with evidence based 
information on the relative harm of nicotine, EC, other nicotine delivery 
systems and smoked tobacco, to enable informed decision-making. This 
will include the publication of an assessment of the risks of nicotine 
addiction.  
• Provide evidence based guidance for health professionals to support them 
in advising smokers who want to use EC or other nicotine delivery systems 
to quit. 
Department of Health 
and Social Care  
• Monitor the impact of regulation and policy on EC and novel tobacco 
products in England, including evidence on safety, uptake, health impact 
and effectiveness of these products as smoking cessation aids to inform 
our actions on regulating their use. 
• Based on the evidence reviews undertaken by PHE, review policy and 
regulation of nicotine delivery systems to provide an environment that 
facilitates smokers taking action to improve their health and the health of 
those around them, while minimising any risk of new nicotine addiction in 
children. 
The MHRA • Ensure that the route to medicinal regulation for EC products is fit for 
purpose so that a range of safe and effective products can potentially be 
made available for NHS prescription. 
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International policy overview 
World Health Organization position statement 
In August 2016, a report was published by the World Health Organization (WHO) on 
Electronic Nicotine Devices and electronic non-nicotine delivery systems (ENDS) for 
discussion at the November 2016 Conference of the Parties to the WHO Framework 
Convention on Tobacco Control (62). The paper concluded with a list of regulatory 
options that Parties might consider to: 1) prevent initiation by non-smoker and youth; 2) 
minimise potential health risks to users and protect non-users from exposure to 
emissions; 3) prevent unproven health claims being made about the products; and 4) 
protect tobacco control activities from all commercial and other vested interests relating 
to the products including interests of the tobacco industry. The vast majority of these 
options have been implemented in England. 
 
Global situation 
At the time of writing, 27 countries ban sales of all types of EC, nine countries prohibit 
the sale of nicotine-containing EC (63).  
 
Within the EU, there were some changes due to the EU TPD with some European 
countries now having fewer restrictions (eg Croatia, Sweden, Switzerland) but others, 
like the UK having greater restrictions (eg Netherlands, Cyprus, France). 
 
Conclusions 
Key findings 
• As with tobacco products, in most parts of the UK, there is a minimum age of sale of 18 
for EC and EC must not be purchased on behalf of someone under the age of 18. 
• The revised EU TPD is now fully operational in England, transposed into UK law 
through the UK Tobacco and Related Products Regulations 2016, and covers EC 
that do not contain nicotine when sold (eg disposable EC and 0% nicotine e-liquies) 
and products that do not have a medicinal licence. These regulations include a 
notification process (to the MHRA), minimum standards for safety and quality of EC 
products, standards for information provision (including a nicotine health warning) 
and advertising restrictions and updated standards. The Advertising Standards 
Authority (ASA) has carried out a consultation on health claims; the results are 
awaited. A system to report side-effects and safety concerns related to EC has been 
implemented. 
• Over 32,000 EC products have been notified which suggests a level of compliance 
with the regulations and that the notification process is not too onerous.  
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• There are some signs that ways are being found to avoid the law, for example 
particularly on size of bottles, but evidence is limited.  
• Alongside products regulated in line with the EU TPD, manufacturers can also apply 
for medicinal licensing from the MHRA. However, no licensed EC has yet been 
marketed.  
• Other EC-related developments include consensus statements from a number of 
organisations and guidance on the use of EC in public places and on their use in 
research. 
• Non-nicotine EC are governed by general product safety regulations (unlike 
combustible tobacco products).  
• There is a separate notification process for heated tobacco products (to PHE) and 
results from a consultation on the tax treatment of these products are forthcoming. 
At the time of writing, two products had been notified.  
• A new Tobacco Control Plan for England was published in July 2017. 
 
Implications 
Research 
• There is a need for continued research on the impact of regulations on smoking 
rates and patterns, use of EC by adults and young people, product design and 
quality and adverse effects of EC.  
• Research should specifically assess the impact of the EU TPD on production (with a 
specific focus on independent manufacturers who were the first to enter this field), 
innovation of products, and EC users and smokers. 
 
Policy and practice 
• Regulations need to balance the risks of EC with their potential benefits – and achieve 
key aims of reducing smoking and continuing to avoid uptake of EC by non-smokers. 
This requires keeping them under regular review and evaluating their impact. 
• Regulations for heated tobacco products should be made as least as stringent as 
for EC.  
• It remains a viable and important goal to facilitate regulation of some EC as 
medicines via the MHRA. A review is needed of how to achieve this, possibly 
including more focus on post marketing surveillance and the provision of licences 
for short-term rather than extended use. 
• Restrictions on communicating relative risks of EC in comparison with combustible 
tobacco should be reconsidered. In any future review of the EU TPD, consideration 
should be given to the wording of the health warning on nicotine per se given the 
public misperceptions of its harmfulness (Chapters 4 and 10).  
• There appears to be no evidence justifying an urgent change regarding non-nicotine 
EC or e-liquids which are currently outwith the scope of the EU TPD.  
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4  Nicotine 
Introduction 
Professor Michael Russell was one of the pioneers of nicotine research (64). In 1971 
Professor Russell (65) explained that over recent centuries ‘no population has 
dispensed with one form of tobacco use without replacing it by another’ and ‘once 
experienced, nicotine use has continued in populations as it does in individuals.’ He 
subsequently commented that ‘people smoke for the nicotine, but die from the tar ’(66), 
and in a later paper (67) discussed the potential for recreational use of cleaner nicotine 
delivery devices to be a solution to the tobacco epidemic. NRTs, while cleaner forms of 
nicotine delivery, have simply not been taken up by significant proportions of the 
smoking population in the way that EC have. In the light of the advent of EC, therefore, 
Russell’s prophecy has now become a realistic possibility, but their widespread use will 
depend on their relative safety and addictiveness compared to smoking tobacco 
cigarettes.  
 
A systematic review of nicotine was not carried out for this report because it was 
agreed by the commissioners that nicotine would have a stronger focus in a 
forthcoming PHE review. This chapter, therefore, briefly summarises and updates 
evidence in the Royal College of Physicians (RCP) report (68), focusing on nicotine 
addictiveness, nicotine delivery in relation to EC, and any recent evidence which 
suggested nicotine use could cause significant harm. Chapters 8 and 9 discuss safety 
and health risks pertaining to EC.  
 
By acknowledging the centrality of nicotine to smoking and other tobacco use, we do 
not wish to diminish the role of other social and environmental factors (69). However, 
because most EC use in England involves nicotine (see Chapter 5 and 6), studying 
nicotine itself is an important focus in improving our understanding of EC use.  
 
Nicotine addictiveness 
It is well established that nicotine is the primary addictive component of tobacco smoke 
(70). In this section we explore the addictiveness of nicotine, as well as the extent to 
which it varies across different forms of nicotine delivery.  
 
Nicotine delivery and dose 
The dose and rate at which a drug reaches the brain influences its addictive potential. 
In one of the earliest studies to assess nicotine delivery, Russell and Feyerabend (71) 
concluded that, for smokers, it was the puff-by-puff high-nicotine bolus, which reached 
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the brain within seconds of inhalation, that made cigarette smoking so addictive. 
Nicotine is inhaled into the lungs in the form of tobacco smoke reaching the brain within 
15-20 seconds; the rate of increase in arterial nicotine concentrations is much faster 
than those achieved by intravenous (IV) injection (68, 72). 
 
All forms of NRT deliver nicotine much more slowly and at lower doses than smoking, 
but the speed and amount vary according to the delivery system (oral, dermal or nasal) 
and the dose. The faster acting NRT products (nasal and mouth spray) deliver peak 
plasma nicotine levels within about 10 minutes. Use of NRT therefore results in much 
slower nicotine delivery than smoking. Absorption of nicotine is also affected by other 
factors such as pH. Overall, the addictiveness of NRT is much lower than that of 
cigarettes, with only a very small proportion of those who use these products 
persevering with use for a year or longer. Around 10% of nasal nicotine spray users will 
use for a year or longer, 5% of those using oral nicotine products, and fewer for the 
patch (68). 
 
It is useful to compare the dependence potential of smokeless tobacco with smoking 
and NRT. Smokeless tobacco covers a heterogeneous array of very different products. 
One product, snus, which is a low nitrosamine smokeless tobacco product with a long 
history of use in Sweden, has been studied as a proxy for the long-term health effects 
of nicotine (see below). We will therefore discuss snus in relation to dependence here. 
Similar to oral nicotine products, nicotine absorption with snus also occurs through the 
buccal route, aided by the alkaline pH of snus. As such, nicotine absorption is slower 
when using snus, than from cigarette smoking, as there are no arterial boli of nicotine 
delivered to the brain. Nevertheless, nicotine exposure overall can be very similar 
between snus users and cigarette smokers. There is strong evidence that using snus 
induces dependence, since snus users exhibit a withdrawal syndrome when attempting 
to quit, with some similarity to that observed in cigarette smokers abstaining. This 
indicates that factors other than speed of delivery are important in the dependence 
potential of nicotine delivery products. It is possible that the higher addictiveness of 
snus relates to the tobacco and other factors such as the pH, compared with oral 
nicotine products. This may be relevant to heated tobacco products (see Chapter 12). 
 
We discussed nicotine delivery of EC in our last report, commenting that no studies had 
allowed an appraisal of the comparison between EC and cigarettes in terms of giving a 
rapid increase in arterial blood nicotine levels after puffing, but that it was likely some 
EC products were providing a degree of lung absorption. Since our last report, nicotine 
delivery has been shown to vary considerably across the variety of EC products, 
(eg(73, 74)). However, experienced users can achieve greater increases in blood 
nicotine levels than naïve users under the same puffing regime, albeit slower than from 
cigarette smoking (75-77). Studies with experienced users found comparable or, in 
some cases, higher venous blood nicotine levels than with cigarette smokers. A study 
with 16 experienced users and high nicotine concentrations (36mg/mL) found a higher 
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pre-post nicotine boost following a standardised puffing regimen than that typically 
seen with tobacco cigarettes (78).A further study (77) with 30 participants (10 smokers 
and 20 experienced EC users) found similar doses and speed of nicotine delivery to 
tobacco cigarettes among those using third generation devices (mods). An additional 
study, with 13 experienced users again during a standardised puffing session 
demonstrated that venous nicotine blood levels of experienced EC users from later 
generation devices were comparable to, and in some cases higher than those of 
smokers (79). Most of the participants had peak nicotine levels within two to five 
minutes after puffing an EC, suggestive of pulmonary delivery and likely to lead to 
dependence, although not all the nicotine retained was absorbed through the lungs 
(79). The same study also included a subsequent ad libitum phase (80). Here the 
authors found that vaping behaviour differed from smoking behaviour in that EC users 
took longer puffs and grouped their puffs in shorter clusters (two to five puffs). The 
intermittent puffing patterns led to a more gradual rise in plasma nicotine levels across 
the session, in contrast to the bolus dosing from cigarette smoking. Nicotine intake was 
related to puff topography only for the tank users but not across the whole sample 
(which included cigalikes and other devices).  
 
In summary, nicotine dose and rate of delivery are important factors in the dependence 
potential of nicotine delivery devices, but other factors such as pH and what comes 
along with the nicotine (also see below) are involved. Experienced EC users can have 
nicotine levels similar to those of cigarette smokers, although the speed of delivery is 
slower. Nicotine delivery varies across the different designed EC products. As yet, it is 
unclear how addictive EC are, or could be, compared to tobacco cigarettes.  
 
Self-reported dependence 
Several studies have found that self-reported dependence is lower in daily vaping ex-
smokers compared with daily smokers (eg (81, 82). In a comparison between EC 
dependence and dependence on nicotine gum, Etter and Eissenberg (83) reported that 
EC were either as addictive or less addictive than the nicotine gum, but more likely to 
be reported as being used to avoid relapse to smoking. Liu and colleagues (82) found 
that self-reported dependence in EC users was lower than among smokers but 
reported that over three-quarters considered themselves addicted to EC.  
 
A recent analysis of US tobacco and nicotine (EC) users, (84) included an instrument to 
assess tobacco dependence across different tobacco and nicotine group users. Using 
this measure, cigarette smokers had the highest mean level of tobacco dependence, 
with similar levels among multiple products users, and slightly lower mean levels in 
smokeless tobacco users; EC only users were among the lowest levels (with cigar only 
users and waterpipe only users).  
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The findings of these studies need to be viewed with caution pending validation of the 
measures.  
 
Uptake among non-smokers 
Concerns have also been raised about the propensity for adolescent non-smokers to 
become dependent on cleaner nicotine products. This propensity is likely to be affected 
by addictiveness (alongside other variables such as marketing and accessibility). 
Consistent with the above, the RCP report concluded that there was no substantial 
evidence of non-smokers becoming dependent on NRT (68). In comparison, the 
dependence of tobacco smoking is much greater with a recent meta-analysis finding 
that around two-thirds of non–smokers who experiment with smoking becoming regular 
daily smokers (85). As we will see later, there is evidence of EC experimentation 
among non-smokers, but little regular use, consistent with these observations for NRT 
(Chapters 5 and 6).  
 
Nicotine effects  
Although the metabolism of nicotine varies considerably between individuals, nicotine 
has a short-half life, approximately two hours which, together with the repeat high boli 
of nicotine resulting from puffing on tobacco cigarettes, enables users to self-titrate. 
Self-titration is also seen in EC users (86). The speed at which nicotine is metabolised 
is affected by a number of factors, and plays a role over and above the rate at which it 
is absorbed and delivered to the brain and the dose received. 
 
At low doses, nicotine is a stimulant. However, tolerance develops quickly and chronic 
exposure results in neuroadaptations, causing withdrawal effects. Addictiveness may 
be related to the severity of these negative withdrawal symptoms. Nicotine has complex 
effects, caused by its binding to and desensitizing nicotine acetylcholine receptors, and 
facilitating the release of a variety of neurotransmitters, including dopamine. Dopamine 
acts as a positive reinforcer, is involved in other addictive drug use, and is likely to 
underpin the pleasure that smokers report from smoking. Addictiveness and pleasure 
are likely to be intertwined. Pleasure is rarely reported from NRT users, but has been 
reported by EC users (87). It can be hard, however, to distinguish positive reward and 
relief from incipient withdrawal. 
 
Other influences on addictiveness of nicotine products 
Other aspects of nicotine products may potentiate addictiveness (68). These include 
the monoamine oxidase (MAO) inhibitors in tobacco smoke, substances added to 
tobacco such as sugars and polysaccharides, flavourings such as menthol or alkaline 
additives, as well as design characteristics. Secondary reinforcers, such as the 
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behavioural aspects, smell or taste, may also be acting to enhance the addictiveness of 
cigarette smoking.  
 
The PHE and the RCP reports detailed how nicotine concentration and other 
constituents of e-liquid, such as the presence of propylene glycol (PG) (probably due to 
its lower boiling point than glycerine), and vaping topography affect nicotine delivery (5, 
68). Thus, similar to tobacco cigarettes, various factors influence the nicotine delivery of 
EC. One study (77) suggested that a floor level of nicotine, rather than a ceiling (as in 
the EU, see Chapter 3) would prevent excessive puffing of EC in order to achieve 
desired nicotine levels. Flavours may also affect the rate of nicotine absorption and 
affect satisfaction from EC (88). 
 
Typologies of nicotine users 
Russell (89) also argued that there were three types of smokers: non-inhalers, peak-
seekers (~ one cigarette per hour gives a blood nicotine profile of repeated high blood 
nicotine peaks), who smoke predominantly for positive pleasure, and trough-
maintainers (~ one cigarette every 30 minutes), motivated by the need to maintain a 
high blood nicotine level to avoid unpleasant withdrawal effects. A recent study (90) 
identified three different accounts of vaping: ‘Vaping as pleasure’ in which ex-smoking 
EC users reported vaping as enjoyable and likely to be sustained over time, held a 
strong vaping identity and rejected a medical model of vaping; ‘Vaping as medical 
treatment’ in which ex-smoking EC users reported vaping as a pragmatic choice to 
medicate one’s smoking addiction, with the aim of treating and reducing their nicotine 
dependence; and ‘Ambivalent e-cigarette use’ in which dual users reported fewer 
benefits and more negative beliefs about EC, rejecting an EC user (or vaper) identity. 
While these typologies have not been shown to be related to duration of use of either 
tobacco cigarettes or EC, they are included to illustrate the heterogeneity of nicotine 
users.  
 
Summary 
In summary, nicotine addictiveness depends on a number of factors including presence 
of other chemicals, speed of delivery, pH, rate of absorption, the dose, and other 
aspects of the nicotine delivery system, environment and behaviour. Tobacco smoking 
with rapid delivery of nicotine to the lungs and absorption, has been demonstrated to 
be highly addictive, compared with the NRT patch, for example, which has much lower 
dependence potential and long term use. Addictiveness is related to pleasure as well 
as severity of withdrawal discomfort, which are hard to tease apart. The addictive 
potential of other nicotine products is likely to be within the two extremes set by the 
cigarette and NRT patch, with some products, eg snus, also being addictive. It is thus 
inaccurate to say that nicotine per se is highly addictive, such statements need to be 
more nuanced, as addictiveness is dependent on the delivery system. 
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Nicotine safety 
Nicotine toxicity 
As we detailed in our last report, the source of the oft-repeated claim about ingestion of 
30-60mg of nicotine being fatal, was hard to locate. A recent study (91) concluded that 
the lower dose limit for fatal nicotine is thought to be considerably higher, in the region 
of 500-1,000 mg ingested nicotine. 
 
Health effects of nicotine use  
The health effects of cleaner nicotine products per se is important, but the key 
comparison should be with smoking as, to our knowledge, no-one in public health is 
recommending nicotine to never smokers. For smokers, cleaner nicotine delivery 
systems will be orders of magnitude safer. Risk benefit assessments are carried out for 
medications routinely and many medications used to treat serious diseases bear some 
risks (92).  
 
The RCP report indicated that short-term nicotine use does not result in ‘clinically 
significant harm’ and concluded that there was no evidence of any increase in the risk 
of heart attack, stroke or death from use of NRT in quit attempts. The best study of 
long-term NRT use, dates from 2009, the Lung Health study (93), a randomised 
controlled trial of five years duration, in which all subjects were offered NRT and 
subjects were followed up for up to seven and a half years. There was no evidence of a 
relationship between NRT and cancers, whereas continued smoking was associated 
with developing cancer.  
 
For harms of longer term use of nicotine, the best evidence stems from snus, described 
earlier. The Global Burden of Disease Study (94), did not find sufficient evidence of a 
detrimental effect of snus on any outcome. This includes oral and pharyngeal cancer 
which had both been linked with smokeless tobacco use in general, and the latter with 
snus.  
 
These studies suggest that, for smokers, the risks of nicotine use are likely to be very 
low or negligible. The risks of long-term inhaled nicotine separate from inhaling smoke 
have not been studied in humans, and it is possible that inhaled nicotine could have 
adverse effects that nicotine taken in through other routes does not have.  
 
The health risks of EC are discussed in more detail in Chapter 9 and below we highlight 
recent studies reported as finding risks of nicotine use which were of concern.  
 
 
58 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
Recent studies assessing nicotine safety  
A recent animal study suggested that nicotine can have adverse effects on the lung 
(95). The study used very large doses of nicotine administered intermittently for four 
months. The organ damage could have been due to systemic poisoning and may not 
be relevant to exposure in smokers and EC users (96). Nevertheless, the effects of 
inhaled nicotine on lung function in humans require further investigation.  
 
A reference made at a conference to a research letter (97) reported that nicotine in EC 
causes transient stiffening of arteries and the author claimed in a media release that 
this shows risks of vaping and that he would ‘not encourage the use of the devices’. 
This generated several headlines, such as the front page headline ‘Vaping as bad as 
fags: E-cigs seriously damage heart’ (McDermott, the Sun 2016, available at: 
https://www.thesun.co.uk/living/1693653/e-cigs-are-just-as-bad-for-your-heart-as-
smoking-fags-as-they-damage-key-blood-vessels-say-experts/) and other similar 
headlines ‘E-cigarettes are as bad for the heart as tobacco: Nicotine vapour damages 
blood vessels and raises risk of disease’; and ‘Vaping as bad for your heart as smoking 
cigarettes’ (http://www.telegraph.co.uk/news/2016/08/29/vaping-as-bad-for-your-heart-
as-smoking-cigarettes-study-finds/). It seems likely that this effect is due to the acute 
sympathetic activation induced by nicotine through the release of norepinephrine. 
However, the same author (98) had previously found that the same effect, but stronger 
and longer lasting, follows drinking coffee, and also after chronic consumption (99). 
Similar effects have also been observed among students who are sitting an exam or 
engage in other common activities that can result in mental stress (100).  
 
A study using the UK Clinical Practice Research Datalink detected a shorter survival 
time in patients with pre-existing CVD who were prescribed NRT compared to those 
receiving stop-smoking advice only (16). The raw data, however, did not control for 
potential selection biases: for example, General Practitioners (GPs) may have a greater 
propensity to prescribe NRT to heavier smokers about whom they are concerned; 
similarly, smokers with more severe symptoms may be more willing to accept the 
prescription. The study also did not control for or assess the duration of NRT use – any 
past use was sufficient to categorise the patient as an NRT user. Further studies 
controlling for relevant covariates would be useful to clarify the above issues.  
 
A new review of possible effects of nicotine in EC on cardiovascular function concluded 
that short-term use of EC appeared to pose low cardiovascular risk in healthy users 
(72). The authors commented that some adverse effects may exist in people with pre-
existing CVD, though these would be lower than risks of smoking. The concern is 
based on a finding that although snus use does not increase CVD risks, among people 
who suffer a myocardial infarction, those who continue using snus have lower survival 
rates compared to those who quit snus. This could be due to post-myocardial infarction 
nicotine use. However, it is also possible that people unable to stop tobacco use 
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despite suffering a myocardial infarction are typically highly dependent and this is 
associated with lower socioeconomic status, less access to health care and a 
possibility that they seek help later than non-tobacco users, have higher levels of 
stress, and a range of lifestyle behaviours detrimental to health. Studies controlling for 
such factors are needed to clarify this issue. 
 
Foetal nicotine exposure 
There has been much concern about the use of EC by pregnant women and the role 
that nicotine may play in harming foetal development. Animal research has suggested 
foetal exposure to very high doses of nicotine has adverse consequences which are 
maintained through to adolescence, but the relevance for humans is unclear (101, 
102).  
 
In humans, it has been difficult to separate the impact of nicotine from smoking in 
pregnancy, given the low use of cleaner nicotine products among pregnant women. 
Thus assumptions about harms from nicotine in human pregnancies, have until 
recently, emerged either as a result of studies of tobacco use in pregnancy or are 
extrapolated from animal research. More recently, however, it has been reported that 
infants born to pregnant smokers, who used NRT for smoking cessation during 
pregnancy, were less likely to have developmental impairments compared with those 
who used placebo two years after birth (103). The reason for this requires more 
research but the authors argued it could be due to reduced smoking early in pregnancy 
as a consequence of NRT use. The licence for prescribing NRT was extended in the 
UK in 2005 to include use in pregnancy and NRT is currently widely prescribed in the 
UK to pregnant women who smoke (104). 
 
Limited research has been conducted with pregnant smokers or ex-smokers who use 
EC (105). Further research is needed and a large trial of EC for smoking cessation in 
pregnant women is now underway in the UK (https://ukctg.nihr.ac.uk/trials/trial-
details/trial-details?trialNumber=ISRCTN60477608 ).  
 
Adolescent nicotine exposure 
As discussed in the RCP report, smoking in adolescence has been associated with 
cognitive and attentional deficits and suggested to impact mental health, although 
confounding factors (such as self-selection) have not been taken into account thus far. 
The recent US Surgeon General’s report (106) gave a comprehensive review of the 
potential impact of nicotine on adolescent brains using human studies with smokers 
and animal studies. It concluded that the use EC by youth should be avoided and 
actively discouraged. We concur with that recommendation. However, we do not see 
this as a major issue when discussing adolescent smokers, who are already getting 
nicotine from tobacco cigarette smoking; and providing smoking and nicotine use 
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among adolescents overall continues to decline (Chapter 5). Nevertheless, careful 
monitoring of these trends is needed and more research of the impact of nicotine, as 
opposed to cigarette smoke, on cognitive functioning and attention would be welcomed.  
 
Summary 
Overall, there is evidence that nicotine plays a very minor role in the harmfulness of 
tobacco smoking. The risk profile may be different with inhaled nicotine but this would 
appear unlikely. As we will see in Chapter 10, this evidence is at odds with public 
perceptions of the harm caused by nicotine in tobacco smoking, and these perceptions 
need addressing.  
 
International developments 
One of the most recent developments internationally, has been the re-emergence of 
policy discussions and initiatives on the role of nicotine-reduced cigarettes for tobacco 
product regulation. In the US, the US Food and Drug Administration (FDA) (107) has 
commissioned research into nicotine reduced cigarettes and released a consultation on 
this. Recently, the need for, and role of, less harmful nicotine delivery devices, 
alongside such a strategy has been given more prominence. Similarly, the WHO has 
discussed the role of nicotine-reduced cigarettes for tobacco product regulation, 
producing an advisory note (108). There is currently no appetite for a nicotine reduction 
strategy in cigarettes in England. Greater discussion of this will follow in a subsequent 
report.  
 
Niaura (109) and Abrams (110) on behalf of the Truth Initiative and Schroeder Institute 
for Tobacco Research and Policy Studies in the US, re-examined the role nicotine 
plays in society and presents a view that nicotine products may contribute to an overall 
tobacco harm reduction and control strategy. In line with the thrust of this chapter, 
Niaura and Abrams assert that most of the physiological harm attributable to cigarette 
smoking derives from the toxicants in tobacco and combustion and that, 
separated from combustion or other toxic modes of delivery, nicotine, by itself, is much 
less harmful. 
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Conclusions 
Key findings 
• The addictiveness of nicotine depends on the delivery system. 
• It is possible that the addictiveness of tobacco cigarettes may be enhanced by 
compounds in the smoke other than nicotine.  
• As EC have evolved, their nicotine delivery has improved. This could mean that 
their addiction potential has increased, but this may also make them more attractive 
to smokers as a replacement for smoking. It is not yet clear how addictive EC are, 
or could be, relative to tobacco cigarettes. 
• While nicotine has effects on physiological systems that could theoretically lead to 
health harms, at systemic concentrations experienced by smokers and EC users, 
long-term use of nicotine by ‘snus’ (a low nitrosamine smokeless tobacco) users has 
not been found to increase the risk of serious health problems in adults, and use of 
NRT by pregnant smokers has not been found to increase risk to the foetus.  
• Adolescent nicotine use (separate from smoking) needs more research. 
• The long-term impact of nicotine from EC on lung tissue is not yet known and may 
be different from its impact systemically.  
 
Implications 
Research 
• More research on nicotine, compared to tobacco cigarette smoking is needed, and 
the popularity of EC enables such research, albeit in the context of the other 
components in EC and EC aerosol.  
• Further research is needed on the similarities and differences in addictiveness of 
EC and tobacco cigarettes and the potential harms associated with inhaled nicotine.  
 
Policy and practice 
• Widespread misperceptions about relative risks of nicotine and tobacco (see 
Chapter 10) need to be addressed and corrected.  
• Clear messages, based on current evidence about nicotine, its relationship with 
harms, and its addictiveness, compared with smoking, are necessary and could 
have a marked impact on public health.  
• Policies on tobacco and EC should have at their core the recognition that nicotine 
use per se represents minimal risk of serious harm to physical health and that its 
addictiveness depends on how it is administered. 
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5  Use of EC among young people  
Introduction  
Our literature search identified studies examining EC use by children and young people 
described in articles published between 1 January 2015 and 18 August 2017, updating 
searches conducted for the 2015 PHE report (5). Twenty-four articles from the UK that 
included data from adolescents were identified and an additional 223 articles were 
identified that included data from countries other than the UK. 
 
The focus of this section is on current patterns of EC use by young people in the UK. In 
this section, therefore, we focus on the existing literature that examines the prevalence 
of EC use in young people rather than the wider literature from the UK which includes 
studies of issues such as EC marketing and young people, qualitative accounts of 
young people’s perceptions of EC, studies reporting on intentions to use EC, or 
perceptions of product characteristics, for example. In addition, the extensive 
international literature identified could not be thoroughly reviewed because of time and 
resource limitations but key points are highlighted below, to put the UK data in context.  
 
The literature on EC marketing in particular is now well-developed, but has recently 
been reviewed in a report for Cancer Research UK (111). This literature largely relates 
to the impact of EC marketing on young people in countries other than the UK. Since 
May 2016, cross-border advertising of EC was prohibited in the UK as discussed in 
Chapter 3.. Thus with the exception of billboard and point of sale promotion, almost all 
forms of EC marketing are no longer permitted in the UK, measures largely designed to 
protect non-smokers and children from marketing. These new changes limit the 
relevance of the available marketing literature on EC to the UK context.  
 
Since the literature search was conducted, the authors of this report, along with other 
colleagues, have published a detailed analysis of the most up to date survey data on 
smoking and vaping among young people in the UK. This paper was in press at the 
time of the cut off for the literature search and published just ten days later. Its findings 
are outlined in detail here, supplemented by more recent data as appropriate.  
 
This section of the report outlines existing data on four key themes: 
 
• use of EC among young people  
• trajectories of smoking and EC use  
• where young people obtain EC  
• the international context  
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Use of EC among 11 to 16 year olds 
Each of the four countries that make up the UK conduct representative surveys of 
young people which now include questions on EC use. Some of these are not 
conducted annually and thus availability of the most recent data varies by year. In the 
2015 PHE report, findings from one survey that covers all of Great Britain, a regional 
survey in the North West of England, two surveys in Wales and one in Scotland were 
included.  
 
The most recent data are from surveys conducted between 2015 and 2017, recently 
published in an article outlining finding from these surveys that include just over 60,000 
11 to 16 year olds from across all of the UK (6).  
 
Five surveys are available for this latest period (also see Chapter 2 for details). These 
include: 
 
• The Youth Tobacco Policy Survey (YTPS) which includes a representative sample 
of young people from the UK including Wales, Scotland, England and Northern 
Ireland (n=1,213 11-16 year olds) 
• The ASH Smokefree Great Britain (GB) -Youth (two surveys) (ASH-Y). This 
includes a sample of 1,205 11-16 year olds in 2016 and 1,361 in 2017 
• The Schools Health Research Network (SHRN) Wales which includes 32,479 young 
people aged 11-16 
• The Scottish Schools Adolescent Lifestyle and Substance Use Survey (SALSUS) 
which surveys a representative sample of pupils in their second year of secondary 
school in Scotland (average age 13, n=13,607) and a representative sample of 
pupils in the fourth year of secondary school in Scotland (average age 15, 
n=11,697).  
 
Questions about EC use were comparable in each survey but employed slightly 
different wording to describe the products. Details on question wording and the data 
collection methods are outlined in the original article (6). Results from these surveys for 
2015 to 2016 are included in  Figure 2. 
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 Figure 2: Prevalence of EC use in teenagers by smoking status, UK surveys 2015/16 
 
Notes: YTPS, N=1,213 (2016); ASH-Y, N=1,205 (2016); SHRN, N=32,479 (11 to 16 year olds in 2015); SALSUS, N=13,607 (13 year olds in 
2015), N=11,697 (15 year olds in 2015). Base for regular smokers in YTPS and ASH-Y is less than 50. 
 
As  Figure 2 illustrates, data was available on: ever use of EC among all respondents; 
regular (defined as at least weekly) use of EC among all respondents; never smokers’ 
use of EC (ever and regular use); and regular smokers’ use of EC (ever and regular 
use).  
 
For 11-16 year olds overall, ever use of an EC ranged from 7-18% among the surveys 
that included this age range. In the SALSUS survey, ever use was 15% among 13 year 
olds and 32% among 15 year olds. This rate of ever use represents an increase 
compared with surveys from previous years. For example, in the single survey that 
covers the UK as a whole, the YTPS, the rate of ever use for 11-16 year olds was 12% 
in 2014 compared with 17% in 2016 (112).  
 
Rates of regular (at least weekly) use among all 11-16 year olds are much lower, 
ranging from 1-3% in all the surveys, including among the sample of 15 year olds in 
Scotland. Rates of regular use have not increased in recent years in the surveys where 
comparisons are possible - for example between the YTPS in 2014 and 2016.  
 
Among young people who have never smoked, some experimentation – or ‘ever use’ – 
of EC is occurring in the UK. This ranges from 4-10% among 11-16 year olds, and up 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Ever use At least weekly Never smokers' ever
use
Never smokers' weekly
use
Regular smokers' ever
use
Regular smokers'
weekly use
YTPS UK, 11-16 yr olds, 2016 ASH Smokefree GB - Youth, 11-16 yr olds, 2016
SHRN Wales, 11-16 yr olds, 2015 SALSUS Scotland, 13 yr olds, 2015
SALSUS Scotland, 15 yr olds, 2015
65 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
to 14% among 15 year olds in the SALSUS survey in Scotland. Never smokers’ ever 
use has increased slightly compared with previous years - for example from 3% in 2014 
in the UK wide survey (YTPS) to 5% in 2016.  
 
However, rates of regular use of EC in young people who have never smoked remain 
very low in all surveys, ranging from 0.1% to 0.5%.  
 
EC use is concentrated in young people who already smoke. As  Figure 2 shows, up to 
91% of regular smoking youth in UK surveys have tried an EC and up to 38% of them 
use an EC at least weekly.  
 
The ASH-Y survey is also available for 2017, representing the most recent data 
available. Figure 3 provides data comparing 2016 with 2017 for 11-16 year olds in this 
particular survey. Ever use increased between the two years when all young people 
were included (from 7% in 2016 to 11% in 2017) but this is largely accounted for by a 
rise in use among young people who are regular smokers. Both ever and regular use 
among never smokers did not increase between the two years. 
 
Figure 3: Prevalence of EC use in 11-16 year olds 2016-2017, ASH-Y 
 
 
Notes: ASH-Y N=1,205 (2016), N=1,361 (2017). Base for regular smokers in 2016 survey is only 14 and for 2017 is only 28. 
 
The ASH-Y survey is also the only UK survey that asked whether EC used by young 
people contain nicotine. Among 11 to 16 year olds who had used EC in the past or 
were currently using (those who had tried EC once or twice were not asked), 22% said 
that the device had always contained nicotine, 39% that it had sometimes contained 
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nicotine, 27% that it had never contained nicotine, and 12% didn’t know. However, it is 
unclear how accurate recall or understanding of this issue is among participants in 
youth surveys. Future research should examine this in more detail. 
 
Use of EC among 17 to 18 year olds 
Comparable data to the above for 17 to 18 year olds are only available from the ASH-Y 
surveys and these are presented here (Table 6).  
 
Table 6: EC use among all 17 to 18 year olds in Great Britain, and by smoking status 
 
 2015 
(n=728) 
2016 
(n=814) 
2017 
(n=790) 
All: Ever Use 22.2% 25.2% 28.0% 
All: At least weekly 1.0% 1.3% 1.8% 
Never smokers: Ever use 5.7% 8.8% 8.5% 
Never smokers: Weekly use 0.3% 0.0% 0.0% 
Regular Smokers: Ever use 81.8% 74.2% 75.8% 
Regular Smoker: Weekly use 3.9% 9.6% 8.2% 
 
Notes: Source ASH-Y 
 
These data are consistent with the data for 11 to 16 year olds, with never-smokers’ 
weekly EC use being negligible and never smokers’ EC experimentation being around 
9% since 2016.  
 
Trajectories of smoking and EC use  
A key question for policy-makers and others is whether EC use contributes to the 
uptake of tobacco smoking in young people. In the period covered by our review, two 
new UK studies were published that provide relevant data. Both were longitudinal 
studies originally designed to focus on other tobacco control topics, with questions on 
EC use added after the studies commenced.  
 
The first study added questions on EC to a project designed to assess the impact of the 
point of sale tobacco display ban in Scotland (113). This particular project has 
produced other papers on EC identified in our review from cross-sectional survey 
results. However, the 2017 paper was distinctive in that it included both baseline and 
follow up data collected from 11-18 year old never smokers who were originally 
surveyed in 2015 and followed up one year later in 2016.  
 
At baseline, 8.6% of never smokers who completed the initial survey and follow-up had 
tried an EC. Of those that had tried EC at baseline, 40.4% had tried smoking by the 
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follow-up stage. This compares to 12.8% of baseline never EC users who had tried 
smoking at follow-up. A total of 22.9% of those that tried cigarettes at follow up had 
previously tried an EC, compared to 77.1% who had never used an EC at baseline. 
The fully adjusted model showed that having tried an EC at baseline was significantly 
associated with trying cigarettes in the following year (OR = 6.64, 95% CI: 3.60-12.26).  
 
The second study took place in England with 13-14 year olds who were originally 
surveyed towards the end of 2014 and followed up one year later. At baseline, 61.5% 
of these school pupils hadn’t tried either EC or cigarettes, 16.0% had tried EC but not 
cigarettes, 4.4% had tried cigarettes but not EC, and 18.2% had tried both. After 
controlling for covariates, having tried EC at baseline was significantly associated with 
having tried smoking at follow up (OR = 4.06, 95% CI: 2.94-5.60). In those that had 
tried smoking at baseline, there was no significant relationship between having tried EC 
at baseline and subsequent increased smoking (OR = 1.89, 95% CI: 0.82-4.33). 
 
Both these studies conducted statistical modelling which attempted to account for other 
factors that might explain the fact that young never smokers who had tried an EC had 
gone on to try smoking by follow up. This included factors such as having friends or 
family who smoked or other measures of susceptibility to smoking. However even after 
controlling for these, EC use emerged as a predictor of subsequent tobacco use. These 
findings are similar to those identified in a number of longitudinal studies in the US 
whose results have been summarised in a recent systematic review identified in our 
literature search (114). They are also similar to a recent study from Canada published 
after the systematic review but employing similar methods. This was a longitudinal 
cohort study of secondary school pupils (115). It identified an association between 
recent (past 30 day) EC use among never smokers at baseline and both ever smoking 
and daily smoking at follow up.  
 
These studies suggest that EC use is associated with subsequent smoking in young 
people. However, all of them face similar limitations which need to be understood 
before assuming that this relationship is causal. One of the most significant relates to 
the measurement of both vaping and smoking. In both the UK studies, for example, EC 
use was classified as ever use meaning that many of the young people included could 
have tried a device just once or twice. Likewise the measure of tobacco use at follow 
up was ever use, which includes experimentation. Some of the American studies and 
also the Canadian study assessed recent use of EC (past 30 day) but not regular use 
of EC. This does not mean that the findings of the US or Canadian studies are 
incorrect, just that the measures are different from those in the UK.  
 
Secondly, smoking uptake is determined by a wide range of factors. Despite the 
statistical analysis techniques employed, the studies can’t control for all relevant 
confounders. There may well be other factors not measured in the studies (such as 
sensation seeking, curiosity, expectancies, genetic vulnerabilities) that explain why 
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some young people had tried smoking by follow up. It is also possible that there are 
groups of teenagers who are more susceptible to trying new things in general, or 
participating in risk-taking behaviour, and this is the group that may try both vaping and 
smoking.  
 
Some support for this explanation, known as a ‘common liability’ theory, comes from a 
study in the UK (and one in the US see below). This study used a cohort of over 1,000 
11-18 year olds surveyed in April 2016 and followed up four-six months later. The study 
used logistic regression models and causal mediation analysis to assess the 
relationships between 1) ever EC use and escalation among baseline never smokers 
and its association with smoking initiation at follow up and 2) ever smoking and 
escalation among baseline never EC users and EC initiation at follow up. As well as 
finding support for relationship 1) between ever EC use and smoking initiation (as 
found in the other studies above), this study also found support for the opposite 
relationship identified in 2) ie that ever smokers at baseline were more likely to initiate 
EC use at follow up (116). 
 
However, the main factor which challenges the ‘vaping leads to smoking’ hypothesis is 
what is happening with rates of youth tobacco cigarette use in the UK (and indeed in 
North America where the other studies were conducted). During the period when 
surveys show that young people are experimenting with EC, including some non-
smokers, tobacco cigarette smoking rates have continued to decline.  
 
To expand on this, we include the latest data on the prevalence of smoking in 
teenagers from UK surveys conducted between 2015 and 2017. As Figure 4 shows, 
rates of ever having tried a tobacco cigarette range from 11-20% in surveys of 11-16 
year olds overall, but were higher (31%) in the sample of 15 year olds in the SALSUS 
survey in Scotland. Rates of regular smoking are much lower - between 1-4% for 11-16 
year olds as a whole and 7% for 15 year olds in Scotland.  
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Figure 4: Prevalence of smoking in teenagers, UK Surveys 2015/16 
 
 
Notes: YTPS, N=1,213 (2016); ASH-Y, N=1,205 (2016); SHRN, N=32,479 (11 to 16 year olds in 2015); SALSUS, N=13,607 
(13 year olds in 2015), N=11,697 (15 year olds in 2015) 
 
These smoking prevalence figures represent much lower rates than in the past. For 
example in Scotland, regular smoking has dropped from 30% in 15 year olds and 10% 
in 13 year olds at the turn of the century to these current low rates of 7% (15 year olds) 
and 2% (13 year olds) in 2015 (117). In England, 10% of 11-15 year olds were weekly 
smokers in 2002, but by 2014 this had dropped to 3% (118). In fact this same survey in 
England found that 18% of youth in 2014 reported ever trying smoking at all, even 
once, which was the lowest level identified since the survey began in 1982 (118).  
 
The ASH-Y survey also gives smoking prevalence among 17-18 year olds which are 
also consistent with the above trends in younger age groups ( 
Table 7). 
 
Table 7: Smoking prevalence in Great Britain among 17 to 18 year olds 
 
 2015 
(n=728) 
2016 
(n=814) 
2017 
(n=790) 
Smoking prevalence (ever) 40.3% 38.4% 45.2% 
Smoking prevalence (regular) 8.7% 6.5% 7.1% 
 
Notes: Source ASH-Y 
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Since the Bauld and colleagues article (6) was released, a further official survey of 
Smoking Drinking and Drug Use (SDD) in young people (aged 11-15 years) in England 
has been published. Consistent with the trends above, it also identified a continued 
decline in youth smoking in England. For example, in 2006, 20% of 15 year olds in 
England were regular cigarette smokers but in the latest results, for 2016, this had 
dropped to 7% (11). Similar declines have been noted in the US including during the 
period when US studies (such as those outlined in Soneji and colleagues, 2017 (114)) 
were reporting a relationship between EC and tobacco experimentation (119, 120).  
 
If EC use was causing smoking at the population level, these reductions in youth 
cigarette smoking would have significantly slowed or indeed reversed in the UK. This is 
not happening, and suggests that EC are not currently undermining what decades of 
efforts to prevent youth smoking uptake have achieved.  
 
Where young people obtain EC 
The SDD survey also included questions on how young people obtain EC, with data 
from 2016 in England (11). Respondents could give more than one answer (Figure 5). 
The most common source was being given them by other people (48%). This compares 
to 63% of current smokers in the same survey who reported being given cigarettes by 
other people. Thirty-nine per cent of regular EC users reported buying (rather than 
being given) EC from other people (mostly friends or relatives) compared to 32% of 
current smokers. Thirty-seven per cent of EC users reported buying an EC from a shop 
compared to 33% of current smokers.  
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Figure 5: Young People’s sources of EC and cigarettes, England 2016 
 
Notes: Smoking, Drinking and Drug Use Survey 2016. EC n=311; cigarettes n=290 
 
The most popular place to purchase EC among regular users was a vape shop with 
24% reporting purchasing from these specialist stores. Slightly fewer (23%) reported 
buying online, making the two most common purchase points for EC different ones 
than for tobacco – with no sales of tobacco reported from vape shops, and just 0.6% of 
smokers buying online. Newsagents were the most popular place to purchase 
cigarettes by young smokers, accounting for 22% of purchases, whereas just 9% of EC 
purchases by young people were from newsagents.  
 
Fifty-six percent of regular EC users reported asking someone else to buy a device or 
refills from a shop compared to 79% of current smokers. Seventy-two percent of those 
who asked someone else to purchase an EC on their behalf reported success 
compared to 85% of those asking someone else to purchase cigarettes.  
 
0
10
20
30
40
50
60
70
80
90
100
Given by
people
Bought
from
people
EC shop Internet Street
Market
News
agent
Super-
market
Other
type of
shop
Found or
taken
Garage
shop
%
 
EC Cigarettes
72 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
These findings have a number of implications. First, it is concerning that young people 
can continue to access tobacco cigarettes, including purchasing them from newsagents 
despite age of sale laws that have been in place for many years in England and 
throughout the UK. Similar age of sale laws (age 18) now exist for EC in England (and 
also in Wales and Scotland – age of sale is not yet in place in Northern Ireland but 
should be enacted soon) but this legislation does not appear to be deterring around 
one third of young EC users in England from purchasing them in retail outlets. In 
addition, almost one in four young people in England who use EC are purchasing them 
online – while online purchase of tobacco by young people is negligible. Online 
purchases of EC by young people should be monitored. 
 
That said, the most common source of young people obtaining either EC or tobacco 
was from friends and relatives and this proxy purchasing needs further attention. This is 
particularly concerning for the much more harmful product - cigarettes - and provides 
the basis for Scotland’s legislation which includes powers to fine adults convicted of 
proxy sales of tobacco – legislation not in place in other parts of the UK.  
 
The international context  
An additional issue of interest is how EC use by young people in the UK compares to 
that in other countries. Direct comparisons are challenging for at least three reasons: 
 
• the ages of adolescents included in surveys varies between jurisdictions 
• many surveys are not representative of young people in the relevant jurisdictions 
but instead include convenience samples or those from particular schools or 
communities 
• surveys do not use identical or even similar questions to assess use of EC  
 
The issue of survey questions is particularly challenging. In the UK, a clear distinction is 
made between ever or occasional use and regular (at least weekly) use. This is rarely 
attempted in other countries where the vast majority of surveys include (or only report) 
measures of ever or recent use, with recent use defined as in the past 30 days, a 
measure not used in the UK. 
 
However, it is possible to describe general trends in countries that report data from 
youth surveys. These are almost all high income countries where EC are available for 
sale. Our literature search identified one systematic review of the international literature 
on youth use of EC (121). This included 22 relevant studies on EC awareness and use 
in under 18s from January 2014 to January 2016. Seventeen of these reported 
prevalence figures on: ever use; recent use (past 30 days); and, in three articles, 
regular use. Given the review was conducted to include articles published up to 2016 
many of these data are now some years old. For example, articles published in 2016 
commonly included data from 2013/14, meaning that this overview may now be five 
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years out of date. In addition, as the authors point out, the surveys vary in terms of the 
age groups involved.  
 
Despite these considerable limitations, Greenhill and colleagues’ paper (14) provides a 
snap shot of youth prevalence figures from a few years ago. Ever use, for example, 
varied from 4.4% in Germany to 38.5% in Romania.  
 
Recent (past 30 day) use of EC in the various youth surveys identified in the systematic 
review (121) ranged between 2 and 14% in the US, 7.2% in Canada and 1.1% in Hong 
Kong. Regular use in the review was defined as at least once per month and only 
reported in one study from the UK (again 2014 figures, at 1.5%), 3.2% in Ireland and 
0.5% in Greece.  
 
These international comparisons paint a rather confusing picture, and as Greenhill and 
colleagues point out, the measurement challenges we identify above make direct 
comparisons very difficult if not impossible.  
 
However, considerable attention has been paid to comparisons between the UK and 
North America and here it may be instructive to look at more recent surveys in an 
attempt to describe whether what is observed in the UK is unusual or not.  
 
One recent large, nationally representative survey of young people in grades 6-12 
(aged 11 to 18) in Canada has recently been published (122). This includes data from 
the Canadian Student Tobacco, Alcohol and Drugs Survey across 336 schools, 
capturing results from 42,094 students between October 2014 and May 2015. The 
Canadian findings for ever use are broadly similar with those in the UK from the 
subsequent year, as outlined above. They found that 17.7% of young people reported 
ever using EC. Overall 5.7% reported use in the past 30 days, but this rate was just 
1.8% in never smokers - illustrating, like UK data, that these products are used 
primarily by young people who also smoke tobacco cigarettes.  
 
Likewise in the US, an analysis of the 2015 National Youth Tobacco Survey (NYTS) 
has recently been published (123). As with the Canadian survey and our UK data, this 
is a representative survey of young people across the US and included 17,711 young 
people in middle school (aged 11-14) and high school (aged 14-19). This is a slightly 
broader age group than in the UK datasets above. The NYTS focuses on ‘current use’ 
of tobacco products and EC which is use in the past 30 days. Overall 11.3% of all 
young people in the survey reported current EC use (124).  
 
Collins and colleague examined the NYTS data in more detail and identified similar 
patterns to an earlier study of the 2014 data from the same survey (125). They found 
that almost all EC users were either currently using another tobacco products (such as 
cigarettes) or had used tobacco at some point in the past. Only 1.6% of never tobacco 
74 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
users (‘tobacco naïve’ youth) were current EC users. Although ‘frequent’ use is not 
reported in the NTYS reports, Collins and colleagues analysed the raw data and found 
that less than 0.1% of tobacco naïve youth reported using EC on 10 days or more in 
the past month.  
 
At least one survey in the US asked questions about whether youth had vaped nicotine 
and found that the vast majority of youth (65-66%) who report trying or currently using 
an EC used one that did not contain nicotine (126). 
 
Although these surveys in Canada and the US cannot be directly compared with data 
from the UK, they suggest similar patterns. First, that ever or recently using an EC is 
not unusual among young people overall. However, both ever and recent use is far 
more common among young people who smoke than young people who have never 
smoked. The very recent analysis by Collins and colleagues also shows that regular 
use of EC is extremely rare among never smoking young people in the US, as the UK 
data also shows. A future priority for research should be to harmonise measures and 
questions across youth surveys to allow reliable and accurate international 
comparisons to be made.  
 
As mentioned above, a recent systematic review of studies on trajectories of use (114) 
has identified in the international literature a link between EC ever use at baseline and 
smoking initiation at follow up. In addition, one of these studies (127) also found a 
relationship between smoking at baseline and recent use of EC at follow up, similar to 
the UK study identified above.  
 
Conclusions 
Key findings 
• E-cigarettes cannot be legally sold to young people under the age of 18 in most 
parts of the UK with the exception of Northern Ireland. Purchasing does occur 
including from sources rarely used for tobacco such as online suppliers. 
• Despite some experimentation with these devices among never smokers, EC are 
attracting very few young people who have never smoked into regular use. 
• EC do not appear to be undermining the long-term decline in cigarette smoking in 
the UK among young people. 
• Never smokers in the UK who try EC are more likely to have tried smoking 
subsequently than those who have not tried EC.  
• A causal link has not been established and neither has progression to regular 
smoking. The ‘common liability’ hypothesis seems a plausible explanation for the 
relationship between EC and smoking experimentation.  
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Implications for research, policy and practice 
• Trends in EC use and smoking among youth should continue to be monitored using 
standardised definitions of use. This should include the use of nicotine in EC and 
checks on the understanding of survey questions. 
• Patterns of EC purchasing by young people should be closely monitored, 
particularly internet sales. Age of sale regulations are in place for EC and cigarettes 
and should be strongly enforced. 
• Research is needed on trajectories of use – not just from EC experimentation to 
smoking, but also from smoking to EC use among young people.  
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6  Use of EC in adults 
Introduction 
The objective of this chapter is to provide an overview of available data on prevalence 
of trial and use of vaping devices/EC in adults in Great Britain and information on 
characteristics of EC use. This information will be followed by a brief overview of 
international evidence on prevalence of trial and use.  
 
Surveys used to describe the situation in Great Britain are the 2016 Office for National 
Statistics (ONS) ‘Adult smoking habits in Great Britain’ (respondents aged 16 and 
over), the Smoking Toolkit Study from England (STS, respondents aged 16 and over) 
and the ASH Smokefree Great Britain surveys of adults (ASH-A, respondents aged 18 
and over). In this chapter, EC use will be presented over time alongside smoking 
prevalence, followed by a breakdown of trial and use by smoking status and socio-
demographic characteristics as available. Characteristics of EC use will be presented 
for all current EC users as well as broken down by vaping and smoking status, mainly 
relying on the ASH-A. International information will be summarised based on the 
literature review described in Chapter 2. 
 
The surveys use different questions to determine EC trial and use. In the ASH-A, two 
questions determine EC use status. First “Which of the following statements BEST 
applies to you? a) I have never heard of e-cigarettes and have never tried them; b) I 
have heard of e-cigarettes but have never tried them; c) I have tried e-cigarettes but do 
not use them (anymore); d) I have tried e-cigarettes and still use them; e) Don’t know”. 
Options c) and d) combined are classed as ‘ever tried’ and those responding c) or d) 
are asked a follow-up question about how often they had used or currently used e-
cigarettes which includes the option “Not applicable – I have only tried e-cigarettes 
once or twice” as well as five options ranging from “Everyday” to “Less than once a 
month” and an additional “Don’t know”. Those responding c) to the first question and 
“Not applicable – I have only tried e-cigarettes once or twice” are treated as past triers, 
those responding c) and any frequency of use in the follow-up question as past users. 
Those responding d) to the first question are treated as current users which includes a 
small percentage who have at the point of the survey only tried once or twice. 
 
In the ONS, respondents were asked to select one response out of a) No, I have never 
used one and I will not use one in the future; b) No, I have never used one but I might 
use one in the future; c) Yes, I have used one in the past but no longer use one; d) 
Yes, I currently use one; e) I tried one, but did not go on to use it; f) I don't know what 
an e-cigarette is (spontaneous only). Little information is provided in publications, so 
the question wording is not available. Those responding c), d) or e) are combined as 
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having ever tried an EC; those responding c) or d) as ever users, and those responding 
d) as current users.  
 
The STS uses a different approach and does not assess whether respondents have 
ever tried or used EC. Depending on smoking status, variations on the question “Are 
you using any of the following?” are asked, followed by a list of products including 
‘Electronic cigarette’. Those who smoked cigarettes in the past year and have made 
any attempts to quit smoking are also asked about aids used, these also include EC as 
an option.  
 
Evidence from recent GB surveys 
Trial and use of EC in adults in GB 
For 2016/17, the estimates for prevalence of current use were very similar across the 
three different surveys and ranged from 5.6% to 5.8%, regardless of different 
geographical coverage and slightly different minimum age of respondents (Figure 6 and 
Table 8). This prevalence translates to about 2.9 million current adult EC users in Great 
Britain.  
 
Figure 6 shows prevalence of EC use and smoking prevalence in adults from the three 
surveys over the last few years. This indicates that EC use prevalence has plateaued 
while smoking prevalence continues to decrease. 
 
Table 8: Current prevalence of EC use and trial in adults 
 
 ONS, 2016, % ASH-A 2017, 
% 
STS 2017, % 
Ever tried EC 18.6 16.7 - 
Current EC user 5.6 5.8 5.6 
 
Notes: Unweighted ns: ONS 7,713; STS 20,395; ASH-A 12,696. Ages 16+ for ONS and STS, 18+ for ASH-A 
 
  
78 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
Figure 6: Prevalence of smoking and EC use in the adult population in three national  
surveys  
 
Notes: STS measured EC use from Quarter 4 in 2013, ASH-A is conducted in March. Ages 16+ for ONS and STS, 18+ for 
ASH-A 
 
EC use and smoking status 
Figures for EC use by smoking status vary a little across surveys (Table 9). This may at 
least partly be due to different questions and categorisations used to define smoking 
status. Additionally, the STS reports figures for past-year smokers (combining current 
smokers and those who stopped within the last 12 months) and long-term ex-smokers 
(those who stopped smoking more than 12 months ago) separately, whereas other 
surveys report data for current smokers and ex-smokers of any length of time. 
However, all recent surveys find the highest level of EC use among smokers (often 
referred to as ‘dual use’) and very low levels of EC use among never-smokers. 
 
‘Dual users’ are not a homogenous group. This label includes a wide range of smoking 
and EC use patterns, from those who smoke many cigarettes a day and use EC only 
very occasionally to those who use EC many times a day and smoke only very 
occasionally, and every combination of behaviours in between. There has been little 
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research into different patterns of using EC while smoking and their effects on health or 
changes in smoking and EC use behaviour over time.  
 
Table 9: Current EC use by smoking status, adults  
 
 ONS, 
2016 
ASH-
A, 
2017 
STS, 
2017 
Smoking status    
Current smokers/ 
past-year smokers 
in STS 
13.7 18.0 20.1 
Ex-smokers/ long-
term (>1 year) ex-
smokers for STS 
12.1 9.5 8.7 
Never-smokers 0.6 0.3 0.6 
 
Notes: Unweighted ns: ONS 7,713; STS 20,395; ASH-A 12,696. Ages 16+ for ONS and STS, 18+ for ASH-A 
 
The smoking status of those who use EC has changed over time; the proportion of 
smokers has been decreasing and the proportion of ex-smokers increasing so that the 
majority of EC users are now ex-smokers (Figure 7).  
 
Figure 7: Smoking status of current EC users  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Notes: ASH-A, reproduced (128). Unweighted bases in the appendix Age 18+ 
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Figure 8 shows ever EC trial and current EC use by smoking status over time as 
recorded in the ASH-A survey. EC trial and use in current smokers seem to have 
levelled off with little change in use between 2014 and 2017; 40% of all current 
smokers have never tried EC. For comparison, in the 2016 survey, 59% of smokers 
had never tried NRT and 3% reported currently using NRT (19% for EC). In ex-
smokers, use continues to increase. In never-smokers, EC use has remained very low 
since surveillance began in 2012 with the highest prevalence of 0.3% recorded in 2017. 
A similar picture emerges from the STS, where EC use among smokers and recent ex-
smokers has plateaued (Figure 9) while use among long-term ex-smokers continues to 
increase (Figure 10). Similar to the ASH-A, the STS has recorded EC use among never 
smokers around 0.5%; interestingly, EC use has been at the same level as use of NRT 
in this group (Figure 10).  
 
Figure 8: Ever trial and current use of EC in adults by smoking status over time  
Notes: ASH-A. Unweighted bases in the appendix Ages 18+  
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Figure 9: Prevalence of EC use among smokers and recent ex-smokers 
  
Notes: STS, N=27,389 adults (16+) who smoke or who stopped smoking in the past year 
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Figure 10: Use of NRT and EC by never smokers and long-term (>1 year) ex-smokers 
over time
  
Notes: STS. N=67,513 never and long-term ex-smokers aged 16+ from November 2013 
 
STS data show a decline in the use of NRT alongside smoking and an increase in EC 
use alongside smoking (Figure 11). The extent to which EC use is cannibalising NRT is 
discussed in Chapter 7. 
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Figure 11: Use of nicotine products while smoking 
Notes: STS. N=25,549 smokers aged 16+  
 
Dual use of EC while smoking is unlikely to be associated with substantial reductions in 
harm, particularly when there is no substantial reduction in the number of cigarettes 
smoked (129). However, a comparison between dual users and smokers also indicated 
that dual use is not associated with an increase in harm. It is also worth noting that dual 
use is not specific to EC; very similar proportions of EC and NRT users also smoke or 
have smoked within the last year (Figure 12).  
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Figure 12: Proportion of EC users and NRT users who are ‘dual users’ (also smoke or 
have recently smoked) 
   
Notes: STS, N=4,408 EC users and N=2,226 NRT users aged 16+ 
 
EC use and socio-demographics 
Prevalence of current use in different socio-demographic groups is shown in Table 10. 
There does not appear to be a clear association with gender or a strong association 
with age, although all surveys report lower prevalence in the oldest and youngest age 
groups.  
 
In terms of socioeconomic status, the association found depends on the population 
analysed (Table 11). In all adults in the general population (ONS and ASH-A), 
prevalence of EC use is higher in groups with lower socioeconomic status. This is 
expected due to a higher smoking prevalence in lower socioeconomic groups and the 
higher prevalence of EC use among smokers (ie groups with higher smoking 
prevalence are likely to have a higher EC use prevalence). In past-year smokers, the 
STS shows no clear gradient in prevalence of EC use, meaning that the socioeconomic 
differences seen in earlier years (5) have shrunk. This suggests that smokers from 
different socioeconomic status groups have a similar likelihood of using EC for quitting 
smoking although this remains to be tested empirically.  
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There are some regional variations; the proportion of adults using EC ranges from 
3.0% in Wales to 11.5% in Yorkshire and the Humber and the proportion of smokers 
who have never tried EC ranges from 34.8% in Wales to 50.0% in the South West and 
in the West Midlands (Table 12).  
 
Table 10: Current EC use by socio-demographics and smoking 
 
 ONS, 2016, adults  ASH-A, 2017, adults  STS 2017, adult past-
year smokers 
Gender    
Men 6.3 6.4 20.2 
Women 4.9 5.3 19.9 
 
Notes: Unweighted ns: ONS 7,713; STS 20,395; ASH-A 12,696. Ages 16+ for ONS and STS, 18+ for ASH-A 
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Table 11: Prevalence of current EC use by age and socioeconomics 
 
ONS, 2016 adults ASH-A, 2017 adults STS 2017 adult past-year 
smokers 
Age Age Age 
Under 25 5.8 Under 25 5.2 Under 25 19.8 
25 to 34 6.9 25 to 34 6.3 25 to 34 20.3 
35 to 49 7.1 35-44 6.9 35-44 22.0 
50 to 59 6.5 45-54 6.9 45-54 21.4 
60 and over 2.9 55+ 4.6 55-64 20.1 
    65+ 14.2 
Socioeconomics  Socioeconomics  Socioeconomics  
Degree 3.6 AB 4.3 AB 22.6 
Higher education 5.9 C1 5.3 C1 20.0 
A-Levels or 
Highers 
6.5 C2 6.5 C2 20.8 
ONC or National 
Level BTEC 
8.2 D 7.3 D 16.8 
O-Level, GCSE, 
CSE, Standard 
Grade* 
6.4 E 7.5 E 20.9 
Other 
qualifications 
5.9     
No formal 
qualifications 
5.3     
 
Notes: Unweighted ns: ONS 7,713; STS 20,395; ASH-A 12,696. Ages 16+ for ONS and STS, 18+ for ASH-A 
 
AB: Higher & intermediate managerial, administrative, professional occupations; C1: Supervisory, clerical & junior managerial, 
administrative, professional occupations; C2: Skilled manual occupations; DE: Semi-skilled & unskilled manual occupations, 
Unemployed and lowest grade occupations.  
 
*Calculated from O-Level or GCSE equivalent (grade A-C), GCSE (grade D-G), CSE (grade 2-5) or Standard Grade (level 4-6) 
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Table 12: Regional prevalence of current EC use in adults in the general population and 
proportion of smokers who have never tried EC, ASH-A 2017  
 
Region Adult prevalence of EC use, % Smokers who have never tried 
EC*, % 
North East 3.8 45.2 
North West 9.9 37.9 
Yorkshire and the 
Humber 
11.5 41.7 
East Midlands 10.3 39.6 
West Midlands 7.6 50.0 
East of England 7.3 36.7 
London 4.9 36.0 
South East 6.1 38.2 
South West 7.2 50.0 
Wales 3.0 34.8 
Scotland 5.5 35.4 
 
* Including those who had never heard of EC and those who didn’t know. Unweighted bases in the appendix. Age 18+ 
 
Characteristics of EC use 
This section mostly presents data from the ASH-A 2017; characteristics will be shown 
for current and past EC users by smoking status. Where the unweighted sample size is 
less than 50, percentages will not be reported because reliability of these figures would 
be low. This means that characteristics of use are not shown for never-smokers who 
currently use (n=15) or never-smokers who used more than once or twice in the past 
(n=45) in the ASH-A. 
 
Frequency of use 
Across different surveys, most respondents who say they currently use EC report daily 
EC use; 75% and 67% of current EC users reported daily use in the ONS 2016 and the 
ASH-A 2017 respectively. In the STS from 2013 to 2017, 62% of smokers who reported 
current EC use and 87% of ex-smokers who reported current EC use were daily users.  
 
Among those who used or tried EC in the past, frequency of use looks very different 
(Figure 13); the most common response, regardless of smoking status, is that they only 
tried EC once or twice. 
 
Among never-smokers who said they had ever used or tried an EC, experience with EC 
was mostly limited to trial. While 2.3% of never-smokers reported ever having tried or 
used EC, around half of those (50.7%) had only used EC once or twice. Among those 
who had used EC more often, the majority had used less than monthly (22.4% of all 
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never-smokers who had ever tried); 10.5% of never smokers who had ever tried EC 
reported they had used or were using every day (this equates to 0.2% of all never 
smokers or an unweighted n of 12 out of 6626 never smokers).  
 
These data are in line with findings that frequent users are more likely to continue use 
from a longitudinal study in the US (130) which assessed frequency of EC use at 
baseline and again after a year. About 27% (95% CI: 18 to 40) of those who at baseline 
used on 1 to 5 days in the past month reported any use at follow-up, while 89% (95% 
CI: 78 to 100) of those who reported daily use at baseline also reported use at follow-
up. To date, there is no evidence as to how EC use changes in the long-term, such as 
more than one year.  
 
Figure 13: Frequency of EC use among past users or triers and current EC users by 
smoking status  
 
 
 
Notes: ASH-A 2017. Unweighted bases in the appendix. Age 18+ 
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Duration of use 
Current EC users appear to be mostly long-term users. About three quarters of current 
users (76.0%) have used for more than 6 months (83.0% among ex-smokers, 68.9% 
among smokers), including one third (33.7%) who have used EC for more than two 
years (Figure 14). Among those who used (not only tried once or twice) EC in the past, 
the majority (71.7%) used for less than 6 months, with half of those (36.6%) having 
used for a month or less.  
 
Figure 14: Duration of EC use among past and current EC users by smoking status  
 
 
Notes: ASH-A 2017. Unweighted bases in the appendix. Age 18+ 
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Device type 
Devices with tanks that can be refilled with liquid continue to be the most popular type 
of devices among current EC users. In 2014, 40.8% of current EC users responded 
that they most often used a tank type; this increased to two thirds of current EC users 
in 2015 (66.2%) and remained at over two thirds in 2016 (71.0%) and 2017 (69.4%). 
Devices that use replaceable cartridges were used by 21.5% of EC users in 2017, 
similar to the previous two years (2015: 26.3%, 2016: 22.7%) and lower than in 2014 
(46.7%). Past EC users (who had used EC more than once or twice) were less likely to 
have mostly used tank models (44.2%, Figure 15), potentially partly because their use 
occurred when these models were less popular or because continuing EC users move 
on to tank models.  
 
The STS uses slightly different categories and also finds tank devices to be the most 
popular among EC users surveyed since August 2016. Split by smoking status, 57.6% 
of ex-smokers who used EC and 51.1% of smokers who used EC used this type of 
device, followed by modular systems [described as “A modular system that you refill 
with liquids (you use your own combination of separate devices: batteries, atomisers, 
etc.)”] that were used by 28.0% of ex-smokers and 22.8% of smokers who used EC. 
Eleven per cent of ex-smokers and 16.6% of smokers who used EC used cartridges. 
 
The ONS used a simpler measure for type of device; here, 20.0% of EC users reported 
using one that resembles a cigarette, 73.9% one that does not resemble a cigarette 
and 6.1% some other kind.  
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Figure 15: Device types used by past and current EC users by smoking status  
 
 
Notes: ASH-A 2017. Unweighted bases in the appendix. Age 18+ 
 
Amount of liquid 
Only daily EC users were asked about the amount of liquid used. The majority (62.2%) 
of them reported using less than 4 mL per day and only a small percentage (1.5%) 
used more than 10 mL a day, the maximum amount allowed under the EU TPD to be 
sold in one refill bottle. Almost a fifth (18.1%) of daily EC users did not know how much 
liquid they use, indicating difficulty with self-report measures for consumption (Figure 
16).  
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Figure 16: Amount of liquid used by daily EC users by smoking status 
 
Notes: ASH-A 2017. Unweighted bases in the appendix. Age 18+ 
 
Nicotine 
In the ASH-A, among current EC users, 69.3% always and 18.9% sometimes used 
nicotine (leaving 6.0% who never used nicotine and 5.8% who were unsure). Among 
past EC users who had used more than once or twice, 49.1% had always and 21.4% 
sometimes used nicotine. Notably, among never-smokers who had used EC, less than 
a third had used nicotine (29.5%) and most of those only sometimes. However, the 
same proportion of never-smokers who had used EC did not know whether they had 
used nicotine (Figure 17).  
 
In the STS from August 2016 to July 2017, 84.5% of smokers and 88.1% of recent ex-
smokers who use EC say that the EC or vaping device they mainly use contains 
nicotine.  
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Figure 17: Use of nicotine-containing liquid used by past and current EC users by 
smoking status 
 
 
Notes: ASH-A 2017. Unweighted bases in the appendix. Age 18+ 
 
In the ASH-A 2017 survey, those responding “always” or “sometimes” to using nicotine 
were asked about the concentration of nicotine in the liquid they used usually 
(strength). Among current EC users using nicotine, 6.0% used strengths over 20mg/mL 
which were still allowed in March 2017 when the survey was run, but not after 20 May 
2017 under the EU TPD (Figure 18). The STS reports a similar figure for the time from 
August 2016 to June 2017 when 4.3% of smokers and 6.7% of ex-smokers who also 
used EC used strengths of 20mg/mL or more (note that this includes 20mg/mL, the 
upper threshold of legal concentrations). While among current EC users, 9.4% did not 
know or remember the strength, this was common among past EC users (39.6%). 
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Figure 18: Nicotine strength used by past and current EC users who at least sometimes 
used nicotine-containing liquid, by smoking status  
 
 
Notes: ASH-A 2017. Unweighted bases in the appendix. Age 18+ 
 
Flavour 
Overall, the most popular group of flavours among current EC users was fruit flavours 
(28.5%), followed by tobacco (26.9%, including 2.4% who used tobacco menthol 
flavour) and menthol or mint flavours (25.3%). The same order was found among 
current smokers who currently use EC (fruit 31.5%, tobacco 30.3% and menthol/mint 
20.9%), while among ex-smokers, menthol/mint flavours were slightly more popular 
(30.2%) than fruit and tobacco (both 25.5%, all figures from the ASH-A 2017). Very few 
current EC users use no flavours (2.6%) or do not know the flavour (2.2%). Data on 
flavours were not collected for past EC users.  
 
Place of purchase 
In 2016/17, specialist vape shops were the most popular source for purchase of EC 
among past-year smokers; 49.2% of current smokers who used EC and 42.8% of ex-
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smokers who used EC had purchased their device there, followed by 16.7% and 15.3% 
respectively who had purchased from a supermarket, 12.8% and 11.9% respectively 
from a newsagent and 9.9% and 11.9% from an online specialist vape shop (STS).  
 
Main reasons for use 
Surveys use different lists of reasons from which respondents can choose, but 
consistently find that the desire to stop smoking is an important reason. In the ASH-A 
2017, across all adults (regardless of smoking status) who had ever tried EC, the most 
common reason was ‘just to give it a try’ (36.0%), followed closely by ‘to help me stop 
smoking entirely’ (35.6%) and ‘Because I had made an attempt to quit smoking already 
and I wanted an aid to help me keep off tobacco’ (24.5%). When excluding those who 
had tried once or twice, ‘to help me stop smoking entirely’ was the most common 
reason (42.0%), endorsed by 35.1% of current smokers, 54.5% of ex-smokers and 
7.2% of never smokers who had used or were using EC. The ONS found similar 
percentages when asking EC users to select their main reason; ‘aid to stop smoking’ 
was the most frequently endorsed (46.6% overall, 50.1% among current smokers, 
48.2% among ex-smokers, unweighted n for never smokers <50), followed by ‘less 
harmful than cigarettes’ (26.6%). Chapter 10 provides further information on harm 
perceptions.  
 
Among smokers, trial, past use and current use of EC appears to be driven by different 
reasons. In one recent analysis of ASH-A 2016 data, among smokers who had ever 
tried or used EC, the most frequent reasons overall were ‘to give it a try’, ‘to help stop 
smoking’ and ‘to help reduce smoking’. However, reasons differed between groups with 
different EC use experience. Current users’ most frequent reason was ‘to reduce 
smoking’ (45.3%) followed closely by ‘to help stop smoking (37.4%). Current users 
were more likely to endorse smoking reduction compared with past users (24.2, 
adjusted odds ratio (AOR) = 2.40, 95% CI: 1.59–3.64) and to endorse overcoming 
smoking restrictions (26.0% versus 13.4%, AOR = 2.03, 95% CI: 1.22–3.38) For those 
who had tried EC but not gone on to use them, the most frequent reason was ‘to give it 
a try’ (50.8%), and compared with past users, they were more likely to endorse this 
reason (20.8%, AOR = 2.99, 95% CI: 1.99–4.50) and less likely to endorse ‘to help stop 
smoking’ (18.9%) which was the most popular reason among past users (36.8%, AOR 
= 0.46, 95% CI: 0.33–0.73)(14).  
 
Motivation to stop smoking 
Among all smokers in the ASH-A 2017, 18.3% were motivated to stop smoking with the 
intention to do so either in the next month or the next three months (131). Broken down 
by EC use status, 23.2% of smokers who were currently using EC gave these 
responses, compared with 13.2% of smokers who had never tried EC. Using 2016 
data, a recent publication has analysed this association in more detail (14). Adjusting 
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for socio-demographics and dependence, current dual users were significantly more 
likely to be motivated to stop smoking in the next three months than those who had 
used EC in the past whose motivation was similar to those who had never tried EC 
suggesting that dual use may be a transient phase of heightened motivation to stop 
smoking.  
 
Gaps in the available data 
There are a few notable gaps in the available data. More information is needed to tease 
out whether ex-smokers are initiating EC use after a period of abstinence, their reasons 
for any uptake and whether this is associated with an increase or decrease of relapse 
to smoking.  
 
Information on the impact of EC on health and economic inequalities associated with 
smoking are scarce.  
 
Notably, no data are currently available to assess prevalence of trial and use of EC in 
disadvantaged groups with high smoking prevalence and smoking-related morbidity 
and mortality, such as those with mental health problems or offenders. In 2014, the 
Adult Psychiatric Morbidity Survey (132) included some questions on EC use as 
advised by Leonie Brose and Ann McNeill; however, the data have not yet been made 
available for analysis. Funding awarded to Leonie Brose has for the first time enabled 
the Smoking Toolkit Study to be extended with a mental health module; data are 
currently accruing.  
 
International overview of EC use  
A large number of surveys has been conducted, but often these are restricted to 
specific regions or populations for example college students in a particular US state. 
For this section, the focus was on national surveys with representative samples, 
surveys with other samples are however included in meta-analyses identified in the 
literature review. A limitation is that data on EC use prevalence can become outdated 
quickly; by the time survey data have been published in peer-reviewed publications, 
they may already be out of date.  
 
Two meta-analyses have reviewed evidence from existing surveys on awareness, ever 
EC use and current EC use. One meta-analysis included all surveys of adults with a 
sample size of at least 200 (133) which provided information on awareness, ever use, 
current use (last 30 day use) or relative harm perceptions. In 28 studies published 
between 2009 and 2014, they found a pooled awareness of EC of 61.2%, ever use of 
16.8% and past 30-day use of 11.1%. In line with findings from GB, figures differed by 
smoking status; ever use was 27.2% among current smokers and 2.5% among never 
smokers; past 30 day use was 16.8% for current smokers and 1.2% for never smokers. 
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A similar meta-analysis of data from 26 surveys published between 2011 and 2015 also 
found that current smokers were far more likely to use EC than non-smokers (adults: 
OR=14.7, 95% CI: 11.0 to 19.5) (134). These findings need to be interpreted in the light 
of some limitations. The included studies often did not survey a representative sample 
of the population, some restricted sampling to those with a specific smoking status 
(excluding never smokers which increases prevalence estimates) or even exclusively 
EC users. Although studies were from a range of countries, the majority was conducted 
in the US and as detailed elsewhere, past 30 day use overestimates actual use (for a 
discussion on this measure see Amato, Boyle and colleagues 2016, and Pearson, 
Hitchman and colleagues 2017 (135, 136)). 
 
Other data from European countries 
Peer-reviewed publications using the Eurobarometer survey (see Chapter 2 for details) 
published recently used 2012 and 2014 survey data (137-140). Data from the most 
recent Eurobarometer 2017 are available in a report (141). Across the 28 EU countries, 
15% of those aged 15 and over have ever tried EC, including 2% who reported current 
EC use (decimal places not reported), which is unchanged since the previous survey in 
2014. Current EC use ranges from 0% in Bulgaria, Croatia, Italy, Romania, Slovakia 
and Sweden to 5% in the UK. Similar to the UK, EC use remains concentrated among 
current and former smokers; overall, 4% of current smokers are current users, ranging 
from 0% (Bulgaria, Croatia, Hungary, Italy and Sweden) to 8% in the UK. Also, 4% of 
ex-smokers are current EC users with a range from 0% (Latvia, Lithuania, Luxembourg, 
Slovakia and Spain) to 14% in the UK. Among never-smokers, EC use is very rare. 
Across the EU, EC use is 0% among never-smokers and only in 5 countries is any use 
among never-smokers reported (all 1%, Austria, Belgium, Cyprus, Estonia and UK). In 
the EU, among those who use EC (base n=565), 67% use them daily, which translates 
to 1% of the EU population being daily EC users. The most popular flavours among 
current users were fruit flavours (47%), followed by tobacco (36%) and menthol/mint 
(22%). The most frequently mentioned reason for taking up EC was to stop or reduce 
tobacco consumption (61%). All other reasons were cited only by a minority; 31% said 
that they started using EC because they saw them as less harmful, and 25% cited the 
lower cost of EC (141).  
 
A very small number of other representative surveys assessing EC use in European 
countries has been published; their findings are presented alongside the figures from 
the Eurobarometer for the country where applicable. A survey of people over the age of 
14 living in Germany in 2016 reported weighted percentages of 11.8% for ever EC use 
and 1.4% for current EC use (142), broadly in line with the 14% and 2% reported by the 
Eurobarometer. EC had ever been used by 32.7% of ever smokers and 2.3% of never 
smokers; 4.3% and 0.1% respectively reported current EC use (compared with 
Eurobarometer 6% and 0%). A 2014 survey of a representative sample of 1,016 
respondents aged 16 and over in Spain (143) found 10.3% ever use, including 2.0% 
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current use (compared with Eurobarometer 12% and 1%). Current EC use was 1.2% 
for never smokers, 1.1% among ex-smokers and 4.8% among current smokers 
(compared with Eurobarometer 0%, 0% and 2%). In Serbian adults aged 18 and over in 
2014, ever EC use was reported as 9.5% and current use at 2.0%. As usual, the 
majority of current EC users were current or past cigarette smokers; there were no 
current EC users among never smokers in Serbia (0.0%, (144).  
 
North America  
US population information on current EC use in the recent peer-reviewed literature 
have been collected by the Population Assessment of Tobacco and Health (PATH) in 
2013/14 and the National Health Interview Survey in 2014. Current EC use among 
adults was 5.5% in the PATH (n=32320) (145, 146), 3.7% in the National Health 
Interview Survey 2014 (n=36697) (147) and 3.5% in the National Health Interview 
Survey 2015 (148). Daily EC use was reported by 1.2% in the PATH and 1.1% in the 
National Health Interview Survey 2014. Some surveys also report the less accurate 
measure of past 30 day use (see above and (130, 135, 136)). A consumer-based 
survey in 2014 (n=4269) reported past 30 day EC use of 4.8% (149), PATH found 6.7% 
(146) and another 2014 survey found 4.9% (150).  
 
Delnevo and colleagues broke down EC use in the National Health Interview Survey 
data by smoking status, separating current daily smokers (16.2% EC use), non-daily 
smokers (14.9% EC use), recent quitters who had quit in the last year (18.0% EC use), 
ex-smokers who had quit smoking 2 or 3 years ago (10.3% EC use), ex-smokers who 
had quit at least 4 years ago (0.8% EC use) and never smokers (0.4% EC use), 
demonstrating that use was extremely low among never smokers as well as long-term 
ex-smokers (147).  
 
Among Canadians aged 15 and over, in 2013, 1.8% had used EC in the past 30 days; 
among current smokers, this was 9.6%, compared with 0.9% among ex-smokers and 
0.3% among never-smokers (151). 
 
Other countries  
A handful of surveys for countries outside Europe and North America was identified. In 
a representative sample of 26021 respondents aged 15 and over in Taiwan in 2015, 
2.7% reported ever EC use; this was 14.2% among smokers, 3.2% among ex-smokers 
and 0.8% among never smokers. Current EC use was not assessed (152). A small 
survey of respondents aged 15 to 65 in Hong Kong 2014 reported a weighted 
prevalence of 2.3% for ever EC use (11.8% among smokers, 4.3% among ex-smokers 
and 1.0% among never smokers; n=809). Again, current EC use was not assessed 
(153). Among adults in the Republic of Korea, the 2013 weighted prevalence of ever 
and current EC use were 6.6% and 1.1 %, respectively (n=5338). Current EC use was 
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reported by 21.8% of current smokers, 4.8% of ex-smokers and 0.7% of never smokers 
(154). One survey conducted among those aged 15 and over in Japan in 2015 has 
been published (155). It collapses use of EC and heated tobacco products and reports 
6.6% ever use and 1.3% past 30 day use (weighted) which was 4.4% among smokers, 
1.7% among ex-smokers and 0.3% among never smokers.  
 
In New Zealand in 2014, a survey of 2594 respondents aged 15 and over reported 
weighted prevalence of 13.1% for ever EC use and 0.8% for current EC use. At 4%, 
current smokers reported the highest rate of current EC use (0.1% for ex-smokers and 
never-smokers) (156).  
 
The International Tobacco Control (ITC) project measures current EC use among 
smokers and recent quitters in a large number of countries, however, published data 
date from 2009 to 2013 (157, 158); these data are currently being updated and will be 
published in Spring 2018. This will, for the first time, provide population-level 
information on EC use in lower or middle income countries.  
 
Conclusions 
Key findings 
Prevalence 
• In GB, prevalence of EC use in adults has plateaued at approximately 6% of the 
adult population.  
• EC use among never smokers in GB remains very rare at less than 1%, similar to 
the level of use of NRT. Among never smokers who have ever used EC, a minority 
have used nicotine-containing liquids and the vast majority have not progressed to 
regular use.  
• Prevalence of EC use and trial among smokers has plateaued while use and trial 
among ex-smokers continue to increase. 
• Socioeconomic differences in EC use by smokers and recent ex-smokers have 
become smaller with no clear gradient in prevalence by occupational grade.  
• Prevalence of dual use (use and smoking) is similar for EC users and NRT users. 
 
Characteristics of use 
• Most EC trial does not become regular use. 
• Most current EC users use daily and have used EC for more than six months. 
• Models with refillable tanks for liquids are the most widely used type. 
• Since May 2017, nicotine concentration in liquids has been limited to a maximum of 
20mg/mL. In March 2017, around 6% of EC users reported using higher nicotine 
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concentrations; substantial proportions had difficulties reporting these figures so 
more may have been affected by the limit.  
• The most popular groups of flavours among current EC users are fruit (29%), 
tobacco (27%) and menthol/mint (25%). 
• Specialist vape shops (physical premises rather than online) are the most popular 
place of purchase (>40%). 
• The most common reason for EC use continues to be in order to stop smoking, and 
smokers who use EC on average have higher motivation to stop smoking than other 
smokers.  
 
International 
• Data can be outdated by the time of publication.  
• Prevalence of current use in GB is at the higher end for countries in the EU where 
the average is 2% for current EC use. Prevalence estimates for current EC use in 
the US are around 4% to 6%, which is similar to GB.  
• Across international surveys, a consistently low prevalence (<1%) of EC use has 
been reported among never-smokers; one exception is one Spanish survey at 1.2%.  
• Prevalence figures found for smokers and ex-smokers vary more widely across 
surveys in different countries (4% to 22% among smokers and 0.1% to 5% among 
ex-smokers) .  
 
Implications  
Research 
• As recommended in the 2015 PHE report, trends in EC use among adults should 
continue to be monitored using standardised definitions of use. Measures should 
include frequency and type of device used including different types of tank models. 
• EC use among ex-smokers needs monitoring and further evidence to understand 
when and why they take up EC use and whether this is associated with an increase 
or decrease of relapse to smoking.  
• More research is needed into different patterns of EC use while smoking and their 
effect on subsequent smoking behaviour to understand how best to move dual 
users to stop smoking. 
• More research is needed on the impact of EC on health and economic inequalities 
associated with smoking, in particular on use of EC in disadvantaged groups with 
high smoking prevalence and smoking-related morbidity and mortality, such as 
those with mental health problems or offenders. Data that have been gathered from 
the Adult Psychiatric Morbidity Survey in England should be released for analysis. 
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Policy and practice 
• As recommended in 2015 and as per existing National Institute for Health and Care 
Excellence (NICE) guidance, all smokers should be supported to stop smoking 
completely, including ‘dual users’ who smoke and use EC. 
• Access to EC should be improved for smokers in disadvantaged groups. 
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7  The effect of EC use on smoking 
cessation and reduction 
Introduction 
The objective of this chapter is to provide an overview of available data about the effect 
of EC on smoking cessation and reduction in England. First, we provide smoking 
cessation data from the Smoking Toolkit Study (a repeated monthly series of national 
household surveys of representative samples of approximately 1800 adults aged 16 
and above on smoking) followed by details of EC use for smoking cessation and 
estimates of long-term quitters resulting from EC use. This is followed by an 
examination of the use of EC in treatment settings using data from English Stop 
Smoking Services. We then examine the use of EC on smoking cessation and 
reduction from systematic reviews of Randomised Controlled Trials (RCTs) and 
observational studies. We comment on comparable data in vulnerable groups where 
this exists.  
 
Smoking cessation rates in England  
The effect of EC on smoking cessation needs to be viewed within the context of overall 
smoking prevalence and cessation rates. As identified in the introduction, the official 
estimate of smoking prevalence has declined to 15.5% in 2016. 
 
Figure 19 and Figure 20 present the proportion of people who tried to quit and were 
successful (defined as those who tried to stop in the preceding 12 months and 
reporting still not-smoking at time of the survey) between January 2007 and December 
2017, using data from the Smoking Toolkit Study (STS). The proportion of people who 
reported trying to quit smoking declined annually between 2007 and 2011 and has 
been variable for the past six years. 
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Figure 19: Proportion of people who tried to stop smoking in past year 
 
Base: Adults (age 16+) who smoked in the past year. Graph shows prevalence estimate, upper and lower 95% confidence 
intervals. From: http://www.smokinginengland.info/latest-statistics/ accessed 12/01/2018 
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Figure 20: Success rate for stopping in those who tried to quit 
 
Base: Adults (age 16+) who smoked in the past year. Graph shows prevalence estimate, upper and lower 95% confidence 
intervals. From: http://www.smokinginengland.info/latest-statistics/ accessed 12/01/2018 
 
In a report which examined quit success rates from 2007 to 2017, Brown and West 
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Use of EC for smoking cessation in England 
The 2015 PHE report on EC (5) stated that since 2013, EC had been the most common 
quitting aid for smokers in England. The most recent data from the STS suggest this is 
still the case (Figure 21) although overall, the use of EC for quitting has plateaued 
since 2015. The popularity of EC as a quitting aid appeared to peak in the last quarter 
of 2016 when 40.6% of participants in the STS samples reported using an EC to quit 
smoking compared to 14.7% who used NRT bought over the counter from a shop 
(OTC) or on prescription (2.8%) and 4.7% who used varenicline. In the most recent 
STS findings (the last quarter of 2017), 38.2% of people reported they used an EC in 
their recent quit attempt compared with 18% who reporting using NRT OTC, or on 
prescription (1.6%) and 2.8% who used varenicline (Figure 21). From a visual 
inspection of the graph in Figure 21 the changes in use of EC and NRT OTC appear to 
be almost a mirror image of each other in that as EC use changes it is accompanied by 
a commensurate change in the use of NRT OTC. We discuss the issue of EC 
cannibalising the licensed NRT market later in the chapter.  
 
Figure 21: Support used in most recent quit attempts 
 
 
N=13,456 adults (age 16+) who smoke and tried to stop or who stopped in the past year; method is coded as any (not 
exclusive) use From: http://www.smokinginengland.info/latest-statistics/ accessed 12/01/2018 
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How EC might help smokers stop smoking 
 
Figure 22 below shows how EC use might in theory help a smoker to stop smoking. 
The most obvious way is through use of an EC in a gradual or abrupt quit attempt. A 
second possibility is that a smoker who is not currently planning to stop tries an EC, 
perhaps out of curiosity or as an alternative to smoking in smoke-free settings and goes 
on to stop smoking without making a conscious decision to do so. Such smokers might 
not classify themselves as having made a ‘quit attempt’. A third route is by preventing 
relapse to smoking in someone who has already stopped. In this scenario, a smoker 
who stopped smoking with or without the use of EC, may subsequently use an EC in a 
way that prevents relapse to smoking.  
 
There are also ways that EC might also hinder quitting, such as if the dual use of 
tobacco cigarettes and EC prevents people from quitting because they feel reassured 
they are reducing tobacco related harm and are less motivated to quit. However, as 
discussed in chapter 6, a recent study found that current dual users were significantly 
more likely to be motivated to stop smoking in the next three months than those who 
had used EC in the past, whose motivation was similar to those who had never tried 
EC (14). Quitting may also be hindered if smokers who also use an EC find quitting 
harder.  
 
Finally, successful quitters may try vaping and then, as a result, relapse to smoking. 
These routes are also included in Figure 22. Note that these are all theoretical impacts 
of using EC on quitting; what happens in practice needs to be examined empirically to 
establish a better of understanding about causal pathways. As there are no data yet on 
EC hindering quitting in England, they are not considered further here, but included in  
Figure 22. The assumptions underpinning estimates of additional quitters due to EC are 
discussed later in this chapter.  
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Figure 22: How EC might impact on stopping smoking 
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Estimates of the impact of EC use on the number of long-term quitters 
West and colleagues (160) and Beard and colleagues (161) have estimated the 
number of long-term additional quitters in England resulting from the use of EC in quit 
attempts, using Smoking Toolkit Study (STS) data and two different methods. Although 
their estimates are for 2014 and 2015, we include these studies here as they were 
published after the 2015 PHE report. Beard and colleagues (161) also assessed the 
temporal association between prevalence of current use of EC in smokers and recent 
ex-smokers (ie not necessarily within a quit attempt) on prevalence of quit attempts and 
success.  
 
2014 estimate 
West and colleagues (160) used an indirect method to estimate the number of 
additional long-term quitters generated by EC in 2014. In summary, using their STS 
data for 2014, they estimated:  
 
1) A total of 891,000 smokers had used an EC to stop smoking (37.3% of all last year 
smokers had tried to stop at least once, 28.2% of whom used an EC without other 
support). 
 
2) The one year (long-term) success rate of such quit attempts was 7.5% (50% more 
than the 5% estimated success rates for those without help or using a licensed nicotine 
product purchased OTC) (162) which would result in ~67,000 smokers successfully 
stopping. 
 
3) As STS has identified no consistent changes in the proportion of smokers trying to 
quit that could be confidently attributable to EC use, they assumed that all these 
smokers would have made quit attempts even in the absence of EC. If these ~67,000 
smokers had used no support/licensed nicotine OTC then 5% (ie two-thirds) would 
have stopped smoking leaving a residual 2.5% (~22,000) who additionally stopped 
because of EC. This gives their upper estimate of ~22,000 additional long-term 
quits in 2014 caused by EC.  
 
4) For the lower bound estimate, they further assumed that EC was contributing to the 
decline in the use of prescription medications over time (which they estimated to be a 
decline of approximately 10% since EC started to become popular). They estimated 
that the decline in use of prescription medicines was approximately 10% of quit 
attempts (3.7% smokers in 2014, 313,000 smokers) and that an upper estimate for the 
contribution of EC to that decline was 80%, thus representing 250,000 smokers.  
 
5) Thus they estimated that if EC had detracted from these methods of stopping, then 
of the initial 891k smokers using EC to quit, this would have resulted only in 641,000 
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additional smokers making quit attempts using EC, with an estimated success rate of 
2.5% over and above had smokers used no support/licensed nicotine OTC, giving 
~16,000 additional long-term quits in 2014, their lower estimate.  
 
Contribution of EC to stopping smoking using time series analysis and 2015 estimate 
The second study (161) used time series analyses of population trends to estimate 
more directly how population-level EC use had been associated with changes in quit 
attempts, quit success, and use of other support in quit attempts between 2006 and 
2015 using STS data and data from people setting a quit date with English Stop 
Smoking Services.  
 
In the discussion section of the paper, the authors estimated the number of additional 
long term quitters due to EC use in 2015. This study also allowed an assessment of the 
assumptions made in West and colleagues (160) described above. To control for 
possible changes in use of stop smoking support, a range of potential confounders 
were included in their analysis such as advertising expenditure and the introduction of 
several tobacco control policies. The prevalence of quit attempts and quit success was 
predicted from current smokers’ prevalence of EC use and prevalence of EC use 
during a quit attempt.  
 
Between 2006 and 2015, data was collected on 170,490 participants aged 16 years in 
the Smoking Toolkit Study. Of these, 41,301 were past year smokers and 37,765 were 
current smokers. The proportion who reported a quit attempt increased and then 
decreased overall changing from 45.4% at the start of the study to 31.2% in the last 
quarter of the study. There was an overall increase in the success rate of those who 
reported a quit attempt (from 10.6% in the last quarter of 2006 to 18.6% in the first 
quarter of 2015). Over the same period, current use of EC among smokers increased 
from negligible use in the last quarter of 2006 to 21.3% at the end of the study, and EC 
use in a quit attempt also rose from negligible use in the last quarter of 2006 to 35.0% 
in the first quarter of 2015. 
 
The data did not show clear evidence of an association between prevalence of use of 
EC by smokers and attempts to quit smoking (supporting the assumption 3 discussed 
above (160)). However, the increase in prevalence of EC use by smokers was 
positively associated with the success rates of quit attempts and the association 
remained after adjustment for a range of confounding variables (161); for every 
percentage point increase in prevalence of EC use by smokers, the success rate of quit 
attempts increased by 0.098 percentage points. EC use in quit attempts was also 
positively associated with quit success, with every percentage point rise in prevalence 
of EC use in quit attempts associated with a 0.058 percentage point increase in the 
success of attempts.  
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The authors focused on the latter finding (that a one percentage point increase in EC 
use in quit attempts was associated with a 0.058 percentage point increase in quit 
successes) as this was likely to reflect a causal link and be a fairer point estimate. 
Using this finding, they estimated the impact on long-term quits as follows: 32.5% of 8m 
smokers (2.6m) made a quit attempt in 2015 and prevalence of EC use in quit attempts 
was 36%; this leads to 54,288 additional short to medium term (<1 year) quitters in 
2015 compared with no use of EC in quit attempts. Assuming a 66% subsequent 
relapse rate, they estimated that EC may have contributed about 18,000 additional 
long-term ex-smokers in 2015 (a figure similar to the 2014 estimates). 
 
Assumptions in quit estimates 
The similarity in the estimates from West and colleagues (160) and Beard and 
colleagues (161) using different methods is reassuring. However, they both still rely on 
certain assumptions. Below, we discuss how the estimate might vary if key parameters 
were changed and then recalculated the estimates varying two parameters for 2014 
and 2016 STS data.  
 
Cannibalisation of other quit methods 
An earlier study using Smoking Toolkit Study data suggested EC were not 
cannibalising the licensed NRT market (for smoking reduction, not quitting) (163). The 
more recent study described above (161) found no significant associations between EC 
use in quit attempts and the use of stop smoking services, NRT, OTC and prescription 
treatment overall. However, a significant association between EC use in quit attempts 
and the use of NRT on prescription was observed (for every percentage point increase 
in EC use in quit attempts, there would be a 0.098 percentage point decline in NRT use 
on prescription). During the study the mean proportion of quit attempts including NRT 
on prescription was 8.9 (Standard Deviation (SD) 2.45). This suggests that the lower 
bound 2014 estimate of 16,000 (160) is probably too conservative as they had allowed 
for a higher level of cannibalisation of other support methods than observed in Beard 
and colleagues (161). In our estimates below (Table 13) we have therefore varied this 
assumption, from 80% to 20% of the 10% decline in use of other methods.  
 
Impact on relapse 
As noted above, it is possible that using an EC in a quit attempt might result in a 
different relapse trajectory from the use of the other stop smoking support. This would 
affect the above estimates of long-term quitting, which would be larger if there is less 
relapse with EC, or smaller if there is more relapse with EC. Additionally, if some ex-
smokers became EC users in order to prevent relapse (and this had worked), this 
would have resulted in the estimate for additional long-term quitters due to EC, being 
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an underestimate. As we are not aware of any data on this issue (and there is a need 
for research here), we have not altered this assumption below.  
 
Success rates of quit attempts involving EC 
This may now be higher than the 50% increase from 5% cited by West and colleagues, 
(160). The estimated 50% increase in success rates over and above no 
support/licensed nicotine OTC due to EC in quit attempts, derives from a previous 
study by the authors using the Smoking Toolkit Study data (162) when the type of 
products on the market were somewhat different, with fewer tank models being used 
(see Chapter 6 and ASH data and see below). We have recently replicated this study 
using a different dataset (ICGBS) which was presented at a conference, and therefore 
not yet peer reviewed (164). We aggregated data from the 2013, 2014 and 2016 waves 
to study the impact of using two different types of EC in quit attempts: non-tank 
(disposable or rechargeable model refillable with pre-filled cartridges) vs tank 
(rechargeable device with a tank that can be refilled with liquids or modular EC). The 
outcome was participant’s self-reported smoking status at time of survey, regardless of 
length of abstinence. Participants stating that they had stopped smoking completely in 
the last year/since the last survey were classified as quit. A range of covariates 
(strength and frequency of urges to smoke, number of recent quit attempts, time since 
last quit attempt started, abrupt of reduction quit method, sex, age, social grade, survey 
year) were controlled for. Quit success rates were 31.2% for self-help/no help, 19.9% 
for non-tank EC, 38.0% for tank EC and 21.7% for licensed nicotine products OTC. In 
the fully adjusted analyses, using tank models increased the odds of quitting 2.19 times 
(OR 2.19 (1.50,3.19) compared with self-help/no help. The overall impact when tank 
and non-tank EC were combined was also significantly higher (OR 1.59, (1.19,2.13)) 
than self-help/no help. 
 
The findings are in line with an earlier study using the ICGBS (20) which suggested that 
tank models were more effective than other EC as quit smoking aids. As approximately 
70% of EC use involves tank models in 2017 (see Chapter 6), it is likely that the 
estimates of quitters generated by EC in more recent years would now be higher than 
the West and colleagues (160), and Beard and colleagues (161), estimates.  
 
In our estimates below (Table 13) we have therefore varied the success rate over and 
above no help/licensed nicotine product from 50% to 100%, to estimate what impact 
that would have on the estimated number of smokers who have quit as a result of EC.  
 
Updated quit rates based on STS 2016 data and varied parameters 
As discussed above, we have recalculated the West and colleagues (160) indirect 
analysis varying two parameters: the success rate over and above no help/licensed 
nicotine product use (from 50% to 100%) and the percentage contribution of EC to the 
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decline in use of existing therapies (from 80% to 20%); we have then replicated the 
original and adjusted estimates using the 2016 STS data. The resulting figures are 
shown in Table 13 below, with the original estimates shaded grey. 
 
Table 13 shows that varying the two parameters for 2014 gave the lowest estimate as 
~21,000, and the highest estimate ~44,000). Using the same parameters as West and 
colleagues, 2014, for the 2016 year gave a lower estimate of ~22,000 and higher 
estimate ~29,000). Varying the two parameters for 2016, gave the lowest estimate as 
~27,000 and the highest estimate ~57,000. 
 
Table 13: Estimates for the additional contribution of EC to long term quitters for 2014 
and 2016 using STS data (original estimates highlighted) 
 
   2014 2016 
   Estimated success rate for EC 
above that of no help/licensed 
nicotine product 
   50% 100% 50% 100% 
% contribution of 
EC to 10% 
decline in use of 
existing 
therapies 
Upper 
estimate 
0 22,245 44,489 28,662 57,324 
Lower 
estimate 
80 15,934 31,868 22,275 44,550 
Upper 
estimate 
0 22,245 44,489 28,662 57,324 
Lower 
estimate 
20 20,667 41,334 27,065 54,131 
 
It should be noted that we have not changed the assumption that in the absence of EC, 
the smokers trying to quit using EC would have tried to quit anyway. This is because 
there is no evidence of a consistent change in quit attempts due to the advent of EC 
and therefore it is not possible to attribute, with any confidence, a proportion of quit 
attempts that would not have happened in the absence of EC. Finally, as noted above, 
there are other routes to quitting smoking other than through traditional quit attempts, 
which have not been modelled.  
 
Summary 
Quit success rates in England are at the highest rates so far observed and for the first 
time, parity across different socioeconomic groups is observed. It is plausible that EC 
are contributing to this. Recent estimates of additional quitters resulting from the 
availability of EC, using the same dataset but two different methods, resulted in similar 
figures within the range of 18,000-22,000. Varying the assumptions, and updating 
these estimates for 2016, resulted in an upper bound estimate of around 57,000 
additional quitters annually resulting from EC. While caution is needed with these 
figures, the evidence suggests that EC have contributed tens of thousands of additional 
113 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
quitters in England annually. Insofar that success rates with EC have increased, then 
an updated time-series analysis including data from 2016 and 2017 may find a larger 
association between the use of EC and quit attempts, which may lead to larger 
estimates in the time since 2015.  
 
EC use in English Stop Smoking Services  
Local authorities were given responsibility for public health by the Health and Social 
Care Act 2012. This transfer of functions was funded through a ring-fenced grant. The 
grant is used to commission a variety of services, including Stop Smoking Services. 
Stop Smoking Services offer smoking cessation support which involves the use of 
pharmacotherapies (NRT, varenicline, EC, bupropion, in combination or alone) and/or 
behavioural support. Data are collected from local authorities every three months about 
the number of treated smokers in each service, the number who successfully quit at 4 
weeks (self-reported and carbon-monoxide (CO) verified) and key measures of the 
service including intervention type, intervention setting and type of pharmacotherapy 
received. A treated smoker is defined according to the Russell Clinical Standard (a 
clinical version of the Russell Standard for outcomes assessment in smoking cessation 
clinical trials) (165); a smoker who has at least one treatment session and sets a quit 
date is counted as a treated smoker, whereas a smoker who attends one treatment 
session but fails to attend future session is not counted in the data. A smoker is 
counted as a 'self-reported four-week quitter if they are assessed (face to face or by 
telephone) four weeks after the designated quit date (minus three days or plus 14 days) 
and declares that they have not smoked even a single puff on a cigarette in the past 
two weeks. A smoker is counted as a CO-verified four-week quitter if they are a self-
reported four-week quitter and his/her expired-air CO is assessed four weeks after the 
designated quit date (minus three days or plus 14 days) and found to be less than 
10ppm. Treated smokers lost to follow up (cannot be contacted for the four week follow 
up assessment) are counted as non-quitters. Since 2014, Stop Smoking Services have 
been asked to record if an EC was used in a quit attempt, either alone or in 
combination with a licensed medication. These data are naturalistic and do not allow us 
to control for things like the severity of tobacco dependence known to influence 
success rates or if the Stop Smoking Service was supportive of EC use. It is also 
possible that that the people using EC alone or in combination with licensed stop 
smoking medicines may differ from the rest of the smokers quitting with these services. 
However, these data provide valuable information about the use of EC within Stop 
Smoking Services and their contribution to quit success.  
 
Between April 2015 and March 2017, 690,007 set a quit date and 51% were self-
reported quitters at four-week follow up (37% were CO validated quitters). In 2016/17, 
the number of people setting a quit date with a Stop Smoking Service and the number 
of successful self-reported quitters fell for the fifth consecutive year (though the self-
reported quit rate has remained relatively stable at 51-52% in recent years).  
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In both 2015-16 and 2016-17, the highest number of quit attempts involved 
combination NRT, though the highest quit rate was in people who used a licensed 
medicine and an EC consecutively. The number of treated smokers using each type of 
support and the quit rates between April 2015 and March 2017 are presented in Figure 
23. These data suggest that smokers who are treated by a Stop Smoking service with 
behavioural support and use EC with or without additional licensed medication, have 
comparable quit success to smokers using a licenced medication.  
 
Figure 23: Self-reported four-week successful quitters by pharmacotherapy type (2015-
2017) 
 
Notes: Data for all age groups 
 
EC use by region 
EC use as part of quit attempt varies by region (Figure 24). In 2015-16, Yorkshire and 
the Humber reported that 1.6% of the people who set a quit date with their services 
used an EC as part of their quit attempt compared to 5.4% in the East Midlands. In 
2016-17, the North East region reported that 2.4% of the people who set a quit date 
with their services used an EC as part of their quit attempt compared to 6.8% in the 
East Midlands. 
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Figure 24: Proportion who used an EC relative to other type of pharmacotherapy* by 
region 
 
 
Notes: * EC use includes people who had used EC either alone or in combination with licenced medication concurrently or 
consecutively. Other type of pharmacotherapy excludes EC use, unknown use and people recorded as no medication used  
 
Similarly, quit rates vary between regions (Figure 25). For context, Figure 26 gives 
overall success rates by region for the same time period, although a range of factors 
will be influencing these success rates. In 2015-16, 45% of people in the North East 
region who used an EC as part of their quit attempt successfully quit (self-reported) 
compared to 70% in the East of England. In 2016-17, 49% of people in the South West 
region who used an EC as part of their quit attempt successfully quit (self-reported) 
compared to 68% in London. 
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Figure 25: Self-reported four-week successful quitters using an EC by region 
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Figure 26: Self-reported four-week successful quitters by region (2015-2017) 
 
In recent years there has been a reduction in the availability and use of Stop Smoking 
Services. In an annual Survey of Tobacco Control Leads in English local authorities 
conducted in June 2016, ASH reported that 59% of local authorities have cut their 
smoking cessation budgets, largely in response to the cut in the national public health 
grant and the wider cost pressures on local authority budgets (166). One in twenty local 
authorities no longer have a Stop Smoking Service beyond that offered by GPs and 
pharmacists and in 20% of Authorities, the Specialist Stop Smoking Service has been 
replaced by an integrated ‘lifestyle’ service of some kind. Without a specialist component, 
these services can be expected to be less effective in helping smokers quit.  
 
Stop Smoking Services increase the chances of a successful quit attempt up to four-
fold (167) and should be available to all smokers. As discussed above, the combination 
of EC with support from Stop Smoking Services is likely to optimise chances of 
stopping smoking when using an EC. Hence, all services should offer support to 
smokers wishing to use an EC to stop smoking. However, not all Stop Smoking Service 
practitioners are supportive of providing help to smokers wishing to use EC. In an 
online survey of 1,801 Stop Smoking Service practitioners and managers, (168) 
reported that less than 5% would recommend EC to all their clients.  
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It seems reasonable to propose that combining the most popular source of support 
(EC) used by smokers in the general population (identified from the STS data), with the 
most effective (Stop Smoking Service support), should be a recommended option 
available to all smokers.  
 
Summary  
EC use alone or in combination with licensed medication and behavioural support from 
a Stop Smoking Service, appear to be helpful in the short term. However, fewer 
smokers use an EC as part of a quit attempt with a Stop Smoking Service compared 
with licensed medication. If ECs are contributing to higher success rates, Stop Smoking 
Services in England may be missing an opportunity to maximise cessation outcomes 
for smokers who use their service. 
 
Randomised controlled trials of EC use for smoking cessation or reduction 
(published since the last report)  
Our literature search identified one RCT published since our previous report. Tseng 
and colleagues (169) compared the efficacy of a nicotine containing EC with a placebo 
EC on smoking reduction. Participants were daily smokers aged 21-35 who were not 
ready to quit smoking. They were randomised to receive either a disposable 4.5% 
nicotine EC (n=50) or a placebo EC (n=49) for three weeks. Participants in both groups 
were also given brief behavioural support about how to reduce their cigarette intake but 
minimal instructions on EC use. The main outcome was self- reported smoking 
reduction of at least 50% in the number of cigarettes smoked per day (CPD), three 
weeks after the start of the intervention. Both groups achieved significant reductions in 
overall number of cigarettes smoked per day. Compared with baseline, a significant 
reduction in CPD was observed at both study time periods (1 and 3 weeks) for the 
group who received the nicotine EC (from an average of 14 CPD to 6 CPD, p< .001) 
and the placebo EC (from an average of 15 CPD to 8 CPD, p< .001). The participants 
in the nicotine EC group were more likely to reduce by 50% or more at end of 
treatment, only after adjusting for EC consumption and baseline readiness to quit. The 
authors acknowledge that the study sample size was small and was underpowered to 
detect the small-moderate effect size observed in smoking reduction at the end-of-
intervention, the intervention was brief and follow up period modest.  
 
Overview of systematic reviews of EC use for smoking cessation or reduction  
We identified 14 systematic reviews of EC for smoking cessation and /or reduction 
published since our last report; seven included a meta-analysis (170-176) and seven 
provided only a narrative synthesis (73, 177-181). The characteristics of the systematic 
reviews which included a meta-analysis are described in Table 14 and their primary 
studies in the Appendix. 
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 Table 14: Characteristics of systematic reviews including a meta-analysis 
Authors & 
funder 
Date 
searche
d up to 
Participants 1] Interventions  
2] Comparators 
Outcomes and 
length of follow 
up  
No of 
studies 
included in 
each review 
Method of 
synthesis 
 
Tools used 
for  
1] Risk of 
bias 
2] Certainty of 
evidence 
Rahman, 
2015(175) 
Funder: No 
external funding 
5/2014 
 
Current smokers 
who had used 
an EC for 6 
months or more 
1] Nicotine EC 
2] Placebo EC 
2] NRT 
2] No intervention  
Self-reported or CO 
validated cessation at 
any follow up  
RCT: 2 
Uncontrolled 
intervention: 1 
Observational 
(longitudinal or 
cross 
sectional):3  
Pooled RR for 2 
RCTs using a Mantel-
Haenszel fixed effects 
model. Pooled ES for 
all included studies.  
 
1] van Tulder 
Scale (182)  
1] Downs and 
Black Scale (183) 
 
Hartmann - 
Boyce, 
2016(171) 
Funder: 
Cochrane 
Collaboration  
 
 
31/1/16 Current cigarette 
smokers at 
enrolment into 
studies, 
motivated or 
unmotivated to 
quit 
1] Nicotine EC.  
2] Placebo EC.  
2] Alternative smoking 
cessation aids, including 
NRT  
2] No intervention. 
1] EC added to standard 
treatment (behavioural 
orpharmacological or both)  
2] Standard treatment alone 
CO validated 
cessation at the 
longest follow-up 
point, (at least 6 
months from the start 
of intervention) 
 
 
RCT: 3  
Uncontrolled 
intervention: 6 
Observational 
(longitudinal or 
cross 
sectional):8 
Pooled RR for 2 
RCTs using a fixed-
effect Mantel-
Haenszel model. 
Other designs: 
narrative synthesis  
 
1] Cochrane Risk 
of Bias tool (184) 
2] GRADE (185) 
 
Khoudigian, 
2016(173) 
Funder: No 
external funding 
reported 
26/5/14 Current cigarette 
smokers 
intending/not 
intending to quit  
1] Nicotine EC 
2] Placebo EC 
2] NRT 
Self-reported or CO 
validated cessation 
and reduction in 
number of cigarettes 
smoked per day at 
least 6 months follow 
up 
RCT: 2  
Various other 
designs: 3  
Pooled RR or 2 RCTs 
using a random-
effects Mantel-
Haenszel model 
 1] Cochrane 
Collaboration’s 
Risk of Bias Tool 
(184) 
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 Vanderkam, 
2016(176) 
Funder: No 
external funding 
reported 
14/6/15 Current smokers  1] Nicotine EC 
2] Placebo EC 
Self-report or CO 
verified cessation and 
reduction on cigarette 
intake of at least 
50% at 3 months or 
longer follow-u 
RCT: 2  
Uncontrolled 
intervention:3 
Observational 
(longitudinal/ 
cross sectional): 
9 
Pooled RR for 2 
RCTs using a 
random-effects 
Mantel-Haenszel 
model. 
Other designs: 
narrative synthesis 
1] Cochrane Risk 
of Bias Tool (184) 
 
 
Kalkhoran and 
Glantz, 
2016(172) 
Funders: 
National 
Institutes of 
Health, National 
Cancer Institute, 
FDA Center for 
Tobacco 
Products 
17/6/15 
 
Current or past 
cigarette 
smokers 
intending/not 
intending to quit 
1] EC use. including any past 
30-day use, ever use 
2] People who have not used 
an EC  
Self-reported and/or 
biochemically-
validated cessation at 
any duration of follow 
up  
 
RCT: 1 
Various other 
designs: 37 
 
Pooled OR for 20 
studies (various study 
designs)  
1] Cochrane Risk 
of Bias Tool (184) 
1] Modified 
ACROBAT-NRSI 
Tool (186)  
Malas, 
2016(174) 
Funder: Ministry 
of Health and 
Long-Term Care 
(Health System 
Research Fund, 
Canada) 
1/2/16 Not reported  1] Nicotine EC 
2] Placebo EC 
2] NRT  
2] No intervention 
Self-reported and/or 
CO-validated 
cessation or reduction 
at any duration of 
follow up  
RCT: 2 
Observational 
(longitudinal/ 
cross sectional): 
9 
Pooled AORs by 
synthesising results 
of studies based on 
methodological 
quality using 
QualSyst tool 
1] QualSyst  
 
2]GRADE (185) 
El Dib, 
2017(170) 
Funder: WHO 
29/12/15 
 
“Cigarette 
smokers, 
regardless of 
whether the 
users were 
using them as 
part of a quit 
attempt” 
1] EC with or without nicotine  
2] No intervention  
2] Stop smoking medication 
and/or behavioural support 
2] Alternative EC with or 
without nicotine 
Self-report or CO 
verified cessation and 
reduction on cigarette 
intake of at least 
50% at 6 months or 
longer follow-up 
RCT:3 
Observational 
(longitudinal/ 
cross sectional): 
9 
 
Pooled RR for 2 
RCTs and pooled OR 
for observational 
studies using a  
random-effect Mantel-
Haenszel model 
1] Modified 
version of the 
Cochrane Risk of 
Bias tool (187) 
1] Modified 
Newcastle -
Ottawa Scale 
(188) 
2] GRADE (185)  
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The authors of the systematic reviews arrived at the same conclusion that further RCTs 
of EC are needed. However the reviews that included a meta-analysis produced 
different results; two found a positive effect (171, 175), four found an inconclusive effect 
(170, 173, 174, 176) and one found a negative effect (172) (Table 15). There appear to 
be several possible explanations for the discrepancies:  
 
Types of studies included in a meta-analysis: Four reviews conducted a meta-
analysis and/or sensitivity analysis that only included RCTs designed to evaluate the 
efficacy or effectiveness of an EC on cessation or reduction (171, 173, 175, 176); these 
studies are Bullen and colleagues, (189) and Caponnetto and colleagues (190) and 
were included in our previous report. The remainder of the reviews included studies 
within a meta-analysis (cross sectional and longitudinal studies) most of which were not 
specifically designed to test if EC resulted in cessation or reduction. Therefore one 
reason for the difference in findings across reviews is due to the inclusion of 
observational study designs, not specifically designed to test if EC resulted in 
cessation.  
 
Types of participants included in a meta-analysis: Some reviews synthesised 
results from primary studies that enrolled only current smokers to their studies (171, 
173, 175, 176); whereas other reviews included studies from a diverse range of 
participants, including current and ex-smokers, smokers who had ‘tried an EC’ but who 
continued to smoke. Studies which analyse results of smokers based on EC use at 
baseline by virtue of their design have already excluded people who have successfully 
stopped smoking using an EC. Such studies only keep patients in their study who are 
classed as treatment failures or who are in the middle of a quitting attempt where they 
may be cutting down to quit. Combining such diverse groups (with differing degrees of 
exposure to an EC) is likely to underestimate the effect of EC for cessation. 
Participants’ motive, frequency and duration of EC use is also likely to influence 
findings, and combining studies of infrequent, brief EC use with more intensive long 
term EC use may influence review results.  
 
Types of outcomes included in a meta-analysis: One of the main reasons for the 
differences between the results of the reviews relates to the length of follow up 
(whether review authors combined participants quit rates at 6 month or 12 month follow 
up) and how missing data was handled (on an intention to treat basis or complete case 
analysis). Two reviews reported cessation at the longest follow-up point from the start 
of the intervention (ie 6 months follow up for the Bullen and colleagues study and 12 
month follow up for Caponnetto and colleagues (190), measured on an intention- to-
treat basis (171, 175), two reviews reported consistent follow up points (at six months), 
also on an intention to treat basis (173, 176). The reason for the difference in the effect 
estimates between these four reviews related to the length of follow up: one participant 
in the Caponnetto control group (placebo EC) changed from being a non-quitter at six 
months follow up to a quitter at 12 months follow up (Table 16). 
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Table 15: Length of follow up of RCTs included in a meta-analysis 
 
Study and length of follow 
up  
Number who 
quit with a 
nicotine EC 
Total 
participants 
Number who 
quit with 
placebo EC 
Total 
participants in 
study 
Bullen, 2013(189): 6 months 21 289 3 73 
Caponnetto 2013(190): 6 
months  
22 200 3 100 
Caponnetto 2013(190): 12 
months 
22 200 4 100 
 
The difference between the findings of El-Dib and colleagues and the two reviews by 
Rahman and colleagues and Hartmann-Boyce and colleagues relates to how missing 
data was handled. El-Dib’s (170) complete cases analysis excluded 181 participants 
from the two RCTs whereas Rahman and colleagues (175) and Hartmann-Boyce and 
colleagues (171) included all randomised participants in an intention to treat analysis. 
In smoking cessation trials, it has been standard practice for several years that 
participants who do not complete follow up assessments or drop out of the trial early 
are counted as smokers. Therefore leaving them out of the analysis or filling in their 
missing data based on their last assessment (if they had quit), would lead to greater 
bias in efficacy comparisons (165). 
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Table 16: Results of systematic reviews that included a meta-analysis of cessation  
 
Characteristics Rahman, 
2015 (175) 
Hartmann-
Boyce, 2016 
(171) 
Khoudigian, 
2016 (173) 
Vanderkam, 
2016 (176) 
Kalkhoran & 
Glantz, 2016 
(172) 
Malas, 2016 
(174) 
El Dib, 2017 
(170) 
Studies 
synthesised, 
(length of follow 
up) 
Bullen, 
2013(189) (6 
months) 
Caponnetto, 
2013 (190) (12 
months). 
Bullen, 2013 (6 
months) 
Caponnetto, 
2013 (12 
months) 
Bullen, 2013 (6 
months) 
Caponnetto, 
2013 (6 months) 
 
Bullen 2013 (3 
months & 6 
months) 
Caponnetto, 
2013 (6 months) 
 
Combined 1 RCT 
(Bullen 2013) 
with 17 
longitudinal 
(interventional & 
non-
interventional) & 
3 cross sectional 
Combined 1 RCT 
(Adriaens, 2014) 
with 4 
longitudinal 
(interventional & 
non-
interventional)  
Bullen, 2013 (6 
months) 
Caponnetto 2013 
(12 months) 
Method for 
participants lost to 
follow up  
Included 
participants with 
missing data and 
counted them as 
still smoking 
Included 
participants with 
missing data and 
counted them as 
still smoking 
Included 
participants with 
missing data and 
counted them as 
still smoking 
Included 
participants with 
missing data and 
counted them as 
still smoking 
Unclear Not reported Excluded 
participants with 
missing data and 
counted 
complete cases 
Effect Estimate RR 2.29,  
(95%CI 1.05- 
4.96)  
p=0.04 
 
RR 2.29,  
(95%CI 1.05- 
4.96) 
p=0.04 
 
RR 2.02,  
(95%CI 0.97- 
4.22) 
p=0.06 
RR 1.91, 
(95%CI 0.93-
3.89) 
p=0.08 
 
OR 0·72,  
(95% CI 0·57-
0·91) 
AOR 0.10, 
(95% CI: 0.05, 
0.22) - 6.07 (95% 
CI: 1.11, 33.18) 
RR 2.03,  
(95% CI 0.94- 
4.38) 
p=0.07 
Authors’ conclusion EC use is 
associated with 
smoking 
cessation & 
reduction 
EC with nicotine, 
compared with 
placebo EC, 
helped smokers 
to stop smoking 
long-term 
Non-statistically 
significant trend 
toward smoking 
cessation in 
adults using 
nicotine EC 
exists compared 
with other 
therapies or 
placebo. 
The use of EC 
with nicotine 
decreases 
tobacco 
consumption 
among regular 
smokers 
EC are 
associated with 
significantly less 
quitting among 
smokers 
While the 
majority of 
studies 
demonstrate a 
positive 
relationship 
between EC use 
and smoking 
cessation, the 
evidence 
remains 
inconclusive  
It is impossible to 
make strong 
inferences 
regarding 
whether EC use 
promotes, has no 
effect or hinders 
smoking 
cessation 
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Summary of systematic reviews  
We identified 14 systematic reviews of EC for smoking cessation and /or reduction 
published since our last report, seven of which included a meta-analysis. The authors 
of the systematic reviews all concluded that further RCTs of EC are needed. However, 
the reviews that included a meta-analysis produced different results because of 
methodological differences. Two found a positive effect, four found an inconclusive 
effect and one found a negative effect for EC use on cessation.  
 
The standardisation of the reporting of smoking cessation trials has been greatly 
improved since the publication of the Russell Standard (165). Researchers continue to 
add other outcome measures in the context of their own trials and this is to be 
encouraged. However, when reporting trial outcomes, a core set of outcomes, as per 
the Russell Standard should be encouraged. Similarly, the standardisation of 
systematic reviews and meta-analytical methods have been improved since the 
development of the Cochrane Collaboration of Researchers, and we encourage 
reviewers to report a core set of outcomes using similar methods to the 
Cochrane Collaboration, in addition to their own outcomes.  
 
Improving the methodological quality of EC research  
Villanti and colleagues (181) provide the most recent narrative systematic review to be 
published and while a narrative synthesis was employed, we include it because the 
authors propose a set of standards for research on EC use and cessation. To improve 
the scientific rigor of EC research, Villanti and colleagues (181) have proposed a 
hierarchy of methodological criteria for considering whether a study provides sufficient 
evidence to assess if EC use leads to smoking cessation or reduction (box 1) and 
tested their proposed hierarchy in a systematic review. They searched relevant 
literature up to the beginning of February 2017 and included any type of research 
design from studies that claimed to have evaluated the impact of EC use on abstinence 
from tobacco cigarettes or the reduction in number of tobacco cigarettes consumed. 
Their search identified 91 identified papers; after assessing if studies assessed the 
outcome of interest, EC use as the exposure and study design (criterion 1-3), seven 
studies remained, though only four articles from three RCTs were considered to have 
met all six of their proposed criteria (169, 189). 
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Box 1: Hierarchy of methodological criteria for assessing EC use for smoking 
cessation/reduction (181) 
 
Criterion Description 
Criterion1 Does the study examine and adequately measure the outcome of 
interest (cigarette smoking abstinence or reduction)? 
Criterion 2 Does the study examine EC use specifically for smoking cessation or 
reduction as the exposure of interest (were EC specifically used with 
the intention to quit or reduce smoking?) 
Criterion 3 Does the study use an appropriate design with control or comparison 
groups to address the potential impact of EC use on smoking cessation 
or reduction? 
Criterion 4 Does the study measure EC use (exposure) before measuring smoking 
cessation or reduction (the final outcome)? 
Criterion 5 Does the study evaluate the dose and duration of exposure, to 
determine adherence and adequate delivery of active ingredients for a 
sufficient time period? 
Criterion 6 Does the study evaluate the type and quality of the EC product used?  
 
Villanti and colleagues (191) reach a similar conclusion to the most recent Cochrane 
Review (171) even though Villanti and colleagues arrived at their conclusion using a 
slightly different process. The Villanti paper may be expected to contribute to improved 
rigour in EC research; although no observational studies met all their criteria (192). The 
strict inclusion and exclusion criteria of RCTs often have limited applicability to patients 
in real-world clinical settings or people in the general population who smoke or use EC. 
Therefore, the conclusion drawn from Villanti and colleagues’ systematic review using 
their new hierarchy may be conservative. Likewise, the requirement of maintaining 
fidelity to an intervention, such as using EC, within certain parameters (eg type, dose, 
duration and frequency) is also discordant with what happens in real life. As EC 
technology has become more sophisticated and varied, and the people who use EC 
more heterogeneous, new and flexible ways of conducting observational studies and 
RCTs to allow for user experimentation (eg trial and error of different types of EC 
products), as well as the inclusion of patient/user reported outcome measures that are 
relevant and meaningful to EC users are necessary (192). 
 
EC use for smoking cessation or reduction in vulnerable groups 
Smoking prevalence in vulnerable groups such as those with a mental illness, 
substance misuse disorder, people who are homeless or prisoners remain considerably 
higher than in the general population (193-196). Similar treatments to those that are 
effective for general population smokers are also effective for people who smoke who 
have a severe mental illness (197, 198) or substance misuse disorder (199). 
Historically, smokers from vulnerable groups have been offered fewer opportunities to 
stop smoking compared to smokers in the general population, although there is now a 
concentrated focus on reducing harm from smoking in this population following recent 
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policy initiatives (200). As the evidence base rapidly grows for EC use in the general 
population, it is important that researchers include vulnerable populations when testing 
EC for smoking cessation or harm reduction. It is also important that practitioners and 
policy makers ensure equal opportunities to all potential cessation aids for these 
populations.  
 
Since the previous PHE report (5), we have found no published RCTs of EC for 
smoking cessation or reduction in the above mentioned vulnerable groups. There has 
been one uncontrolled study of EC use in smokers with severe mental illness and one 
in people who smoke who are maintained on methadone. Pratt and colleagues (201) 
provided EC for four weeks and instructions on how to use them, to 21 people with 
schizophrenia or bipolar disorder and assessed participants weekly for four weeks. 
Nineteen participants completed weekly assessments. Thirteen (68%) of participants 
were female, their mean age was 42 and they had been smoking for an average of 24 
years. Between baseline and four weeks, two participants quit and 17 reduced their 
mean tobacco cigarette intake from 192 to 67 cigarettes/week (p = 0.005), confirmed by 
reduction in breath CO levels from 27 ppm to 15 ppm (p=0.004). Temporary and mild 
side-effects were reported by 58% of participants and included dry/sore throat, nausea, 
dizziness, and cough. Pratt and colleagues (201) also captured subjective experiences 
of using an EC and reported participants commented that they perceived that EC were 
healthier and helped them feel more accepted by non-smokers. However, some 
participants felt that the EC did not provide the same “hit” they were used to and some 
participants reported that they tended to use their regular tobacco instead of the EC 
when they were experiencing emotional distress.  
 
Stein and colleagues (202) provided EC for six weeks and instructions how to use them 
to 12 smokers who were maintained on methadone. Participants were all male, and 
their mean age was 46 years. Participant’s reduced their CPD by an average of 13.4 at 
nine weeks follow up and one participant quit. Temporary and mild side-effects were 
reported by the minority of clients and included headache, cough and sore throat. Both 
studies had high adherence rates to EC and low attrition rates.  
 
A similar uncontrolled pilot study of EC (203) with smokers with serious mental illness 
not intending to stop smoking soon and who were accessing community services, 
currently under peer review, found similar reductions in tobacco use and measures of 
smoke intake while using the EC. 
 
International overview of EC use for smoking cessation or reduction 
The previous section on systematic reviews is largely international literature; here we 
provide a brief summary on national surveys with representative samples and finish 
with a framework for considering the potential deaths that could be averted by 
hypothetically replacing cigarettes with EC.  
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In Chapters 6 and 10 we report data from the Eurobarometer 2017 study (EC special 
Eurobaromter 458 (141)) about EC use in 28 Member States of the European Union. 
Of 3,612 respondents who reported they currently smoked or used to smoke and have 
at least tried EC, 14% indicated that using EC enabled them to stop smoking tobacco 
entirely and 17% reported they had reduced their tobacco consumption due to the use 
of EC, but did not stop using tobacco entirely. Men (43%) were slightly more likely than 
women (37%) to say that using EC helped them reduce their tobacco consumption: 
nearly half (46%) of those aged 55 or over said that using EC helped them cut their use 
of tobacco, compared with less than a third (32%) of those aged between 15 and 24. 
The longer someone spent smoking, the more likely they were to say that EC helped 
them stop or reduce their tobacco consumption. More than two-thirds of former daily 
smokers (67%) found EC helpful, compared to 58% of former occasional smokers 
(58%). 
 
In the US, Zhu and colleagues (204) used the US Current Population Survey-Tobacco 
Use Supplement included data from five surveys, (2001-02, 2003, 2006-07, 2010-11, 
and 2014-15) to assess the relationship between EC use and smoking cessation in a 
representative sample of the US population. Of 161,054 respondents to the 2014-15 
survey, 22,548 were current smokers, and 2136 recent quitters. EC users were more 
likely than non-users to make a quit attempt (65.1% v 40.1%), and more likely to 
succeed in quitting (8.2% v 4.8%). The overall quit attempt rate in 2014-15 (45.9%) was 
significantly higher compared with the previous surveys. The overall population 
smoking cessation rate increased between 2010-2011 (4.5%) and 2014-15 (5.6%) 
representing approximately 350 000 additional US smokers who quit in 2014-15. Zhu 
and colleagues (204) explain the limitations of their study design and data collection 
methods and suggest there may be many reasons other than the use of EC that 
contributed to an increase in quit attempts and quit success (eg an increase in federal 
tobacco tax and national media campaigns). However, their findings are consistent with 
Beard and colleagues (161) discussed earlier in this chapter. 
 
Modelling the overall impact of EC 
Mathematical and computational modelling play an increasingly important role in 
guiding public health policy, though are not without their limitations; in this section we 
report two studies about the potential population impact of EC use in the US. Cherng 
and colleagues (205) used an agent-based modelling approach to examine 
hypothetical scenarios of EC use by smoking status and the effects of EC on the 
initiation and cessation of tobacco smoking). Using multiple sources of data from 
national surveys, census and epidemiological studies, the model simulated a 
population of U.S. adults, aged 18 to 85, and their smoking and EC use status. The 
model included four nicotine-use states: 1) exclusive EC user, 2) exclusive cigarette 
smoker, 3) dual user of both EC and cigarettes and 4) never user of either product. 
Cherng and colleagues (205) found larger reductions in smoking prevalence than 
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potential impact on smoking initiation. They reported if EC increased individual-level 
smoking cessation probabilities by 20%, the model estimated a 6% reduction in 
smoking prevalence by 2060 compared to baseline model (no effects) outcomes. In 
contrast, prevalence of EC use among never smokers would have to rise dramatically 
from current estimates, with EC increasing smoking initiation by more than 200% 
relative to baseline model estimates in order to achieve a corresponding 6% increase in 
smoking prevalence by 2060. 
 
In the second modelling study, Levy and colleagues (206) present a framework for 
considering all the potential contributions that EC might make to population health. 
They modelled the potential deaths that could be averted in the US by hypothetically 
replacing cigarettes with EC using a model that took account of potential cohort effects. 
They compared projected smoking rates and health outcomes over a 10 year period 
(2016-2026) using a Status Quo Scenario (essentially a world where EC do not exist) 
with two Substitution scenarios (a world where cigarettes are replaced with EC, taking 
an optimistic and pessimistic view) (Box 2). The Status Quo Scenario focused on 
cigarette use only with the population classified as never, current and former cigarette 
smokers. Smoking rates were projected forward using age and sex-specific initiation 
and cessation rates. The number of smoking related deaths of current smokers was 
calculated by age, sex and year as the product of their excess mortality risks (ie current 
smoker mortality rate minus never smoker mortality rate) multiplied by the number of 
smokers. A parallel process was used to calculate estimates for former smokers. Their 
findings are in Box 2.  
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Box 2: Assumptions for substitution scenarios (207) 
 
OPTIMISTIC SCENARIO PESSIMISTIC SCENARIO 
Replacing 10% of cigarette by EC users 
over 10 years, so that a residual of 5% 
cigarette smoking prevalence remains in 
2026 
Replacing 10% of cigarette by EC users 
over 10 years, so that a residual of 10% 
cigarette smoking prevalence remains in 
2026 
Never smokers who would have smoked 
cigarettes instead become EC users at 
the same rates as initiation of cigarette 
use in the Status Quo Scenario after the 
5% smoking prevalence is reached 
EC initiation is assumed to occur at 
150% of the Status Quo smoking 
initiation rate to reflect some 
renormalisation of nicotine 
EC users each year quit at the same 
age-specific and sex-specific cessation 
rate as smokers in the Status Quo 
Scenario 
EC users each year quit at half the rate 
of cigarette smokers in the Status Quo 
Scenario 
An excess risk of EC use at 5% of 
cigarette excess risk is applied to current 
EC users 
An excess risk of EC use at 40% of 
cigarette excess risk is applied to current 
EC users 
Predicted potential 6.6 million fewer 
premature deaths and an estimated 
86.7 million fewer life years lost 
Predicted potential 1.6 million fewer 
premature deaths and an estimated 
20.8 million fewer life years lost.  
 
Conclusions 
Key findings 
• In the first half of 2017, quit success rates in England were at their highest rates so 
far observed and for the first time, parity across different socioeconomic groups was 
observed. It is plausible that EC have contributed to this.  
• Recent estimates of additional quitters resulting annually from the availability of EC, 
using the same dataset (STS) but two different methods, resulted in similar figures 
within the range of 16,000-22,000. Varying the assumptions, and updating these 
estimates for 2016, resulted in an upper bound estimate of around 57,000 additional 
quitters annually resulting from EC (lower bound around 22,000). While caution is 
needed with these figures, the evidence suggests that EC have contributed tens of 
thousands of additional quitters in England.  
• EC use alone or in combination with licensed medication and behavioural support 
from a Stop Smoking Service, appear to be helpful in the short term. However, 
fewer smokers use an EC as part of a quit attempt with a Stop Smoking Service 
compared with licensed medication. 
130 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
• We identified 14 systematic reviews of EC for smoking cessation and /or reduction 
published since our last report, seven of which included a meta-analysis. The 
authors of the systematic reviews arrived at the same conclusion that further 
randomised controlled trials of EC are needed. However, the reviews that included a 
meta-analysis produced different results; two found a positive effect on cessation for 
EC use, four found an inconclusive effect for cessation and one found a negative 
effect.  
 
Implications  
Research  
• An important focus of future research is longer-term relapse trajectories of people 
who use EC for quitting compared with other stop smoking treatments and also 
assess whether the uptake of EC after quitting can prevent relapse back to 
smoking. 
• Funders should consider that although RCTs may yield higher internal validity this is 
at the cost of lower generalisability. Future robust observational and RCTs should 
consider allowing for user experimentation (eg trial and error of different types of EC 
products), as well as the inclusion of study outcomes that are relevant and 
meaningful for EC users.  
• Funders should commission research about the effect of EC on smoking cessation 
in vulnerable populations (eg people who smoke who have a mental illness, 
substance misuse disorder, homeless or prison populations).  
 
Policy and practice  
• Stop smoking practitioners and health professionals should provide behavioural 
support to smokers who want to use an EC to help them quit smoking.  
• Stop smoking practitioners and health professionals supporting smokers to quit 
should receive education and training in use of EC in quit attempts.  
• Local authorities should continue to fund and provide Stop Smoking Services in 
accordance with the evidence base. 
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8  Poisonings, fires and explosions 
Introduction 
The objective of this chapter is to summarise the evidence on poisonings, fires and 
explosions attributed to EC and their component parts. These incidents are examined 
in two categories: harm caused by exposure to e-liquids (poisoning) and harm caused 
by malfunctioning EC (injuries from fires and exploding EC or EC batteries). Incidents 
of this nature often gain media attention (208-211), yet little is known about their 
prevalence and context. This chapter will summarise the evidence available and, where 
possible, will provide context by reporting risks from other commercially available 
products. The health implications of inhaling vapour during regular EC use are 
discussed in Chapter 9 and are not covered here. This chapter presents data from peer 
reviewed literature published since January 2015, a FOI request sent to Fire Rescue 
Services (FOI-F) and a FOI request sent to burn treatment centres (FOI-B); these data 
sources are described in Chapter 2. Of the 29 FOI requests issued to burn treatment 
centres, data was returned from nine. We are very grateful to those centres that did 
provide data, however the total response was insufficient to draw either inference or 
conclusions, therefore the data are not presented in this report.  
 
EC Poisoning 
E-liquids typically consist of a solution containing PG, VG, nicotine and flavourings. 
This section reviews the evidence on cases of poisoning resulting from exposure to e-
liquids that far exceeds that from routine EC use but which nevertheless provide 
valuable background and context to poisoning from e-liquids.  
 
The data here are presented in four sections: National Poison Information Service 
(NPIS) data for the UK, UK case reports, non-UK case reports and activity reports from 
international poison treatment centres.  
 
National Poisons Information Service Data (NPIS) 
The NPIS collates and summarises UK wide data from its telephone and online 
(TOXBASE) poison enquiry services as described in Chapter 2 (in 2015 a TOXBASE 
app was introduced for iOS and Android mobile devices which is not discussed further 
here as it only accounts for less than 2% of all queries received). The NPIS records 
enquiries made by clinicians and the public about the assessment and treatment of 
poisoning cases. Unlike hospital records it can capture incidents that involve accident 
and emergency services (A&E) attendance but that do not require a hospital admission.  
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In 2016/17 the NPIS recorded 662,105 TOXBASE user sessions. The most commonly 
accessed pages were those for Paracetamol (99,584) Ibuprofen (27,675), Sertraline 
(25,524), Diazepam (23,913) and Codeine phosphate (23,322). The NPIS reported a 
total of 43,611 patient-related telephone enquiries for all causes of poisoning in 
2016/17, a reduction from 48,000 the previous year. These included 1,210 for enquiries 
for drugs of misuse, 694 for iron poisoning, 498 for dishwashing tablets, 419 for carbon 
monoxide, and 295 enquiries for automotive screenwashes.  
 
For EC poisoning, the NPIS reported 230 patient-related telephone enquiries in 
2016/17 compared to 272 such enquiries in 2015/16. Of the 230 enquiries in 2016/17, 
185 were recorded as accidental poisoning, 32 intentional poisoning and 13 “all other” 
or “unknown” (Figure 27). The vast majority (95%) of EC telephone poisoning enquiries 
recorded by NPIS between 2015 and 2017 were recorded as minor, or no toxicity; 2% 
resulted in moderate toxicity; 1% (n=2) in severe toxicity and 2% of unknown toxicity 
(Figure 28). Both incidences of severe toxicity in 2016/17 involved a cardiac arrest. 
There were 608,868 user sessions of the online NPIS service TOXBASE concerning all 
poisoning causes in 2015/16, and 602,012 user sessions in 2016/17. Online enquiries 
for EC were down from 3,724 in 2015 to 2,664 for the 10 months of 2017 (the number 
from the equivalent 10 months in 2015 were 3,044).  
 
Figure 27: Telephone enquiries of EC poisoning by cause 2015 - 2017: NPIS data (all 
ages) 
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Figure 28: EC poisoning by level of toxicity 2015 - 2017 NPIS Data (all ages) 
 
 
Review of UK case reports from the literature 
There were no peer-reviewed case reports from the UK identified by our literature 
search. We did identify a letter to an academic journal and a conference abstract that 
described poisoning by EC. Despite the limitations of these articles they can provide 
some detail and context to poisoning events and are often used to highlight emerging 
issues. The research letter reported accidental application of e-liquid to a person’s eye 
after confusing the e-liquid for eye-drops (212). The letter reported that the liquids were 
stored adjacently in the same cabinet. The person was treated for eye irritation but 
suffered no long-term damage. The conference abstract reported a man who presented 
at A&E having ingested two bottles of e-liquid (213). He was treated with 
benzodiazepines to control and prevent seizures and was discharged after 36 hours 
and suffered no long-term effects.  
 
Review of case reports from outside the UK 
We identified ten papers detailing 11 case reports of EC poisoning outside the UK 
(Table 17). 
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Accidental exposure 
Five cases described accidental exposure to e-liquid. In two of these cases the e-liquid 
was mistaken for a medication. In one case report a parent gave 5mL of e-liquid to their 
15-month old child mistaking it for cold medicine (214). A second case was of a parent 
who had prepared and stored e-liquid in an old liquid ibuprofen bottle. They then 
mistakenly gave 10mL of e-liquid to their six-year-old child believing it to be ibuprofen 
(215). In other cases, children were reported to have ingested e-liquid from bottles that 
had no safety cap or child resistant lid (216, 217) one of these incidents resulted in 
death (216) (Table 17). 
 
Intentional exposure to e-liquid and exposures of uncertain intent  
Three cases involved intentional use of e-liquid in a suicide attempt. One reported IV 
injection of 4mL of 32mg/mL liquid. The patient survived following medical intervention 
(218). Another case involved subcutaneous injection of between 100 and 400mL e-
liquid of uncertain strength resulting in a fatality (219). The third case involved oral 
ingestion of e-liquid of unknown quantity or strength also, resulting in a fatality (220). 
An additional three case reports, two of which were fatal, were uncertain about whether 
the ingestion was intentional or accidental (218, 221, 222) (Table 17).
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Table 17: Non–UK e-liquid poisoning case studies from the peer reviewed literature 
 
Author, 
Publication 
year, 
country 
Number 
of cases 
Gender Age Type of liquid/container Storage Intent Route  Outcome/symptoms 
Bartschat, 
2015(222)  
Germany 
1 Male 34 Three empty 50mL vials of e-
liquid were found. Bottles 
marked as 72mg/mL 
In bedroom; 
liquids ordered 
online 
Inconclusive.  Oral  Fatal 
Chen, 
2015(220)  
US 
1 Female 24 Two empty 15mL vials of 
concentrated liquid nicotine 
(100mg/mL) were found 
Not stated 
 
Intentional suicide 
attempt 
Oral  Fatal 
Eggleston, 
2016(216) 
US 
1 Male 18 
months 
100mg/mL nicotine bottle size 
not stated. In an uncapped, non-
child-resistant container 
 
Not stated Accidental Oral Fatal  
 
Gill, 
2015(217)  
Canada 
1 Female 2 One 60mL bottle over 3/4s full 
was found containing 24 mg/mL 
nicotine. Liquid was grape 
flavoured; the bottle was similar 
to an eye dropper, had no safety 
cap and had cartoon monkeys 
on it 
Not stated - but 
the toddler was 
found with the 
bottle in her 
hand 
Accidental Oral Patient vomited for 30 
minutes 
Lam, 
2017(223)  
China 
1 Male 24 A nicotine free flavoured mix, 
with liquid from an unmarked 
bottle purchased online as "liquid 
cannabis". The patient reported 
to have ingested two drops. 
Not stated  Accidental Oral Acute confusion, 
agitation, visual 
hallucinations, rapid 
irregular heart rhythm 
Noble, 
2017(215)  
US 
1 Female 6 E-liquid was stored in an 
ibuprofen container. The patient 
was given 10mL of e-liquid which 
was analysed and found to be 
70.3mg/mL nicotine - pH 8.97. 
In the fridge (in 
a liquid 
ibuprofen bottle 
having been 
mixed at home)  
Accidental  
E-liquid was 
mistakenly given to 
the patient as 
ibuprofen 
Oral Vomiting, sweating, 
visual disturbance, 
muscle twitching, 
incontinence and brief 
loss of consciousness 
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Author, 
Publication 
year, 
country 
Number 
of cases 
Gender Age Type of liquid/container Storage Intent Route  Outcome/symptoms 
Rasanen, 
2017(219)  
Finland 
1 Female 29 Patient injected between 100 
and 400 mg of e-liquid of 
undisclosed strength. This was 
combined with an undisclosed 
intake of diazepam and alcohol. 
Not stated Intentional suicide 
attempt 
Subcutaneous 
injection 
Fatal 
 
Seo, 
2016(214)  
South Korea 
1 Female 15 
months 
5mL of liquid nicotine, 
(10mg/mL); the e-liquid was 
mistaken for cold medicine. 
Not stated Accidental Oral Fatal 
Sommerfeld, 
2016(218)  
Poland 
2 Female 21 The patient drank 30mL e-liquid 
with a concentration of 12mg/mL 
(12.4mg/mL on analysis) 
Not stated Not stated  Oral Vomited profusely 15 
minutes after ingestion. 
Abdominal pain, motor 
agitation, anxiety and 
difficulty breathing. Low 
pulse and blood 
pressure. The patient 
returned to normal after 
12 hours and was 
discharged after 40 
hours. 
Sommerfeld, 
2016  
Poland 
 Male 32 32mg/mL nicotine (32.2mg/mL 
on analysis). Injected approx. 
4mL. 
Not stated Intentional suicide 
attempt 
IV Injection Abnormal slow 
breathing and loss of 
consciousness after 
approx. 1hr 
You, 
2016(221)  
South Korea 
1 Male 39 EC with liquid bottle was found. 
7.2mg/mL 
Not stated Not stated  Oral  Fatal  
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Review of data from poison centres outside the UK 
The literature review identified six articles of EC incidents from poison treatment 
centres, all based outside the UK (Table 18). Five articles were from the US and one 
was from the EU (this study did not analyse any data from UK poison centres). Four 
articles reported EC poisoning for all age groups and two focused on EC poisoning 
events in children. Three articles from the US reported activity at a regional level, and 
two provided national statistics (224, 225). Accordingly, some poisoning incidences 
may contribute to both regional and national reports and so caution must be used when 
comparing or combining these data. 
 
In reports that included all age groups, there were 3,609 incidences reported in children 
aged five or under compared to 2,755 in all other age ranges. These reports covered all 
of the US, as well as ten EU member states; each report included data from between 3 
and 5 years. Most of these poisoning events were accidental; however intentional 
overdose and self-harm incidents were also reported. Intentional incidents accounted 
for 5 to 18% of the total number of EC poisonings where reported. The most common 
route of exposure was ingestion followed by inhalation, with these making up over three 
quarters of events in all reports. Dermal, ocular and “other” routes of exposure were 
also reported. The most commonly reported side-effect was vomiting, with the following 
adverse health effects also reported: drowsiness, tachycardia, agitation, dizziness, 
headache, eye pain, red eye, conjunctivitis, blurred vision, corneal abrasion, lethargy, 
throat conditions, abdominal conditions, diarrhoea, breathing conditions and tremor. 
There were two fatalities (224), one accidental ingestion of e-liquid by a child aged 
under five, and one suicide attempt involving injection of e-liquid.  
 
In the two studies that focused specifically on children, over half of the events reported 
by Forrester (226) and Kamboj and colleagues (225) involved children under two years 
old, with marginally more incidents attributed to males in both studies. Here ingestion 
was again the most common route of administration accounting for 93% (Forrester) and 
82% (Kamboj and colleagues) of cases, with low levels (<5%) reported for dermal, 
inhalation and ocular routes. Vomiting was the most common side-effect, with other 
adverse health effects including coughing and choking, eye pain, respiratory arrest, 
seizures, and tachycardia. Forrester and colleagues reported one “major effect”; 
Kamboj and colleagues reported five “major effects” and one fatality where a one year 
old accessed an open refill container. Kamboj compared this to two “major effects” and 
no deaths from tobacco cigarette poisonings during the same period, noting that overall 
the number of EC poisonings in children was less than a quarter of the number of 
poisonings from cigarettes during the same period
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Table 18: E-liquid poisoning summaries from poison centres 
 
All ages  
Article Location and 
date range 
Proportion by age 
(n)1 
EC n Cigarettes 
n 
Gender Intent2 Data source Route of administration 
% 
Chatham 
Stephens et al., 
2016 (224) 
US 
2010-2014 
0-5 = 58% (3,341) 
6-10 = 1.9% (108) 
11-19 = 5.5% (314) 
20+ = 34.7% 
(2,001) 
 
5,807 
 
20,372 54% male 
46% female 
Not reported Calls to the US national 
repository and surveillance 
system  
Ingestion = 65.8% 
Inhalation/nasal = 11.0% 
Eye = 8.6% 
Multiple routes = 8% 
Skin = 6.5% 
Ear = 0.2% 
Ordonez et al., 
2015 (227) 
Texas, US 
2009-2014 
0 – 5 = 53% (119) 
6-19 – 6% (13) 
20+ = 41% (93) 
 
225 1,893 49% male 
51% female 
87% unintentional 
5% intentional 
 
Exposures reported to the 
Texas Poison Center 
network 
Ingestion = 78% 
Multiple routes = 10% 
Inhalation = 9% 
Dermal = 8% 
Ocular = 4% 
Weiss et al., 2016 
(228) 
Wisconsin, US 
2010-2015 
0 – 5 = 58.2% (57) 
6 – 19 = 11.2% (11) 
20+ = 30.6% (30) 
 
98 
 
671 Not provided 86.7% 
unintentional 
8.1% intentional  
 
Calls to Wisconsin Poison 
Centre 
Ingestion = 66.3% 
Inhalation = 14.3% 
Ocular = 6.1% 
Dermal = 2.0% 
Other = 9.3% 
Vardavas et al., 
2017 (229) 
Ten EU Member 
states 
2012-2015 
0 – 5 = 33.2% (92) 
6 – 18 = 9.8% (27) 
19+ = 57.0% (158) 
277 N/A 51% male 
49% female 
71.3% 
unintentional 
17.8% intentional 
 
Data from poison information 
centres from ten EU States 
Ingestion = 67.5% 
Respiratory = 16.6% 
Dermal = 9.0% 
Ocular = 7.6% 
Other = 2.2% 
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Studies focusing on children 
Article Location and 
date range 
Age range~ EC n Cigarettes 
n 
Gender Intent*  Data source Route of administration 
Forrester, 2015 
(226) 
Texas, US 
2010-2014 
0 = 8.9% (18) 
1 = 35.2% (64)  
2 = 38.5% (85) 
3 = 11.8% (28) 
4 = 3.9% (5) 
5 = 1.6% (3) 
203 N/A 51.2% male 
48.8% females 
All accidental Exposures reported to the 
Texas Poison Center 
network concerning children 
under five years old 
All alone or in 
combination 
Ingestion = 93.1% 
Dermal = 11.3% 
Ocular = 3.0% 
Inhalation = 2.0% 
Multiple routes = 9.9% 
Kamboj et al., 
2016 (225) 
US  
2012-2015 
0 = 8.9% (267) 
1 = 35.2% (1,452) 
2 = 38.5% (1,591) 
3 = 11.8% (487) 
4 = 3.9% (161) 
5 = 1.6% (67) 
4,128 
 
17,512 55.2% Male 
44.6% Female 
0.2% 
Unknown 
All accidental NPDS The National Poison 
Data System holds data on 
calls to all US poison control 
centres 
Ingestion = 81.5% 
Ingestion = 9.7% 
Dermal = 3.3% 
Inhalation/nasal = 3.2% 
Ocular = 1.6% 
Other = 0.5% 
Unknown = 0.1% 
 
1 Total calls may differ from sum of ages as age was not always recorded. 2 Intent of all events not known so percentages do not always combine to make 100
140 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
EC fires and explosions 
EC along with many other personal and portable electrical appliances use rechargeable 
lithium-ion batteries. In common with all types of batteries, lithium-ion batteries can fail; 
this is usually typified by a slow decline in performance to the point where the battery 
needs replacing. On rare occasions, a battery may fail by discharging all its stored 
energy at once. This can be triggered by mechanical damage, exposure to extreme 
heat, unsafe charging, short-circuiting or by design and manufacturing faults within the 
battery. This type of immediate failure is known as “thermal runaway” and can occur in 
all battery types (230). When thermal runaway occurs, the pressure and temperature of 
the battery increases and can cause the battery to vent flammable gasses at high 
pressure (231). This can cause the battery and device in which it is stored to be 
propelled at high velocity. This has the potential to be more extreme in lithium-ion 
batteries than in other types of batteries because of the large amount of energy they 
can store. The immediate and dramatic nature of such events means that they are 
often given a high media profile (208-210). Lithium-ion batteries are commonly used in 
consumer electronics and although their instability and potential for fire is rare, it has 
been documented in other products such as mobile phones (232). It is because of the 
use of lithium-ion batteries that we sought to compare EC fires/explosions with those 
attributed to mobile phones.  
 
This section of the chapter summarises data from FOI requests made by the authors to 
UK fire rescue services and burn treatment centres as described in Chapter 2. We will 
also summarise the peer reviewed literature published since January 2015 on EC fires, 
burns and explosions.  
 
Data from individual UK Fire Rescue Services 
Forty-nine fire rescue services responded to the FOI request described in Chapter 2. 
Six were unable to provide any data, citing high costs or that the data requested were 
not available. Data on fires and false alarms attributed to EC were available for 41 fire 
rescue services (Figure 29); and data on both EC and mobile phone incidents from 
2015 to 2017 were available for 38 fire rescue services (Figure 30). For 2017 data, fire 
rescue services reported data that was available at the time of the FOI request (August 
2017).  
 
Call outs for EC related fires increased from 2015 to 2016, with 93% of this increase 
attributed to false alarms. In 2016 (the most recent full year data) fire services included 
in this analysis recorded a total of 269 call outs comprising 202 false alarms and 67 
fires. There were nine casualties reported in 2015, 11 in 2016 and four in the data 
available for 2017. No fatalities were recorded in the data available between 2015 and 
2017. 
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Figure 29: EC fires and false alarms recorded by 41 fire rescue services 2015-2017 
 
Figure 30: Fire attributable to EC and mobile phones for 38 fire services 2015-2017 
 
Data on EC and mobile phones from 2015 to 2017 were provided by 38 fire rescue 
services (Figure 30). False alarms were excluded from this analysis because EC can 
trigger false alarms by either observers mistaking the vapour for smoke, or by the 
vapour triggering fire detection mechanisms (correspondence to the authors from Tyne 
and Wear, Royal Berkshire, and East Sussex Fire and Rescue Services). Mobile 
phones do not cause false alarms in these ways and so comparisons of false alarms 
between devices are not appropriate in this context. There were 151 fires related to EC 
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and 84 related to mobile phones between 2015 and 2017, and no fatalities recorded for 
either EC or mobile phones in this analysis. 
 
National fire statistics 
National data on fires attributed to smokers’ materials are available from official Home 
Office statistics (25). These are drawn from all 52 fire rescue services and from 
mandatory recording procedures which do not apply to EC, so are not directly 
comparable with the FOI-F data presented above but provide useful context.  
 
In the UK in 2015/16 there were 3,608 fires caused by smokers’ materials causing 584 
non-fatal casualties and 77 fatalities. In 2016/17 there were 3,156 fires caused by 
smokers’ materials causing 479 non-fatal casualties and 68 fatalities.  
 
London fire brigade 
In their response to the FOI request, London Fire Rescue Service volunteered 
additional data on both EC and cigarettes enabling a direct comparison of EC and 
cigarette data from a single service. It is important to note that these data was used in 
the FOI analyses above and will have also fed into the national data in the same time 
period for EC.  
 
Table 19 compares fires attributed to EC and to smokers’ materials in London between 
2015 and August 2017. London Fire Rescue Service reported 3,527 fires attributed to 
smokers’ materials compared to 13 attributed to EC. Cigarettes were associated with 
395 injuries and 44 fatalities compared to no injuries or fatalities recorded in the same 
time period for EC.  
 
Table 19: Fires recorded in London 
 
 Total 2015 2016 2017 
(Available data) 
 EC Smoking 
related 
EC Smoking 
related 
EC Smoking 
related 
EC Smoking 
related 
Total Fires 13 3,527 4 1,346 6 1,214 3 967 
Injuries 0 395 0 130 0 145 0 120 
Fatalities 0 44 0 14 0 22 0 8 
 
Limitations 
The FOI-F data has considerable limitations. Recording of EC as the cause of fire is not 
mandatory, and requires use of a free-text box. The reliance on searching a free text 
box for EC events means that events may be excluded if they are misspelled or 
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abbreviated. The numbers reported from different services were varied. For example, 
one service reported a nil return against our criteria, where another reported 79 call 
outs indicating the potential for a wide range in recording practices across fire services 
in the UK. This is also reflected in the discrepancies between  
Figure 29 and Figure 30 which include data from different numbers of fire services.  
 
There are no data sources that are sufficient to determine the prevalence of EC 
poisonings fires or explosions in the UK given that such questions are not included in 
population wide surveys. Individual cases within the data presented here are 
confidential and cannot be identified. It is therefore possible for single incidents to be 
reported to the NPIS and to be written up as a case study and hence be included more 
than once in this summary. Similarly, there may be potential overlap between regional 
and national poison centre reports in the US. It is also likely that these data 
underestimate incidences of poisonings, fires and explosions attributable to EC. Not all 
incidences are reported to health, fire or medical services, and incidences that are 
reported may not always be recorded as related to EC.  
 
Case reports concerning injury from fires and explosions 
We reviewed the literature on injuries from EC fires and explosions following the 
protocol outlined in Chapter 2. The search identified 25 articles, three of which are case 
reports or case series from the UK and 21 of which were non-UK case reports or case 
series. There were three additional articles from the international literature, one was a 
review of EC fires and explosions in the US using information reported to federal 
agencies, and two were retrospective audits of referrals to burn centres.  
 
Case reports originating from the UK  
We identified three articles describing six case studies of EC related burns in the UK 
(233-235) (Table 20). All patients were male and their average age was 33 years. In 
five cases, patients sustained burn injuries as a result of an EC exploding in their 
trouser pocket. One of these reported having coins in the same pocket as the EC. One 
case occurred while the EC was charging.  
 
Injuries included superficial partial thickness and mixed depth thermal burns covering 
1-7% of the total body surface area; injuries occurred to the lower extremities (foot, 
thigh, genitals) and hands, one case included alkali chemical burns from the lithium 
battery. Treatment included wound management with one person needing a skin graft. 
In addition to describing three cases, Arnoult and colleagues (233) included information 
about a further nine male patients aged 24-63 who sustained superficial partial 
thickness and mixed depth thigh burn injuries from EC batteries, although information 
about the context and cause of these injuries was not included.  
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Case reports originating outside the UK  
We identified 21 papers describing 43 cases from outside the UK (18 in the US, one 
each from Canada, Germany and Malaysia) (see table in appendix). Forty-one patients 
were male and two were female and their average age was 29 years. Twenty-three 
cases described patients who had sustained injuries as a result of an EC (and/or EC 
battery) exploding while being carried in a trouser pocket; four of which reported they 
were carrying keys and/or coins in their pocket at the time of the explosion. There were 
13 explosions that occurred when the EC device was in the patient’s mouth, four while 
holding it, one while modifying their device and one during a motorcycle accident.  
 
Injuries included thermal and chemical burns to the face, hands, thighs, buttocks and 
genitals; puncture wounds, fractures, loss of teeth and eye injuries. Thirty-six cases 
resulted in burn injury; the mean total surface area of the burn was 6% (range 0.5% to 
27.5%) in 27 cases. Treatment included wound management, dental and maxillofacial 
surgery; 13 patients required a skin graft. 
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Table 20: UK case reports concerning injuries caused by EC explosion 
 
Author, year 
and setting 
Number 
of cases 
Gender Age Circumstance of 
EC explosion 
Nature of injury Treatment Details of EC 
Arnaout et al., 
2017 (233), UK. 
 
3 Male 22 While charging  1% TSBA superficial partial thickness 
burns to hands and sole of right foot 
Wound 
management 
Rechargeable 
device  
Male 22 While in right trouser 
pocket  
1% TSBA mixed depth burn to right 
thigh and scrotum, superficial, partial 
thickness burns to left hand 
Wound 
management 
Not reported  
Male 49 While in trouser 
pocket with coins 
(lithium battery only) 
7% TBSA, superficial partial thickness 
burns to right thigh 
Wound 
management 
Rechargeable 
device  
Nicoll et al., 
2016 (234), UK 
2 Male 39 While in trouser 
pocket (lithium battery 
only) 
4% TSBA, superficial partial thickness 
burns to his right thigh, minor 
superficial burns to the right hand  
Skin graft EC showed no 
sign of damage 
before explosion  
Male 30 While in trouser 
pocket (lithium battery 
only) 
3% superficial partial thickness burns 
to his right thigh. Superficial burns 
were also sustained to the right hand. 
Wound 
management 
Not reported 
Walsh et al., 
2016 (235) , UK 
1 Male 35 While in right trouser 
pocket (with keys) 
1.5% Total Body Surface Area, mixed 
depth burn to right thigh 
Wound 
management 
Not reported 
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Additional international literature  
Rudy and Durmowitz (236) reviewed EC fires and explosions in the US. They searched 
media outlets, five US federal agencies and the scientific literature, identifying 92 
events related to EC overheating, catching fire or exploding. There were 45 incidents 
involving injury to 47 people, and 67 incidents involved property damage. The majority 
of injuries sustained were burns (thermal = 33, chemical = 4) and the remainder were 
blast injuries (fractures and lacerations to the upper extremities). Most incidents 
happened during charging (n=44) with fewer occurring while inhaling or between puffs 
(n=20); the remainder occurred during transportation or storage. It was suggested in 
some occurrences that EC user actions may have contributed to the malfunction, for 
example when using a substitution charger, charging a non-rechargeable battery, using 
a recalled or incorrect battery or using an EC near oxygen containers. This review was 
limited by inconsistent and incomplete primary reports, lack of device identifiers and 
device damage, reliance of voluntary reporting to agencies and the possibility of 
undetected duplicate cases reported to Federal agencies and the media.  
 
A retrospective case note audit of referrals to three burn centres in California, US, (237) 
identified 29 patients who had sustained injuries caused by EC explosions between 
February 2015 and July 2016 as well as one patient in 2014. Twenty-four of the 30 
patients (80%) were male and their average age was 30 years. Explosion of a fully 
assembled EC was described in 16 cases and an isolated battery in 10 cases; with the 
EC status unclear in the remaining four cases. Patients sustained burn injuries to the 
lower part of the body (legs and genitalia) and upper part (hands, torso and face). The 
burn size ranged from less than 1 to 8% of the total body surface area, with a mean 
total body surface area of 4%. Nine patients (30%) received surgical intervention. 
 
In a retrospective case note audit of referrals to one burn centre in California (a 
different burn centre to the one reported by Ramirez and colleagues (237)), US, Toy 
and colleagues (238) identified 24 male patients and one female patient who sustained 
a burn injury from an EC. Their average age was 34 years. The majority (72%) of burn 
injuries occurred when the EC (and/or EC battery) exploded in the patient's pocket, the 
remainder while in use. Thigh and genital areas were the most commonly affected 
areas of the body. The area of burns averaged 4.1% total body surface area with a 
range of 1% to 9% and five patients required a skin graft.  
 
Limitations of case reports 
Case reports and case series have long been accepted as a way to present unusual, 
uncontrolled observations regarding symptoms, clinical findings and novel treatments 
and are often written to educate other clinicians. However, as a methodology, they are 
limited; they are not chosen from representative population samples and cannot be 
generalised, they rely on the patients’ recall of events and the observer’s subjectivity 
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can bias the quality and interpretation of the observation (ie information bias). Case 
reports often deal with rare and atypical events and can be easily over- interpreted or 
misinterpreted, as they often have an emotional appeal on readers. In the case of EC 
the above information cannot therefore provide information on incidence or prevalence 
of explosions and cannot be generalised to the current 2.9 million EC users in the UK. 
Although explosion events are very rare, the case reports can alert us to precautions 
that can be taken to minimise further events and guide clinical treatment decisions.  
 
Conclusions 
Key findings 
Poisonings  
• There are recorded cases of poisoning from e-liquid in the UK. These have 
predominantly involved accidental ingestion with fewer incidences of other routes 
(eg ocular or dermal) of exposure.  
• Intentional poisoning using e-liquids has been reported in self-harm and suicide 
attempts.  
• Toxic effects from EC poisoning are usually short in duration and of minimal 
severity; severe cases and fatalities, while very rare, have been recorded.  
• EC poisonings reported to medical centres most commonly occur in children under 
five years old. Toxic effects for this age group are usually short in duration and non-
severe. Fatalities, while very rare, have also been recorded in this age group.  
• Incidents of poisoning in children are often preventable and have involved liquids 
stored non-securely, in unmarked containers or in containers without safety caps.  
 
Fires 
• EC fires are recorded at the discretion of individual fire rescue services in the UK. 
Information provided to us through a FOI request suggest that, where recorded, 
they occur in low numbers and are vastly outweighed by fires caused by smokers’ 
materials. There were no fatalities from fires caused by EC in the reporting period. 
• EC and/or their batteries are recorded as the cause of fires by UK fire rescue 
services. The root cause of EC fires is likely to be through a malfunctioning lithium-
ion battery.  
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Explosions 
• Exploding EC can cause severe burns and injuries that require intensive and 
prolonged medical treatment especially when they explode in users’ hands, pockets 
or mouths. 
• Incidents are very rare. The cause is uncertain but appears to be related to 
malfunctioning lithium-ion batteries.  
 
Implications 
Research 
• Research is required on the prevalence of e-liquid poisoning, fires and explosions 
caused by EC in England. This will require some synthesis of existing datasets.  
• Research on presence and effectiveness of safety features and instructions should 
be part of a future review of the EU TPD.  
 
Policy and practice  
• Monitoring of fires caused by EC should be recorded by Fire Rescue Services in a 
mandatory way (similar to “cooking appliances”, “smokers’ materials” and “other 
electrical appliances”) and should not continue to rely on free text entry. 
• EC can trigger fire/smoke detectors and therefore consumers should be advised to 
move away from detectors when using them. 
• It is too early to assess the impact of the EU TPD in reducing poisonings, fires or 
explosions, or whether further regulations are needed. Therefore, continued 
monitoring is required to assess effectiveness of EU TPD regulations (such as 
childproof containers), in reducing accidental ingestion of e-liquid.  
• Regulations should require that labelling on e-liquid bottles advises customers to 
store products away from similar looking medicines such as eye drops, ear drops 
and children’s medicine. 
• Regulations should require that labelling reinforces advice on the safe storage and 
transportation of batteries used by EC. For example, advice should be given that EC 
should not be carried in pockets with coins, keys or other metallic objects, and that 
the correct charger should always be used.  
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9  Health risks of EC 
Introduction 
The 2015 PHE report (5) reviewed studies that had raised concerns about potential 
health risks resulting from using EC. It identified that most toxins responsible for health 
damage from smoking are absent in EC aerosol and that those that are present are 
there at much lower levels (below 5% and mostly below 1%) than in tobacco cigarettes. 
Regarding ingredients specific to EC, no significant health risks had been identified at 
the time. We therefore concluded that the new studies did not demonstrate substantial 
new risks and thus did not change the conclusions of previous reviews that EC were 
substantially less harmful than smoking (4). We considered a 5% residual risk to be a 
cautious estimate allowing for uncertainty over risks in the longer term. Since the 2015 
PHE report, the Royal College of Physicians (RCP) has also reviewed evidence on the 
safety of EC and concluded that they were “unlikely to exceed 5% of the harm from 
smoking tobacco”. Over the past two years, many new studies were published of which 
several raised concerns regarding EC safety.  
 
This chapter reviews the new evidence to update conclusions on potential health risks 
from using EC. In this chapter, we focus on studies that provide new relevant 
information, EC adverse events from the MHRA Yellow Card reporting system, reviews 
and high profile studies. We start with a brief consideration of approaches to assess 
health risks of vaping and a summary of the adverse reactions data. Following this, the 
Chapter organises the new findings into thematic sections according to the safety 
concerns they cover, beginning with overall effects and followed by studies concerning 
propylene glycol and glycerine, aldehydes, flavours, metals and passive vaping. 
Nicotine was discussed in Chapter 4, therefore the discussion below focuses on other 
EC constituents. Within each section, where appropriate, we report the different 
categories of studies including: animal and cell studies; studies of the chemical 
composition of EC aerosol; and, studies of toxin intake and vaping effects in EC users. 
As EC are a product that is competing with tobacco cigarettes, the focus of the review 
is mainly on risks of vaping compared to risks of smoking. In addition, given we believe 
that biomarkers of exposure might be particularly informative at this time, we include a 
more detailed analysis of four candidate biomarkers of exposure, an analysis not yet 
peer reviewed but which brings together different study findings and is therefore 
relevant. Finally, we have an additional section at the end in which we explore the 
misreporting of some studies and possible reasons why this may be happening.  
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Considerations for assessing the health risks of EC 
There are different approaches to assessing risks of vaping, with each posing certain 
methodological challenges. The weakest evidence comes from animal and cell studies, 
because their relevance for estimating effects of vaping for human exposure is unclear. 
In addition, it can be difficult to emulate realistic vaping conditions and generate 
realistic dosing of EC aerosol. However, such studies can provide indications of which 
constituents of EC aerosol human research should focus on. Another approach is to 
look at the chemical composition of EC aerosol. Such studies are essential and can 
obviously generate important information, but they too can suffer from using EC 
settings that generate unrealistic exposure.  
 
The strongest evidence for relative risks of EC and tobacco cigarettes will eventually 
come from actual health outcomes in cohorts of EC users compared to cohorts of 
smokers and non-smokers. However, this will take time. EC prevalence has only been 
at a measurable level since about 2011/12, not long enough to measure long term 
impacts of vaping on health. There is also the issue that most EC users are former or 
current smokers and smoking-related health risks can persist for a long time, therefore 
assessment of harm/risk from EC has to account for the possible damage related to 
current or past smoking. Cohort studies will need to include ex-smokers quitting with 
different methods as well as those who switched to vaping, those who carry on 
smoking, and those who never smoked.  
 
An additional approach is to study switching to EC versus quitting smoking among 
smokers with established smoking-related disease – these studies might expose any 
benefits or risks sooner than in studies largely of healthy smokers. Reported adverse 
reactions to EC can also be assessed from research studies of EC users, and any 
mandatory reporting schemes.  
 
An alternative option is to assess biomarkers of potential or actual harm, such as lung 
function, premalignant lesions or chromosomal aberrations. Here, changes might occur 
more quickly and before health outcomes can be measured, thereby ameliorating 
problems with time lags. It does not, however, necessarily help to discriminate between 
the effects of smoking and the effects of EC use among people who have used both. 
Special attention needs to be given to the extent to which any acute effects indicated 
by biomarkers translate into chronic effects and relevant health outcomes. 
 
A further option is to look at biomarkers of exposure such as measuring internal 
exposure to eg constituents of tobacco smoke or EC aerosol which can be measured in 
bodily fluids – one such example are tobacco specific nitrosamines which can be 
measured in urine samples. This has the benefit of accumulating evidence quickly 
about short term and reversible harms. Such biomarkers must be reasonably specific to 
the exposure and related to a disease to provide evidence of harm. Advantages of 
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using biomarkers of exposure include that they are less affected by prior exposure to 
smoking and they can be observed in users of the products.  
 
Adverse reactions  
MHRA Yellow Card Scheme 
No population-based studies on adverse outcomes of EC use were identified in the 
search. Instead, we report data from the Yellow Card Scheme. Run by the MHRA, is a 
reporting system to record suspected adverse reactions to medicines from health 
professionals, manufacturers or members of the public. To coincide with 
implementation of the EU TPD 2014/14/EU (see Chapter 3), on 20 May 2016 the 
MHRA extended its Yellow Card reporting system to include EC and e-liquids, although 
some reports had been received prior to this date. Consumers and healthcare 
professionals can report both side-effects and product safety concerns. A report can be 
made when a medicine (or EC) is suspected to have led to an adverse reaction. The 
person making the report does not need proof that the medicine/EC caused the 
symptoms, only to suspect that it may have, or that there was a close temporal 
relationship to the administration of the medicine/EC. The MHRA provided us with 
anonymised reports for spontaneous suspected adverse reactions for EC along with 
details of spontaneous suspected adverse drug reactions for Nicotine Replacement 
Therapy (NRT) products for context. Due to differences in adverse reaction reporting 
requirements between marketing authorisation holders of nicotine containing licensed 
medicines and EC producers it is not possible to directly compare the number of 
reports, therefore we have included this information for context only. Adverse reaction 
reporting rates are influenced by the seriousness of adverse reactions, their ease of 
recognition, the extent of use of a particular product, and may be stimulated by 
promotion and publicity about a product. There is a requirement for all medicinal 
products to have details of reporting to the Yellow Card Scheme in their product 
information; however this does not extend to EC.  
 
A total of 37 reports were received with a suspected adverse reaction to EC between 1 
January 2015 and 20 October 2017, 263 reports were received associated with a 
suspected adverse drug reaction to NRT during the same reporting period (Figure 31). 
EC reports listed 23 EC or e-liquid brands (two brands were indicated twice and it was 
unreported in 12 cases). The dose of e-liquid content was reported in 14 cases and 
ranged from 3-24mg (mean= 12.5mg). As reported in Chapter 6, there are 
approximately 2.9 million adult EC users in GB in 2017. In the same survey (ASH-A) in 
2016 1.18% of participants responded that they had “tried NRT products and still use 
them” from which we can estimate that approximately 600,000 people were using NRT 
in GB.  
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Figure 31: Number of reports of a suspected adverse reaction to EC or NRT 
 
 
It is not possible to determine from this data source if an EC or NRT caused or 
contributed to a suspected adverse reaction or if it was coincidental. We also do not 
have information if the EC user was also a smoker or if the NRT user was a smoker 
and/or used an EC. There may also be differences between propensity to report EC 
and NRT suspected adverse reactions, for example if consumers are more likely to 
perceive EC as a consumer product than medicinal, compared to NRT. As ECs are not 
subject to the same regulations around safety reporting as licensed medication there is 
no legal obligation for manufacturers to provide the MHRA with reports; therefore it is 
not possible to directly compare two different products. 
 
Between 2015 and 2017, the 37 reports included 99 suspected adverse reactions (with 
many individuals reporting multiple adverse reactions such as nausea and headache). 
The most commonly reported adverse reaction related to gastrointestinal disturbance 
(n=19, eg nausea) and respiratory problems (n=17, eg cough). One report was of a 
non-fatal cardiac arrest. Additional data from the Yellow Card Scheme noted that this 
patient had a relevant cardiac history. In the same reporting period, the 263 NRT 
reports included 649 suspected adverse drug reactions including one report of suicide 
where NRT was recorded.  
 
Adverse reaction reports from research studies 
In the most recent Cochrane systematic review of the effect of EC on cessation (see 
chapter 7 for details about primary studies), Hartmann-Boyce and colleagues (171) 
concluded that none of the studies included in the review found that smokers who used 
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EC for up to two years had an increased health risk compared to smokers who did not 
use EC. Ten studies included in the review assessed adverse effects; the findings are 
described narratively in the review and were not subject to a meta-analysis. In an RCT 
by Bullen and colleagues (189) the event rate was 0·8 events per person month in the 
nicotine EC group and NRT patch group, and 0·9 in placebo EC group and the 
difference was not significant (incidence rate ratio 1·05, 95% CI 0·82–1·34, p=0·7). In 
an RCT by Caponnetto (190) there was no difference in the frequency of adverse 
events at three or 12-month follow-up between the three groups receiving 1) an EC 
containing a 7.2mg nicotine cartridge for 12 weeks; 2) an EC containing a 7.2mg 
nicotine cartridge for six weeks and 3) a nicotine free EC for 12 weeks. The frequency 
of adverse events decreased significantly over time, with the exception of throat 
irritation. Eight cohort studies reported they assessed adverse effects though only five 
provided numbers and/or proportions of adverse events (189, 190, 239-243). Duration 
of EC use for these five studies was between one week and 6 months and the most 
common adverse effects reported were dry cough, mouth and throat irritation.  
 
Overall effects of EC vapour exposure in users 
In the absence of long-term use data, the RCP discussed the likely effects of EC use, 
in relation to the main constituents of concern. The RCP report (68) commented that 
most reviews raising concerns about constituents, related to their presence, rather than 
absolute levels which are “generally the more important determinant of toxicity”. They 
commented that all of the constituents identified were at lower levels than in cigarette 
smoke, but that long-term use of even these low levels could be problematic although 
“the magnitude of these risks relative to those of sustained tobacco smoking is likely to 
be small”.  
 
Recent studies  
Animal and cell studies 
A recent study (244) exposed laboratory rats weighing around 250 grams to a variable 
voltage EC with a setting that is avoided by human users when using the particular 
device used in the study (15 Watts). The volume of exposure to the animals (6-second 
puffs with 5-second inter-puff interval delivered for 5 days a week for 4 weeks) was also 
discordant with the puffing regime observed in people who use EC. In comparison, EC 
users typically take puffs of under 3 seconds with 18 second inter-puff intervals (245). 
Also, there was no comparison with rats exposed to tobacco smoke. The authors 
detected a range of effects. The title of the paper (‘E-cigarettes induce toxicological 
effects that can raise the cancer risk’) did not mention that the study focused on 
animals forced to vape in these conditions, rather than human EC users. The abstract 
concluded ‘Our results demonstrate that exposure to e-cigs could endanger human 
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health, particularly among younger more vulnerable consumers’ (244), which did not 
appear to be borne out by the study. 
 
Another study exposed cells to EC vapour or cigarette smoke (246) and found that EC 
vapour generated some damage after several weeks of exposure, while smoke killed 
the cells within 24 hours. The abstract did not mention the cigarette smoke results and 
the press release claimed that the study showed the dangers of vaping.  
 
Composition of EC and EC aerosol 
A recent study (247) was accompanied by a press release claiming that ‘cancer-
causing benzene was found in EC vapours operated at high power’. The authors did 
not find any benzene in vapour from cartridge-based EC that used benzoic acid (this 
can be transformed to benzene, but this does not seem to happen at normal vaping 
temperatures). They then created their own benzoic acid-containing e-liquid and 
submitted it to high ‘dry puff’ temperatures and this did generate benzene - albeit in 
levels lower than those in ambient air (248). 
 
In a separate study (249), published data on emissions from cigarettes and EC and 
their cancer potencies were used to calculate lifetime cancer risk using daily 
consumption estimates. EC cancer potencies were largely found to be only a small 
fraction of those of smoking (0.4%). Where findings exceeded 1% of the risks of 
smoking, the relationship between formaldehyde levels and user aversion (248) 
suggests that they were associated with dry puffs.  
 
Studies with EC users 
Biomarker data 
 
A presentation at a meeting of American Urological Association in 2017 reported 
finding two out of five putative carcinogens in the urine of 12 of 13 EC users. It is not 
clear what the levels of the carcinogens were – only the abstract of the conference 
presentation was published (250) - but both chemicals (o-toluidine and 2-
naphthylamine) are normally found in urine of non-smokers as well (251). Neither has 
been reported in EC liquid or aerosol so far, so their presence or absence remains to 
be verified.  
 
A comparison was recently published of biomarkers of nicotine and a range of 
carcinogens and toxins - three TSNAs and 14 Volatile Organic Compounds (VOCs, 
including aldehydes and acrolein, a major contributor to the respiratory effects of 
smoking)- in the body fluids of smokers, EC users who stopped smoking, NRT users 
who stopped smoking, and dual users of EC or NRT and cigarettes (129). There were 
no differences in nicotine intake. NRT-only and EC-only users had significantly lower 
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levels of all biomarkers than groups that continued to smoke. The messages from this 
study were that: i) EC only users were comparable to NRT users in terms of exposure 
to the toxins and carcinogens studied; ii) dual users did not differ in toxin intake from 
smokers and should be encouraged to stop smoking altogether. For the latter finding, it 
is not known whether the dual users were heavier smokers prior to taking up EC and 
further research is needed to explore toxin intake across the range of dual use (eg 
predominantly smokers or predominantly EC users).  
 
A recent study of smokers who switched to vaping for two weeks, supported these 
findings. There was no change in nicotine intake, but a substantial reduction in 
exposure to a range of carcinogens and toxicants (252). 
 
Other data from switching/cessation studies 
 
Several small sample or uncontrolled studies have suggested some benefits in 
smokers switching to vaping on some respiratory and other measures. Smokers who 
switched to vaping during the ECLAT study in Italy (Chapter 7) and who had elevated 
blood pressure initially lowered their systolic blood pressure compared to baseline 
(253). A tobacco – industry funded study randomised smokers to switch partially or 
completely to vaping or stop using nicotine products altogether for a period of five days 
(15 smokers per study condition). The study findings suggested little difference 
between vapers and abstainers in terms of blood pressure, heart rate, lung function 
(one-second forced expiratory volume and forced vital capacity), exhaled CO and 
nitrous oxide (254).  
 
An uncontrolled longitudinal study of 16 smokers with asthma who switched to vaping 
found improvements in lung function and respiratory symptoms which were maintained 
up to 24 months after switching (255). This was also observed in dual users.  
 
An on-line survey asked established EC users about any changes in the incidence of 
respiratory infections following their switch to vaping (256): 29% reported no change, 
5% reported worsening, and 66% reported an improvement.  
 
Other data from adolescent studies 
 
Adolescents who tried EC were reported to have increased rates of ‘chronic bronchitic 
symptoms’ (257). Participants were asked about wheezing, cough, phlegm and 
‘bronchitis’ (definition not provided). The unadjusted analysis suggested an association 
between trying an EC in the past three months and bronchitis, but this association 
disappeared when smoking status was controlled for. EC experimentation in the past 
remained associated with ‘bronchitis’ in the current year, but also with a significant 
decrease in wheezing.  
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Self-reported asthma symptoms among adolescents were associated with current EC 
use even after controlling for smoking within the past 30 days in one study(258). Past 
asthma was significantly associated with current EC use which suggests confounding. 
Further studies are needed in this area. 
 
Summary 
In summary, a study of cancer potencies of EC emissions suggested that these are 
largely less than 0.4% of smoking. There are no similar data-based estimates available 
for cardiovascular and lung risks. There are chemicals whose presence or absence in 
EC vapour remains to be assessed, but the main carcinogens and toxins that are 
inhaled by smokers have been detected in smokers who switched to EC use at levels 
that are much lower and similar to those in NRT users. Adolescents who tried vaping 
reported more respiratory symptoms than those who did not. Some small scale or 
uncontrolled studies have noted improvements in asthma and in respiratory infections 
in smokers who switched to vaping, but more research is needed in this area.  
 
Propylene glycol (PG) and glycerine 
Propylene glycol and glycerine, both organic compounds, are used in varying 
proportions to make the e-liquids for EC. The RCP report (3) summarised that in 
relation to both PG and glycerine, studies with animals have been generally reassuring 
in relation to health consequences. There was some evidence, from one study in 
humans, that PG was an airways irritant and a further one of a relationship between 
exposure in the home and asthma and rhinitis in children. Glasser (73) reported that 
PG and vegetable glycerine in EC liquids were not cytotoxic for any human and animal 
cell types. Indeed, a recent case study reported a resolution of recurrent tonsillitis in a 
non-smoker who started to use EC, proposing that such effects could be due to 
bactericidal properties of PG. It has been suggested that a controlled trial with nicotine 
free EC in non-smoking patients (so they are not given nicotine) with recurrent throat 
infections could provide more definitive answers (259).  
 
Aldehydes 
Heating PG or glycerine can release aldehydes such as formaldehyde, acrolein and 
acetaldehyde, which are also produced during smoking. The 2015 PHE report 
discussed the phenomenon of ‘dry puff’ when the e-liquid is overheated which creates 
an aversive taste that EC users avoid. A study published at the end of 2015 (260) 
which used these conditions reported that, at a maximum power setting of a variable 
voltage EC, the EC emitted up to 15 times more formaldehyde than tobacco cigarettes. 
EC users however do not vape under these conditions. The phenomenon has been 
compared to toasters that can burn toasts so severely that the resulting char contains a 
range of carcinogens, but the taste would be so aversive that people would be very 
157 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
unlikely to eat it. In a recent replication of the above study, using the same apparatus 
and conditions, experienced EC users reported dry puffs well below the power setting 
at which high aldehyde levels were detected (248).  
 
Recent studies 
Composition of EC and EC aerosol 
A recent study also reported very high aldehyde emissions, from an EC using a top-coil 
device and silica wick, operated at 3.8 and 4.8V (261). The results were unprecedented 
and an attempt at replication using even higher settings failed to replicate the 
phenomenon (262). The same settings in newer devices which do not overheat the e-
liquid, generate aldehyde emissions that are much below regulatory limits and much 
lower than in cigarette smoke (262). This tallies with a study showing that newer EC 
devices that use bottom coils produce less aldehydes than earlier EC devices (263). 
 
Another study (264) found that aldehydes in EC aerosol generated at normal settings 
were either absent or present at low levels, well below safety limits for cumulative 
exposure that is normally used for assessing exposure hazards. However, levels of one 
of these aldehydes, formaldehyde, exceeded a threshold (the American Conference of 
Governmental Industrial Hygienists acute (one inhalation) exposure) ceiling limit of 0.3 
ppm (0.38mg/m3) in over 50% of the samples and the median was nearly twice as high 
as the ceiling limit. This appeared of concern but no comparison with smoking was 
provided. Smokers are commonly exposed to acute concentrations of 60-130 mg/m3, 
ie at least a hundred times higher (265). In addition to this, the acute exposure 
presented as if it was exceeding the exposure limit was in fact far below the ceiling 
limit. The authors’ calculation assumed that the full inhalation consists of the EC puff. In 
reality, 45-80mL puffs from EC get mixed with air so that the resulting 500mL inhalation 
dilutes the puff contents at least six-fold.  
 
Another recent study compared tobacco smoke and six e-liquid refills and their 
resultant aerosol emissions (using a realistic setting and puffing regime) on a range of 
chemical constituents (266). The e-liquids were accurately labelled and contained none 
or only a very small fraction of potentially harmful chemicals including trace elements, 
metals, pesticides and polycyclic aromatic hydrocarbons (PAHs) compared to tobacco 
smoke. Compared to tobacco smoke, levels of carbonyls were <1 vs 1,540 ng/mL for 
acetaldehyde; none to 2.2 vs 171 ng/mL for acrolein and 0.4 to 1.5 vs 82ng/mL for 
formaldehyde.  
 
Studies with EC users 
One of the aldehydes, acrolein, that is considered to present a particularly strong health 
risk as a potent respiratory irritant, produces a specific and stable primary metabolite 
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(3-HPMA) and this allows estimates of its actual intake in EC users. The 2015 PHE 
report included studies which demonstrated lower aldehyde including acrolein levels in 
switchers (smoking to vaping) and dual users (267, 268). These findings have now 
been confirmed by further studies which have found levels in EC users that are much 
lower than those in smokers and similar to those in non-smokers ((252) and (129) 
described above). 
 
Summary 
In summary, although EC can release aldehydes and the levels can be high if the e-
liquid is overheated, the overheating generates an aversive taste and this ensures that 
such emissions are avoided. At normal vaping temperatures, aldehyde content in EC 
aerosol is only a small fraction of levels inhaled by smokers.  
 
Flavours  
The RCP report summarised that flavours used in e-liquids are generally recognised as 
safe (GRAS) but this is in relation to eating or drinking, rather than inhalation following 
being heated.  
 
One of the most commonly heard safety concerns about flavourings used in e-liquids is 
that flavours that contain diacetyl might cause bronchiolitis obliterans (also referred to 
as 'popcorn lung)', a serious disease that has been linked to the exposure to high levels 
of this chemical in popcorn plant workers. Diacetyl has been detected in some EC 
flavourings, but at hundreds of times lower levels than observed in cigarette smoke 
(269). Given that even at these levels, smoking is not a major risk factor for this rare 
disease, the diacetyl content in EC flavourings is unlikely to pose much risk. In any 
case though, manufacturers are now avoiding flavourings that use this. The Glasser 
review (73) reported that in cytotoxicity studies, cinnamon flavour was found to be the 
most cytotoxic when comparing different flavours. Concerns about tobacco flavoured e-
liquids having potentially higher tobacco specific nitrosamine (TSNA) levels do not 
appear to be founded; one study found that tobacco flavoured e-liquids (sometimes 
made through using natural extracts of tobacco), did not have higher TSNAs but 
possible higher nitrate content than other e-liquids; nevertheless they were all 
consistently (orders of magnitude) lower than levels in tobacco smoke (270). 
 
Recent studies  
Animal and cell studies 
Several in-vitro studies have examined flavourings. For example, cells which were 
exposed to direct contact with flavouring chemicals (not EC aerosol) for 24 hours 
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showed signs of damage (271). Similar results were reported with directly exposed 
human umbilical vein endothelial cells. Some flavourings showed some negative 
impact, but less than tobacco smoke, even at high EC extract concentrations (272).  
 
In another study, bronchial epithelial cells were exposed to EC aerosol with various 
flavourings, tobacco smoke or air. Some flavourings in EC aerosol generated adverse 
effects on the cells, but again this was less than tobacco smoke (273). The actual 
levels of chemical constituents responsible for the effect were not established. It is not 
known whether EC release higher levels of relevant compounds than occupational 
safety limits, and this issue warrants further attention.  
 
The exact relevance of these cell studies for human vaping is unclear. However, these 
types of studies can help to provide information on the relative risks of different 
flavourings overall, which could be used by EC users for guidance and provides 
information for quality standards.  
 
Composition of EC and EC aerosol 
A new concern was raised by a study that reported that e-liquid flavourings released 
high levels of aldehydes (274). Such levels were previously only found with dry puffs as 
discussed above in the section on aldehydes. In this instance, the authors reported that 
while flavoured e-liquids produced aldehydes, unflavoured e-liquids used with the same 
device settings released no aldehydes at all, suggesting that it was the flavours which 
were causing the aldehyde production. The report is in contrast to other studies that 
detected no such phenomenon (275, 276). Indeed, the Klager and colleagues (264) 
study reported above, looked specifically at correlations between a range of flavourings 
and aldehydes and detected no significant relationship.  
 
We are aware of a recent replication of the original study using the same EC device 
and e-liquids. The manuscript has been submitted for publication (277). One of the 
flavoured liquids generated aldehydes at levels statistically higher than the unflavoured 
sample, but at very low levels, much below environmental safety limits and several-fold 
lower than in the replicated study. The replication results tally with previous studies and 
suggest that the earlier finding was likely to be an artefact of problems with laboratory 
procedures, equipment or data analysis. Further studies of effects of flavouring on 
aldehydes will provide definitive answers.  
 
Summary 
In summary, while no clear evidence that specific flavourings pose health risks has 
been identified so far, there are suggestions that inhaled chemicals in some flavourings 
could be a source of preventable risks. Further research on the presence and effects of 
inhaled flavourings is warranted.  
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Metals 
Previous studies found several metals in EC liquid and aerosol, but at very low levels, 
comparable to those in nicotine inhaler, and considerably below the levels found in 
cigarette smoke. A comparison of the levels detected in these studies with several 
safety norms confirmed this (278). The RCP report (68) concluded that this was 
probably not a major concern because of the low levels and that they could be reduced 
further by manufacturing improvements. These were perceived to be unlikely to pose 
any risks to health.  
 
Recent studies  
Composition of EC and EC aerosol 
A recent study (279) analysed metals in e-liquids removed from cartridges of five 
‘cigalike’ EC brands. (The pre-filled cartridges in which e-liquid is exposed to metal 
continuously for weeks to months can be expected to have higher metal content than 
refillable tank systems). The authors presented a list of dangers associated with various 
metals when ingested or inhaled in large doses, but the study provided no indication of 
whether the levels actually detected could pose any risks. The levels were expressed in 
different metrics than in previous studies. Using conservative assumptions, they are 
concordant with previous findings and so signal very low risk. The study, however, 
identified one issue that is of relevance. EC products differed in metal emissions. This 
could be related to the age of different cartridges, but also to materials used in 
atomisers and coils, and requires further study. 
 
A later study (280) confirmed that EC products differ in nickel and chromium levels 
released in the aerosol from the heating coil and that this is reflected in salivary and, to 
a lesser extent, also in urinary levels of these metals in EC users using these products. 
This does not necessarily signal a health risk as the metal levels were very low, with 
urine nickel concentrations lower than population norms. Levels of chromium (which is 
non-toxic apart from chromium IV that is unlikely to be generated by EC) were higher, 
but still in the range that could be influenced by environment and diet. As with the 
previous study though, the finding is informative as it suggests that manufacturing 
practices can and should be adopted that keep metal emissions to a minimum, and 
users should avoid nickel or nichrome coils.  
 
Summary 
In summary, the levels of metals identified in EC aerosol do not give rise to any 
significant safety concerns. However, product differences show that metal emissions, 
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however small, are unnecessary. EC that generate minimal metal emissions should 
become an industry standard.  
 
Passive vaping 
There is no side-stream vapour emitted from the end of EC, just the exhaled aerosol 
entering the atmosphere. In the 2015 PHE report, we discussed a particular concern 
about nicotine being deposited on surfaces raised from one study, but this did not 
reflect levels of vaping and had indicated very low levels; we concluded that there were 
no identified health risks to bystanders. Particle exposure was another concern that we 
discussed in the 2015 PHE report in which we concluded that it was the content of the 
particles, rather than their presence or size which had health implications. Given the 
low levels of toxins we report above in the EC aerosol, there are unlikely to be health 
implications. The Glasser review (73) found that second-hand vapour studies showed 
that non-users may be exposed to nicotine vapour but the level of exposure was low, 
and exposure to other compounds were also very low, or at trace or non-detectable 
levels when compared with second-hand smoke. Glasser and colleagues (73) however 
reported that it was unclear if any levels were sufficient to be of biological concern to 
humans and that more definitive studies were needed before conclusions about harm 
can be made. We discuss several new studies below. 
 
Recent studies 
Composition of EC and EC aerosol 
A recent modelling of passive exposure suggested that bystanders could be exposed to 
aldehydes (281), but the modelling was based on the study discussed above that used 
a laboratory set-up generating dry puffs (261).  
 
Studies with EC users 
A recent study (tobacco industry funded) examined air in an experimental chamber with 
air exchange rate typical for office buildings where 10-11 EC users used different EC 
devices for four hours (282). A wide range of potential toxicants was evaluated. 
Negligible levels of chemicals were detected, which were much below permissible 
exposure limits. In addition, with regards to concerns about metals in EC aerosol 
reviewed above, no emissions of nickel or chromium were detected. There was also no 
significant increase in nicotine deposits on surfaces.  
 
A study analysing the exhaled breath of EC users reported that of chemicals inhaled, 
only 6% of nicotine, 8% of PG and 16% of glycerine was exhaled (79). This therefore 
suggests that 94% of nicotine is retained by EC users. Indeed, a study that examined 
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surface samples from homes of EC users found no difference in nicotine levels 
compared to homes of non-tobacco users (283). 
 
In relation to particles, an extensive study measured indoor air quality in 193 
households with children under 14 to assess the impact of a range of occupant 
activities and home characteristics (284). The study included week-long airborne 
particle measurements. Cigarette and marijuana smoking as well as other activities 
such as burning candles and variables such as home type affected mean weekly 
particle counts, but vaping (present in 43 out of 193 homes) had no discernible effect.  
 
Concentrations of vaping-related chemicals in the air of a vape shop were well below 
occupational exposure limits and nicotine was undetectable (285). Other unpublished 
reports on the results of checking air quality in vape shops by California Department of 
Public Health and by the National Institute for Occupational Safety and Health in 
Cincinnati reported that even in a shop with relatively poor ventilation where 13 
customers used EC during the shift, creating a visible cloud, a range of flavouring 
compounds and formaldehyde were all below the lowest occupational exposure limit 
and nicotine was virtually undetectable (285).  
 
Summary 
In summary, to date there have been no identified health risks of passive vaping to 
bystanders.  
 
Comparison of studies assessing biomarkers for exposure 
In this section we summarise evidence from twelve, mostly new, studies, with different 
methodologies and designs (Table 21), that evaluated differences in four candidate 
biomarkers for exposure between smokers and EC users (286). The participants varied 
across the studies, in some cases smokers who used EC for just a few hours, in others, 
smokers who had switched to EC for a year or more. Unadjusted raw data was used 
and the amount for EC users was divided by the amount observed for smokers, to give 
a percentage reduction compared with smoking. Levels observed in people not 
smoking (either smokers abstaining or never-smokers) are taken into account only in 
the final section. Four of the studies were funded by the manufacturer of ECs tested, 
presenting a conflict of interest which may bias findings. It should be emphasised that 
this assessment has not been peer reviewed but a version of it was presented at a 
recent conference (286).
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Table 21. Study characteristics 
 
Authors Design Duration Population Groups/comparisons Funding 
Cravo et al, 
2016 (287) 
RCT 12 weeks Smokers, n=387 
 
Switched to EC use, n=286 
Continued cigarette smoking, 
n=101 
(Part in confinement1) 
Fontem Ventures B.V., 
subsidiary of Imperial 
Brands plc 
D’Ruiz et al, 
2016 (288) 
O’Connell et al, 
2016 (289) 
RCT 5 days Smokers, n=105 Switched to EC use, n=45 
Switched to dual use EC + 
cigarette, n=45 
Nicotine abstinence, n=15 
(All in confinement) 
Fontem Ventures B.V., 
subsidiary of Imperial 
Brands plc 
Goniewicz et al, 
2017 (252) 
Longitudinal 
cohort  
2 weeks Smokers, n=20 Before (baseline) and after 
encouragement to switch to using 
EC (provided) 
Ministry of Science and 
Higher Education, 
Poland; National 
Institutes of Health, US 
Hecht et al, 
2015 H (267) 
Kotandeniya et 
al, 2015 K (290) 
Historical 
comparison  
N/A EC users, n=55  
Smokers, n=262 
 
n=28 H +27 K Smokers, n=224 H 
+38 K 
National Cancer Institute 
at the National Institutes 
of Health, US 
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Authors Design Duration Population Groups/comparisons Funding 
Martin et al, 
2016 (291) 
Cross-
sectional 
N/A EC users 
(regularly for ≥6 
months and ≤5 
cigarettes per 
week), smokers, 
non-smokers, 
n=39 
EC users, n=12  
Smokers, n=14 
Non-smokers, n= 13 
National Institutes of 
Health, US; Foods and 
Drug Administration, 
Center for Tobacco 
Products, US 
McRobbie et al, 
2015 (268) 
Longitudinal 
cohort 
4 weeks Smokers, n=33, 
supported to quit  
Baseline before quit date 
compared with follow-up 4 weeks 
post quit date, EC provided from 
quit date. At follow-up: Not 
smoking, using EC, n=16; 
smoking, using EC, n=17  
UK Medicines and 
Healthcare Products 
Regulatory Agency 
Pulvers et al, 
2016 (292) 
Longitudinal 
cohort 
4 weeks Smokers willing 
to switch to EC, 
n=40 
Before (baseline) and after 
encouragement to switch to EC 
(provided). Throughout follow-up 6 
exclusive EC users. 
University of Minnesota, 
US; California State 
University San Marcos, 
US 
Shahab et al, 
2017 (129) 
Nelson et al, 
2015 (293) 
Additional 
unpublished 
data2  
Cross-
sectional 
N/A EC users (≥6 
months use), 
NRT users (≥6 
months use), 
smokers, ex-
smokers (≥6 
months quit), 
n=181/n=144 
Never-smokers2 
EC-only users (ex-smokers), n=36 
EC users and smokers, n=36 
NRT users and smokers, n=36 
NRT-only users (ex-smoker), n=36 
Smokers, no NRT or EC, n=37 
(only in Shahab et al) 
Cancer Research UK; 
Society for the Study of 
Addiction, UK; National 
Institute on Drug Abuse 
and National Cancer 
Institute, National 
Institutes of Health, US; 
Roswell Park Alliance 
Foundation, US 
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Authors Design Duration Population Groups/comparisons Funding 
Wagener et al, 
2017 (294) 
Cross-
sectional 
12h 
abstinence 
followed by 2h 
EC use 
session 
Smokers, EC 
users, n=30 
EC users, n=20 
Smokers, n=10 
Intramural funds, US; 
Oklahoma Tobacco 
Settlement Endowment 
Trust, US; Oklahoma 
Shared Clinical and 
Translational Resource, 
US 
Vansickel et al, 
2010 (295) 
Cross-over For each 
product 12h 
abstinence 
followed by 
2.5h use 
session 
Smokers, n=32  EC use 
Cigarette  
Unlit cigarette 
National Cancer Institute, 
US Public Health Service 
Walele et al, 
2016 (296) 
Cross-over For each 
product 
overnight 
abstinence 
followed by 3h 
use session 
Smokers, n=12  EC 
NRT inhalator 
Cigarette 
(All in confinement) 
Fontem Ventures, 
Imperial Tobacco Group 
[Imperial Brands] 
Yan & D’Ruiz, 
2015 (297)  
Cross-over For each 
product: 36h 
abstinence 
followed by 
1.5h use 
session  
Smokers, n=23 EC 
Cigarette  
LOEC Inc, subsidiary of 
Lorillard [BAT] 
1 Confinement means that participant stayed in a controlled environment and were not given access to other products.  
2 Available on request.
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4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) 
NNAL is a marker for exposure to nitrosamines (nicotine-derived nitrosamine ketone 
(NNK)) which are potent lung carcinogens. It is specific to tobacco use and linked to 
subsequent cancer risk (298) and its urinary half-life is about 10 days (299). There 
were 10 published papers reporting on eight studies between 2015 and 2017 that 
evaluated tank-type EC (total n=658). Figure 32 shows NNAL levels in EC users as a 
percentage of NNAL levels in those who smoked cigarettes. Overall, there was a 
91.4% average difference in NNAL levels (weighted by sample size in each study); this 
increased to 96.4% when restricting only to those who had been abstinent from 
smoking for at least four weeks (129, 267, 290, 292, 293).  
 
Figure 32: Level of NNAL in EC use relative to smoking 
 
 
1-hydroxypyrene (1-HOP) 
1-HOP is a urinary metabolite of the non-carcinogen pyrene, and is a biomarker for 
polycyclic aromatic hydrocarbons which include carcinogens such as benzo[a]pyrene 
(300). Its urinary half-life is about 20 hours (301). There were four papers covering 
three studies between 2015 and 2017 with a total of 271 participants; mostly evaluating 
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tank-type EC. The studies showed an average difference in 1-HOP of 57.6% in EC 
users relative to smokers. However, one of the studies (252) found only a 4.1% 
difference, although it is important to note that this study did not require abstinence 
from smoking or substantial reduction in cigarettes smoked (Table 21; Figure 33). 
Excluding this study resulted in an average difference in 1-HOP of 61.9% in EC users 
relative to smokers.  
 
Figure 33: Level of 1-HOP in EC use relative to smoking 
 
3-hydroxypropylmercapturic acid (3-HPMA) 
This is a marker of the volatile organic compound acrolein, a potent respiratory irritant 
(302). It is relatively specific to tobacco use, toxic and is a short-chain aldehyde; 
several short-chain aldehydes have been linked to cancer (303). Its urinary half-life is 
about one day (304). There were eight papers covering seven studies published 
between 2015 and 2017 with 658 participants in total; again mostly evaluating tank-
type EC. They found an average difference in 3-HPMA levels of 59.6% in EC users 
compared to cigarette smokers (Figure 34).  
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Figure 34: Level of 3-HPMA in EC use relative to smoking 
 
Carbon Monoxide (CO) 
CO is a highly toxic gas (265) that is the product of incomplete combustion, produced 
when smoking tobacco and linked to CVD (305). In exhaled breath it has a half-life of 
about 5 hours (306).  
 
Between 2010 and 2017, there were nine papers reporting on eight studies (total 
n=245) measuring exhaled CO levels among EC users; these studies included earlier 
cigalike and tank-type EC. Across the studies there was an average difference of 
77.9% in CO levels (Figure 35).  
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Figure 35: Level of CO in EC use relative to smoking 
  
Comparison with smokers abstaining or non-smoker levels 
Importantly, five of the studies also compared the levels of some or all of these 
biomarkers in smokers who had switched to EC with the levels in non-smokers or 
smokers abstaining/using NRT, and found those levels comparable (Figure 36). While 
some comparisons were with smokers only abstaining for a short period (Table 21), 
overall this suggests how some of these biomarkers have other endogenous and 
exogenous sources which can result in exposure. Hence there cannot be a reduction of 
100% when comparing the risk of EC with smoking.  
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Figure 36: Levels of biomarkers of exposure in EC use and never-smokers or smokers 
abstaining relative to smokers. 
 
Notes: Full bars are levels observed in EC use; striped bars are levels observed in non-smoking groups (D’Ruiz/O’Connell nicotine 
abstinence condition; Martin non-smokers; Shahab/Nelson never smokers; Vansickel unlit cigarette condition ; Walele NRT inhalator 
condition; see Table 21 for length and details of studies).  
 
Limitations 
There are limitations with these data as only a few specific biomarkers are included in 
these analyses, and it is unclear whether there are linear or threshold effects (ie would 
a 95% reduction in exposure represent a 95% reduction in harm). Most of the non-
smoker comparisons were with smokers abstaining for short periods. It should also be 
noted that some of the studies were tobacco industry funded. Additionally, the mode of 
delivery may affect risks of harm, and harm may change with changing patterns of use 
and products.  
 
Summary 
The biomarker data assessed in this section are consistent with significant reductions 
in harmful constituents and in EC users some biomarkers show similar levels to non-
smokers or smokers abstaining from smoking. 
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Misreporting of scientific studies  
Over the past few years, a number of research findings have been presented as 
documenting serious risks of vaping and received widespread coverage. Of course all 
studies have strengths and weaknesses in their research designs, and that includes 
those that demonstrate that EC use is much less harmful than smoking. However, the 
way the results of some studies with particular limitations have been designed and 
reported, and then subsequently presented in the media, may have caused serious 
concerns about EC use as shown by growing misperceptions of the health risks of EC 
in Chapter 10.  
 
We believe that there are a number of contributory reasons for this:  
 
1. Studies that compare EC and tobacco cigarette exposures and show the latter 
as much more toxic are not viewed as newsworthy (eg Husari and colleagues 
(307))  
2. Understandably, journals, authors and research organisation press offices are 
keen to seek publicity for articles in order to gain impact, resulting in press 
releases. Sometimes, these do not accurately represent the article on which 
they are based. 
3. Study findings can be further exaggerated when discussed in the media.  
4. Posters or presentations at conferences, when there is not yet a peer-reviewed 
article to accompany them, are sometimes reported as if they have been 
through peer review and taken as definitive findings. 
 
These are some recent headings in the media generated from some of the studies 
previously described in this chapter: 
 
• E-cigarettes are no better than regular smoking’ 
(http://www.dailymail.co.uk/health/article-3377730/E-cigarettes-NO-better-regular-
smoking-Toxins-devices-cause-cancer-nicotine-FREE.html) 
• ‘Cancer alert’ headlines (eg http://www.mirror.co.uk/science/e-cig-cancer-alert-
smokers-10004747; http://www.dailymail.co.uk/news/article-4303316/Chemicals-e-
cigs-cause-cancer.html 
• ‘Bladder cancer’ headlines eg http://www.dailymail.co.uk/health/article-4514542/E-
cigarette-smokers-high-bladder-cancer-risk.html 
 
None of these headlines would be justifiable from the research studies they refer to. 
However, it is understandable how some of these headlines were generated from press 
materials accompanying the papers or, in one case, conference presentation.  
 
As we have seen, the most frequent source of concerns is from animal and in-vitro 
studies which have unclear relevance for human exposure. They also typically avoided 
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comparisons with smoking. Often the studies suffer from one or both of two major 
methodological problems.  
 
The first is that EC exposure was much greater than the level of exposure to which 
human EC users would be exposed. For example, in in-vitro studies, cells are bathed in 
e-liquid or exposed directly to EC aerosol. In animal studies, laboratory animals that are 
a fraction of the size of humans and much more sensitive to nicotine and other 
chemicals, including strong smells, are exposed to emissions that are of much higher 
magnitude than those to which human EC users are exposed relative to body weight. 
The animals are also sometimes severely distressed over extended periods of time. 
Systemic poisoning and an aftermath of chronic distress are then interpreted as a sign 
of the toxicity of vaping.  
 
The second problem, as discussed in detail above, is that when the e-liquid is 
overheated it releases toxic aldehydes, but this is not applicable to human EC users 
because overheated e-liquid generates acrid aversive tasting emissions which EC 
users avoid. When the toxic products from overheated e-liquid are detected in the 
bodies of animals, or affect tissues and cells, this is again claimed to show risks of 
vaping, despite the fact that EC users do not generate, or absorb, these chemicals.  
 
The consequences of this inaccurate or inadequate reporting are that the general 
public is misled. This could induce smokers to carry on smoking rather than switching 
and EC users to relapse to smoking. While such inaccurate reporting is not confined to 
the tobacco harm reduction and EC field, the impact is rarely as large. Smoking is 
uniquely dangerous and each year in England around 80,000 smokers die because of 
tobacco use (2) . There are few other scientific areas where the gains and losses to 
public health are so high. It is very likely that these reports and headlines are playing a 
key role in the persistent misperceptions that the public have about the relative risks of 
EC and tobacco cigarettes as explored in Chapter 10 of this report. 
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Conclusions  
Key findings 
• One assessment of the published data on emissions from cigarettes and EC 
calculated the lifetime cancer risks. It concluded that the cancer potencies of EC 
were largely under 0.5% of the risk of smoking. 
• Comparative risks of cardiovascular disease and lung disease have not been 
quantified but are likely to be also substantially below the risks of smoking. Among 
EC users, two studies of biomarker data for acrolein, a potent respiratory irritant, 
found levels consistent with non-smoking levels. 
• There have been some studies with adolescents suggesting respiratory symptoms 
among EC experimenters. However, small scale or uncontrolled switching studies 
from smoking to vaping have demonstrated some respiratory improvements.  
• EC can release aldehydes if e-liquids are overheated, but the overheating 
generates an aversive taste. 
• To date, there is no clear evidence that specific flavourings pose health risks but 
there are suggestions that inhalation of some could be a source of preventable 
risks. 
• To date, the levels of metals identified in EC aerosol do not give rise to any 
significant safety concerns, but metal emissions, however small, are unnecessary. 
• Biomarkers of exposure assessed to date are consistent with significant reductions 
in harmful constituents and for a few biomarkers assessed in this chapter, similar 
levels to smokers abstaining from smoking or non-smokers were observed.  
• One study showed no reductions across a range of biomarkers for dual users (either 
for nicotine replacement therapy or EC dual users).  
• To date, there have been no identified health risks of passive vaping to bystanders. 
• Reporting of some academic studies has been misleading. 
 
Implications 
Research 
• More research is needed with human users about biomarkers of exposure, risk and 
harm and health effects over time.  
• More research with biomarkers across the range of different combinations of dual 
use is needed. 
• Any adverse effects of passive vaping should be monitored.  
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Policy 
 
• Policy makers and regulators should ensure that EC are manufactured in a way that 
minimises harm. An advantage of EC is that particular constituents can be removed 
or minimised in a way that is not feasible with tobacco cigarettes.  
• Regulations should therefore be flexible to ensure any emerging evidence of 
constituent harmfulness can be acted upon, such that products are modified to 
remove any components shown to pose avoidable risks.  
• Consumers and health professionals should be encouraged to use the Yellow Card 
Scheme for reporting adverse reactions to EC use. 
• Vaping poses only a small fraction of the risks of smoking and switching completely 
from smoking to vaping conveys substantial health benefits over continued smoking. 
The previous estimate that, based on current knowledge, vaping is at least 95% less 
harmful than smoking remains a good way to communicate the large difference in 
relative risk unambiguously so that more smokers are encouraged to make the 
switch from smoking to vaping. It should be noted that this does not mean EC are 
safe. 
• The lack of difference in biomarkers between dual users and smokers found so far 
underlines the need to encourage and support dual users to stop smoking 
altogether.  
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10  Perceptions of relative harms of 
nicotine, EC and smoking  
Introduction 
The 2015 PHE report (5) described an increase over time in the proportion of the 
population believing EC to be at least as harmful as cigarettes. The objective of this 
chapter is to update the previous findings with the latest data available for Great Britain 
for adults and youth and to provide a brief overview of recent findings from other 
countries.  
 
Evidence from recent GB surveys 
ASH-A, ASH-Y, ONS, STS and the ICGBS all include questions about (relative) harm 
perceptions of different products.  
 
Adults’ perception of harm of EC relative to cigarettes 
Among adults in Great Britain, the ASH-A shows that the previously observed trend of 
increased perceived relative harm of EC has continued (5, 21). In 2017, 44.2% 
perceived EC as less harmful than cigarettes, the lowest percentage since tracking 
started in 2013, and 25.8% perceived them to be equally (22.7%) or more harmful 
(3.1%), which is the highest percentage recorded (28.7% don’t know, Figure 37). 
 
The ONS also asked about relative perceived harm among all adults, without providing 
a ‘don’t know’ option. Here, about 74% responded that EC were less harmful than 
cigarettes (21.1% about as harmful, 5.1% more harmful). The difference between the 
two surveys could suggest that if forced to choose a response, respondents are likely 
to pick less harmful but possibly without particular confidence in this response.  
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Figure 37: Perception of relative harm of EC compared with cigarettes over time. ASH-A  
 
Notes: Adults aged 18+. Unweighted base sizes in the appendix 
 
A downward trend in accurate understanding of the relative risks of cigarette smoking 
and EC use has also been observed among current smokers in the STS, where a 
declining minority believe EC are less harmful than cigarettes (Figure 38). Smokers 
who also use EC are more likely to perceive EC to be less harmful than smokers not 
using them. 
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Figure 38: Perception that EC are less harmful than cigarettes in smokers over time 
 
Although accurate perception seems to be a little higher among smokers in the ASH-A 
2017 than in the STS, breaking down the ASH-A 2017 data by smoking and EC use 
status, it becomes apparent that relative harm perceptions of EC are particularly poor 
among groups who could benefit from EC use. It is lowest among current smokers who 
have never tried EC, where only one third (33.1%) think that EC are less harmful than 
cigarettes. Among smokers who tried or used EC in the past and stopped EC use but 
still smoke, only half (51.5%) think that EC are less harmful than smoking (Table 22). In 
comparison, 90% of ex-smokers who use EC accurately perceived EC as less harmful 
than cigarettes.  
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Table 22: Proportion selecting accurate response by smoking and EC use status. ASH-A 
2017 
 
Smoking 
status 
EC use status EC less 
harmful than 
cigarettes, % 
NRT less 
harmful than 
cigarettes, %1 
Portion of health 
risk of smoking 
due to nicotine – 
none or very small, 
%1 
Never 
smokers  
Any/all 42.4 57.9 4.6 
 Never used EC 42.0 59.2 9.2 
 Ever tried/used2 55.8 56.5 4.6 
Ex-
smokers 
Any/all 45.2 61.6 9.7 
 Never used EC 37.5 61.6 5.9 
 Used /tried in the 
past 58.3 63.0 18.9 
 Current EC use 89.8 65.7 30.4 
Smokers Any/all 48.9 52.9 13.5 
 Never used EC 33.1 53.4 10.6 
 Used/tried in the 
past 51.5 53.7 14.8 
 Current EC use 73.9 56.7 18.4 
 
1 The figures for any/all are in some instances lower than the figures for all subgroups shown; this is because the additional 
subgroup consisting of those who did not know or provide their vaping status (1.9%) mostly also responded ‘don’t know’ to 
these questions, thereby lowering the overall average.  
 
2Tried or used in the past or currently, combined for never smokers due to small ns, combined unweighted n=110. Unweighted 
ns for EC question: Never smokers n=6,256, ex-smokers n=4,276, smokers n=1,569. 
 
Notes: Adults aged 18+. Unweighted ns for NRT and nicotine questions: Never smokers n=6,626, ex-smokers n=4,438, 
smokers n=1,632 
 
 
To further assess perception of relative harm and the effect of replacing tobacco 
cigarettes with vaping, the ICGBS asked respondents to estimate the change in health 
harms including perception of harm reduction achieved by replacement. Responses 
differentiated complete replacement (10/10 CPD replaced by EC) and partial 
replacement (5/10 cigarettes). Very small proportions believed that replacement would 
increase health harms a little or a lot (3.5% for complete, 3.8% for partial replacement). 
Considerable minorities thought that complete (12.2%) or partial replacement (18.4%) 
of cigarettes would not have any effect on health harms; 29.4% and 45.4% respectively 
responded that health harms would be a little reduced. Only 38% of the sample of 
smokers and ex-smokers thought that complete replacement would reduce health 
harms a lot, compared with 15% for partial replacement. While it may be desirable that 
fewer smokers think that partial replacement will be beneficial, it is striking that only a 
minority think that their health would benefit from what would in effect be smoking 
cessation.  
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Addictiveness 
Little evidence has been collected on perceptions of addictiveness of EC. In the 
ICGBS, 6.3% thought that EC/vaping devices are more addictive than tobacco 
cigarettes, 47.2% that they are equally addictive, 29.0% that EC are less addictive and 
17.5% didn’t know. There was some variation across groups with different levels of EC 
use experience (Figure 39). 
 
Future research should aim to assess to what extent the perception of addictiveness 
contributes to the misperceptions of relative harmfulness of EC compared with 
cigarettes.  
 
Figure 39: Perceived addictiveness of EC relative to tobacco cigarettes  
 
Notes: ICGBS 2016. N=3,431 adult smokers, ex-smokers and EC users aged 18+ 
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Perceived health impact of EC on others 
Only the ONS asked about perceptions of health impact of EC on individuals who are 
exposed to them but do not use them directly. Responses were presented separately 
for current and ex EC users and those who had never been a user (but may have tried) 
EC. The latter group was further divided into those who were current or ex-smokers 
and those who had never smoked. Among ever EC users, 72.9% believed that EC 
would have no health impact on those exposed second-hand and 23.9% that they 
would have a damaging impact. Among never EC users who were current or ex-
smokers, 53.9% believed EC would have no impact and 42.1% believed they would 
have a damaging impact. Among never EC users who had never smoked, this was 
49.6% and 46.1% respectively. Raw data for this survey were not available, so the data 
could not be split primarily by smoking status. It would be useful to be able to 
specifically assess smokers’ thoughts on the health impact on others of EC relative to 
smoking, eg do they think those around them would benefit from not being exposed to 
smoke but to EC emissions instead?  
 
Perceived relative harm for NRT, EC and cigarettes 
Perceived harm for NRT relative to cigarettes is inaccurate in large proportions of the 
general adult population. In the ASH-A 2017, just over half (58.4%) responded that 
NRT is any less harmful than smoking cigarettes and there is less variation by smoking 
and vaping status than for EC harm perception (Table 22). This means that the lack of 
knowledge extends to smokers and ex-smokers with only small majorities thinking that 
NRT is less harmful than cigarettes (Figure 40). Particularly among smokers, there is 
little difference between relative harm perception for NRT (52.9% less harmful than 
cigarettes) and EC (48.9% less harmful than cigarettes) (Figure 40). 
 
The ICGBS also included questions about perceived harm of EC and NRT relative to 
cigarettes. Proportions responding more, equally, and less harmful were almost 
identical for both types of products relative to cigarette smoking (Figure 41). In this 
survey, these questions were followed by a direct comparison of EC and NRT; 
respondent’s views were fairly evenly distributed across response options and the 
modal response was ‘don’t know’ (30.0%), suggesting smokers and ex-smokers may 
find the difference in harm between EC and NRT difficult to judge (Figure 41).  
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Figure 40: Perceived harm of NRT and EC relative to cigarettes among smokers and ex-
smokers  
 
Notes: ASH-A 2017. Unweighted base sizes in the appendix. Adults aged 18+ 
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Figure 41: Perceived relative harm of EC and NRT  
 
Notes: ICGBS 2016. N=3,431 adult smokers, ex-smokers and EC users aged 18+ 
 
Perceived harms of nicotine 
The common factor for cigarettes, NRT and (most) EC is nicotine, and misperceptions 
of relative harm may be linked to the perception of nicotine (see also eg (308) for an 
association between perceived nicotine content and perceived harm of cigarettes).  
 
Knowledge about the portion of harm of smoking attributable to nicotine in the general 
adult population is poor and not improving. In 2017, only 7.5% thought that none or a 
very small part of the risk of smoking comes from nicotine (the correct response) 
whereas 14.0% thought that it was nearly all the risk; almost a quarter (24.2) of the 
population chose ‘don’t know’ (Figure 42). Smokers overall may be slightly better 
informed with 13.5% thinking it is none or a very small part of the risk and 6.0% that it is 
nearly all the risk, although again 24.6% did not know. However, among smokers who 
have never tried EC, only 10.6% give the correct response (Table 22), repeating the 
pattern seen for relative harm perception of EC use vs smoking among smokers with 
different EC use status. It is interesting that the highest accurate response to this 
question was given by ex-smokers who were current EC users (30.4%). Responses 
from the ICGBS which surveys smokers and ex-smokers, are in line with the population 
0
10
20
30
40
50
60
70
80
90
100
More harmful Equally harmful Less harmful Don't know
%
 
NRT compared with smoking
EC compared with smoking
EC compared with NRT
183 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
 
data for these groups with 12.9% thinking that only a very small portion of the risk of 
smoking is due to nicotine. 
 
The ICGBS also asked whether respondents believed that nicotine is the chemical in 
cigarettes that causes most of the cancer and a considerably proportion of respondents 
(39.5%) erroneously believed this to be true. This question was not included in any of 
the other recent surveys, but these results are in line with older data from the ITC study 
for smokers and ex-smokers in the UK, US, Canada and Australia (309); for more detail 
see Figure 44 and Figure 45. 
 
Figure 42: Perceived portion of the harms of smoking due to nicotine, ASH-A, 2017  
 
Notes: Unweighted base sizes in the appendix. Adults aged 18+ 
 
Harm perceptions among youth 
For youth, a recent publication reports harm perception in the ASH-Y over time among 
those aware of EC (8) and shows a similar trend to adults. In 2013, 73.4% of youth 
aware of EC thought that EC were less harmful than cigarettes and this dropped 
significantly to 62.3% in 2016 (8). In 2017, this perception was held by only 61.9% of 
youth (Eastwood, personal communication).  
 
An analysis using the 2016 ASH-Y found that accurate perception was more likely 
among youth 14 years and older, those who had tried or used EC sometimes 
(compared with those who had never used EC), those who had at least one family 
member who used EC and those who thought that the public either approve or neither 
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approve nor disapprove of EC use. Respondents’ own smoking status was not 
associated with perception (116). 
 
Nicotine knowledge among youth is also poor; in 2017, 6.5% thought that none or a 
very small part of the risk of smoking comes from nicotine and about a fifth thought it 
was nearly all the risk (Figure 43). In the 2016 ASH-Y data, accurate nicotine 
knowledge was higher among those who were 16 years and older and those who had 
at least one family member smoking. Again, respondents’ own smoking status was not 
associated with nicotine knowledge (116).  
 
Figure 43: Perceived harm of EC relative to cigarettes in youth. ASH-Y, 2017 
 
Notes: Unweighted base n=1977, aged 11-18. 
 
International overview 
Many surveys, mostly from the US, have included questions about perceived 
harmfulness. This section will focus on reviews and surveys reporting on national 
samples of adults or youth. 
 
ITC project 
The ITC Project has collected data on nicotine perceptions over time among smokers in 
four industrialised countries, Australia, Canada, UK and US. Given these are cohort 
data with replenishment, binary generalised estimating equation models were used to 
estimate the adjusted percentage of smokers correctly responding that nicotine in 
cigarettes does not cause cancer, for each country. The adjusted estimates controlled 
for sex, age group, income, education, daily vs. non-daily smoking status, Heaviness of 
Smoking Index, use of NRT, survey mode and time in sample. The general pattern in 
the UK is similar compared with the other three countries although more recently, the 
level of misperceptions seems to be slightly lower in the UK than in the other countries 
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(Figure 44). Misperceptions vary consistently by indicators of socioeconomic status 
across the four countries, with more disadvantaged smokers and recent ex-smokers 
having higher rates of misperceptions (Figure 45). 
 
Figure 44: Proportion correctly responding that nicotine in cigarettes does not cause 
cancer in the ITC 4 country study over time  
 
 
Notes: Adult smokers and ex-smokers aged 18+ 
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Figure 45: Proportion correctly responding that nicotine in cigarettes does not cause 
cancer in the ITC 4 country study over time by educational level  
 
Notes: Adult smokers and ex-smokers aged 18+ 
 
The ITC Project has also collected data on perceived harmfulness of EC relative to 
tobacco cigarettes among smokers across a variety of countries (Table 23). These data 
show that misperceptions of relative harm abound in other countries too, with smokers 
in England being better informed than in most other countries. 
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Table 23: Percentage of adult smokers across different countries thinking EC are 
equally as harmful or more harmful than cigarettes (ITC data) 
 
Country Year ‘EC equally or more harmful 
than cigarettes’, % 1 
High income   
Republic of Korea 2016 66 
United States 2016 37 
Netherlands 2015 32 
Canada 2016 30 
England 2 2016 24 
Australia 2 2016 22 
Uruguay 2014 19 
Middle income   
Malaysia 2013 70 
Zambia 2014 57 
Thailand 2012 54 
Mexico 2014-15 38 
Bangladesh 2014-15 37 
Brazil 2012-13 22 
China 2013-15 15 
 
1 Among smokers who have heard of EC.  
 
2 Figure from ITC, amended from presentation by Professor Geoffrey T Fong at European Network for Smoking and Tobacco 
Prevention (ENSP) conference, Athens, 2017. 
 
The data for Australia and England are preliminary and unweighted. The data for England are adjusted for oversampling of 18-
24 year olds; there was no such oversampling in Australia  
 
Two reviews of studies from any country have included perceived harm of EC relative 
to cigarettes. Reviewing 50 samples from 23 studies, Czoli and colleagues found that in 
70% of samples a majority perceived EC to be less harmful than cigarettes (310). The 
comprehensive review of studies by Glasser and colleagues (73) concluded that 
generally, EC are perceived to be less harmful and less addictive than cigarettes 
regardless of the respondent’s tobacco use status. They also concluded that evidence 
from the US and GB shows that the belief that EC are less harmful has eroded over 
time, with more individuals mistakenly believing EC are as harmful or more harmful 
than cigarettes (73).  
 
Other data from European countries 
As far as we are aware, peer-reviewed publications using Eurobarometer data and 
reporting on harm perception (139) have not yet used the latest wave, but 2017 
Eurobarometer data are available in a report (141). In contrast to most other surveys, 
the Eurobarometer asks about absolute perceived harm to the health of users, rather 
than relative risks. In 2017, just over half (55%) of EU citizens thought that EC are 
harmful to the health of their users, an increase of three percentage points since the 
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last survey in 2014. In 22 out of 28 countries, at least half of respondents agreed that 
EC are harmful and in seven of these countries, over three quarters gave this answer 
(Estonia 75%, Luxembourg and Cyprus 76%, Denmark 79%, Latvia 80%, Lithuania 
80%, Finland 81% and the Netherlands 85%). The lowest proportion agreeing with this 
statement was found in Italy (34%). The proportion of respondents who think that EC 
are harmful has increased in almost all countries since the previous survey. For the UK, 
the Eurobarometer reports that 50% thought EC were harmful. The meaning of an 
absolute harm question without any option of grading the response or a comparator is 
somewhat difficult to interpret. 
 
One representative survey of those aged 14 and over conducted in Germany in 2016 
(142) found that 20.7% of respondents believed EC to be less dangerous than 
cigarettes, 46.3% equally dangerous, and 16.1% believed they were even more 
dangerous (17.0% no response). This was similar among current smokers, where only 
25.5% believed that EC are less dangerous and 15.9% believed EC to be more 
dangerous than cigarettes.  
 
United States 
For US adults, data on relative perceived harm from the Health Information National 
Trends Surveys (HINTS) 2012 to 2014 have been published. Among those who were 
aware of EC (77% in 2012 to 94% in 2014), perception that EC were less harmful than 
cigarettes declined from 50.7% in 2012 to 43.1% in 2014 (311). In a separate 
publication, data from the Health Information National Trends Survey (HINTS-FDA) 
2015 show absolute harm perception of different products; 90.5% perceived cigarettes 
and 48.7% EC to be very harmful; cigarettes were perceived to be moderately harmful 
by another 8.9% while 41.9% perceived EC to be moderately harmful (312). Another 
representative survey of US adults, the Tobacco Products and Risk Perception Survey 
waves 2012, 2014 and 2015 also show a decline in the proportion believing EC to be 
less harmful than cigarettes (39.4% in 2012, 35.2% in 2014 and 30.7% in 2015) and 
steep increases in the proportions believing EC to be equally (11.5% to 35.7%) or more 
harmful (1.3% to 4.1%) than cigarettes (313).  
 
The HINTS-FDA and the Tobacco Products and Risk Perception Survey each also 
included a question on addictiveness. Under a third (28.7%) of adults believed that 
using EC was very addictive and 21.1% that it was moderately addictive, compared 
with 76.8% and 10.5% for cigarettes (314). The proportion of adults agreeing that 
people can become addicted to EC increased from 32.0% in 2012 to 67.6% in 2015 
(313).  
 
One review summarised US studies examining perceptions of EC during pregnancy 
and found that mostly, these were perceived to be less harmful than cigarettes but this 
was accompanied by considerable uncertainty (315). This lack of information is further 
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supported by findings from one national survey of US adults where 11.1% believed 
using EC during pregnancy was less harmful than smoking, 51.0% believed it was 
equally harmful, 11.6% believed it was more harmful, and 26.2% did not know (316).  
 
Among US youth, data are available from the PATH and the NYTS. In the first wave of 
the PATH in 2013-14, perceived relative harm was measured using both a direct 
measure asking respondents to compare EC with cigarettes and an indirect measure 
that asked about the harm to the user separately for each product. In the direct 
measure, 50.2% of the 12 to 17-year old respondents perceived EC to be less harmful 
than cigarettes; this was true for 67.3% when using an indirect measure (317). Data 
from the 2012 and 2014 NYTS (318) are unusual compared with other youth and adult 
surveys in that they show an increase in the proportion of respondents perceiving EC to 
be less harmful than cigarettes. In 2012, 30.6% responded that they perceived EC to 
be less harmful which increased to 50.7% in 2014, a figure which is comparable with 
the PATH direct measure. This increase is mirrored by a decrease in the proportion 
who were unaware of EC or who didn’t know enough to respond to the question (50.9% 
in 2012 to 30.6% in 2014). The NYTS also asked about addictiveness compared with 
cigarettes; 31.3% thought EC were less addictive, 29.7% equally addictive, 5.4% more 
addictive and 33.8% were unaware of the product or didn’t know enough to answer the 
question (318).  
 
Conclusions  
Key findings 
• Perceived relative harm of EC compared with cigarettes has continued to increase; 
less than half of adults in GB think EC are less harmful than smoking.  
• NRT is subject to similar misperceptions and only just over half of adults in GB think 
that NRT is any less harmful than smoking. 
• Adult smokers are poorly informed about relative risks of different products.  
o Only half of smokers believe that EC are less harmful than smoking and this 
decreases to one third among smokers who have never tried EC. 
o In contrast to evidence to date, it appears that a majority of smokers and ex-
smokers does not think that complete replacement of cigarettes with EC would 
lead to major health benefits.  
o Only half of all adult smokers believe that NRT is any less harmful than smoking  
• As the common factor for cigarettes, NRT and (most) EC is nicotine, these 
misperceptions may be linked to the perception of nicotine.  
o When adults in GB are asked what proportion of the health harms of smoking is 
due to nicotine, the accurate response (most health harms are not caused by 
nicotine) is the least common response consistently chosen by 8-9%. Smokers’ 
knowledge around nicotine is similarly poor.  
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o Four in ten smokers and ex-smokers incorrectly think nicotine in cigarettes is the 
cause of most of the smoking-related cancer.  
o Misperceptions around nicotine and cancer are greater in more disadvantaged 
groups. 
• It is unclear to what extent the perception of addictiveness underpins the perception 
of harm.  
• Among youth in GB, perceived harm of EC relative to cigarettes has also increased 
over time and nicotine knowledge is similarly poor (7% correctly responded that 
none or a small portion of the harms of smoking is due to nicotine).  
• Where available, international data show similar misperceptions around nicotine and 
relative harmfulness of EC and smoking as in England. International data also 
support the trends of increased harm perception of EC with the exception of one 
survey in youth in the US. 
 
Implications 
Research 
• Future research should aim to assess causes and effects of misperceptions of the 
relative harmfulness of EC and NRT compared with cigarettes, including to what 
extent the perception of addictiveness contributes to these misperceptions.  
 
Policy and practice 
• Misperceptions of nicotine and different nicotine-containing products need to be 
addressed. These have deteriorated further since the 2015 PHE report in 2015 
which called for clear and accurate information on relative harms (5).  
o Misperceptions of the relative harms of NRT and EC compared with cigarettes 
need to be addressed, particularly among smokers who would benefit from 
switching to NRT or EC.  
o Knowledge about the role of nicotine in the development of cancers and other 
diseases caused by smoking needs improvement. 
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11  Indicative EC pricing  
Introduction 
To illustrate the price range of EC, the ECigIntelligence Global Database was used.  
 
Price of different products  
Cheapest disposable EC 
The price of the cheapest disposable EC has fluctuated from less than 4 GBP to 6 GBP 
over the time period from August 2015 to July 2017 (Figure 46). For cheapest 
disposable EC, online prices were generally lower than those of specialisded vape 
shops. Other brick and mortar shop prices appeared to be the highest. 
 
Figure 46: Average monthly price of cheapest disposable EC 
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Cheapest closed system kit 
The average price of the cheapest closed system kit remained between 10 and 20 GBP 
between August 2015 and June 2017, with an increasing trend observed towards the 
end of the study period which was probably due to a considerable increase in the 
maximum price of cheapest closed system kit. Although average price data for EC sold 
in vape shops were available only for a few months at the end of study period, they 
suggest that prices were slightly higher in vape shops than online (Figure 47). 
 
Figure 47: Average monthly price of the cheapest closed system kit 
 
 
 
Cheapest pre-filled clearomiser/cartomiser 
The price of the cheapest pre-filled clearomiser/cartomiser has remained relatively 
stable, at around 2 GBP throughout the study period. It appears that in May/ June 2017 
the average price increased, but this is likely to be explained by a steep increase in the 
maximum price of the cheapest pre-filled clearomiser on some websites (Figure 48).  
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It is possible that the increase in minimum price after April 2017 is related to 
implementation of the TPD, but in order to explore causality long term trends are 
required. As with other products, the average price of pre-filled 
clearomisers/cartomisers was considerably lower when purchased online.  
 
Figure 48: Average monthly price of cheapest pre-filled clearomiser/ cartomiser 
 
Cheapest basic open system kit 
The price of the cheapest basic open system kit has remained relatively constant, but 
decreased towards the end of the study period, and unlike other products was slightly 
higher from online suppliers towards the end of the study period (Figure 49). 
 
  
0
1
2
3
4
5
6
7
8
9
10
Pr
ic
 e
in
 G
BP
 
Average price cheapest pre-filled clearomiser / cartomiser (online, GBP)
Average price cheapest pre-filled clearomiser (vape stores, GBP)
Min price cheapest pre-filled clearomiser (online, GBP)
Max price cheapest pre-filled clearomiser (online, GBP)
194 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
 
Figure 49: Average monthly price of the cheapest basic open system kit 
 
 
Cheapest clearomiser 
As with the average monthly price of a basic open system kit, the average price of the 
cheapest clearomiser has remained relatively stable during the study period. However, 
an increase towards the end of the study period has been observed, possibly due to an 
increase in the maximum prices of the cheapest clearomisers (Figure 50). Prices from 
vape shops , available only in the last few months of the study period, appeared lower 
than from online retailers.  
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Figure 50: Average monthly price of the cheapest clearomiser 
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Most expensive clearomiser/tank 
Prices of the most expensive clearomiser/ tank have been available in the dataset 
since December 2016. The prices have remained almost unchanged, and only minor 
fluctuations in minimum and maximum prices have been observed (Figure 51). 
 
 
  
0
20
40
60
80
100
120
140
Pr
ic
e 
in
 G
BP
 
Average price most expensive clearomiser/ tank (online, GBP)
Min price most expensive clearomiser/ tank (online, GBP)
Max price most expensive clearomiser/ tank (online, GBP)
Figure 51: Average monthly price of the most expensive clearomiser/ tank 
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Variable wattage/variable voltage kits 
The average monthly price of variable wattage/ variable voltage kits has been available 
only since March 2016 and has remained stable over time with a slight decrease 
towards the end of the study period (Figure 52). However, in this category, the range of 
prices available from various online sources is wide, from about 20 GBP to 130 GBP. 
As with other open system kits described above, average prices of these products in 
vape shops appear to be below those observed in online retailers.  
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Figure 52: Average monthly price of variable wattage/ variable voltage kit 
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Cheapest e-liquid 
The average price of the cheapest e-liquid has decreased over time, and appears to 
have been higher in vape shops than online (Figure 53). It appears that despite 
restrictions on e-liquid bottle size included in the EU TPD price of e-liquid per mL has 
not increased.  
 
 
 
Limitations 
These data are descriptive and most of the data presented refer to the cheapest EC 
product online. It is difficult to investigate trends particularly in relation the 
implementation of the TPD given the relatively short period of time since full 
implementation; in addition some data points are missing. 
 
 
 
 
 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
Pr
ic
e 
in
 G
BP
 
Average price cheapest e-liquid (online, GBP)
Average price per ml cheapest eliquid (vape stores, GBP)
Average price per ml cheapest eliquid (other bricks and mortar, GBP)
Min price cheapest e-liquid (online, GBP)
Max price cheapest e-liquid (online, GBP)
Figure 53: Average monthly price per 1mL of the cheapest e-liquid 
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Conclusions 
Key Findings 
• Price varies considerably between products, and there appear to be differences 
between online and bricks and mortar shop prices, with closed system products 
tending to be cheaper online, and open system kits cheaper in bricks and mortar 
shops.  
• Generally, average maximum and minimum prices seem to have remained relatively 
stable from August 2015 to July 2017 for all product categories.  
• There appear to have been no major and consistent changes in price over the first 
year since implementation of the EU TPD. 
 
Implications  
• Current available data provide minimum, maximum and average prices, but do not 
provide detail on nicotine levels, brands and flavours that would be helpful to our 
understanding of market developments. 
• Currently EC products are available in a wide range of prices and therefore 
affordable to various types of EC users. Any changes in pricing need to ensure that 
EC are affordable to smokers to avoid discouraging smokers from switching away 
from smoked tobacco which would be counter-productive in public health terms. 
There should therefore be a competitive advantage for the prices of EC compared 
to combustible tobacco products. 
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12  Heated tobacco products 
Introduction 
Heated tobacco products are products that do not combust tobacco like cigarettes but 
heat it to a lower temperature with the aim of avoiding the harmful products of 
combustion; they are often referred to as ‘heat-not-burn’ tobacco products. In contrast 
to EC, heated tobacco products in general apply heat to tobacco, instead of liquids. 
There is however a range of different types of heated tobacco products, and some 
classifications include products where vapour is produced from non-tobacco sources 
and then passed over processed tobacco to be flavoured (319). Typically, heated 
tobacco products are rechargeable and include a holder, and tobacco sticks, plugs or 
capsules to be heated with an electronically controlled heating element.  
 
Heated tobacco products have been launched by tobacco companies since the 1980s 
(320, 321) but failed to attract consumers. The heated tobacco products described in 
the current literature are also manufactured by tobacco companies. Philip Morris 
International’s (PMI’s) heated tobacco product IQOS was launched initially in test 
markets in cities in Japan, Italy and Switzerland in 2014 before expanding into all of 
Japan and other countries. As of July 2017, it was available in 27 countries worldwide 
including Great Britain (322). In some countries IQOS is branded as Marlboro, 
representing co-branding with cigarettes. PMI is preparing city tests for further products 
such as TEEPS (https://www.pmi.com/smoke-free-products). Other heated tobacco 
products currently include glo by BAT which was first available in Japan in late 2016, 
followed by a small number of other countries (Canada, Switzerland, Korea), and 
Ploom TECH by Japan Tobacco International which was launched in Japan and 
Switzerland in summer 2017. 
 
In Great Britain, IQOS has been available from a dedicated shop in London since 
December 2016 and more recently also online and a couple of other outlets in London. 
Other heated tobacco products are expected to be launched in the UK soon, therefore 
the UK government is seeking to develop a specific taxation category for heated 
tobacco products (319). Before being put on the market, heated tobacco products need 
to be notified to PHE (see chapter 3). In the US, PMI has submitted an application 
equivalent to millions of pages to the FDA to be able to market its heated tobacco 
products as a modified risk tobacco product (323).  
 
The objective for this chapter was to review the existing peer-reviewed evidence on 
emissions and use of current heated tobacco products and to supplement this with 
recent evidence from UK surveys. 
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Systematic review of existing literature 
Description of studies 
From 843 records identified after the initial search, 19 studies were included in the 
review (Figure 54). Of these, seven studies were funded independently of the tobacco 
industry, eleven were funded by the manufacturer of IQOS and one study was funded 
by a competitor tobacco company (Table 24). 
 
Manufacturers researching their own products or competitor products experience a 
conflict of interest which may bias findings and interpretations, so results need to be 
interpreted with caution (324). A further study we became aware of through contact 
with the study authors was also included, making a total of 20 studies. 
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Figure 54: Heated tobacco products review flowchart 
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Different types of products assessed in these studies were categorised as:  
 
i. Loose-leaf tobacco vaporiser: One study focused on Pax by Ploom. 
ii. Carbon heated tobacco product: This predecessor of TEEPS by PMI was the focus of 
one study. A specifically designed electric lighter lights the carbon heating source which 
then heats a tobacco plug. Twelve puffs of the Carbon Heated Tobacco Product (CHTP) 
are reported to yield 3 mg tar, 2 mg glycerol, 0.4 mg nicotine, and 1 mg of CO (325). 
iii. Tobacco heating system 2.1 (THS 2.1): Developed by PMI, a predecessor of IQOS, was 
assessed in two studies. 
iv. Tobacco heating system 2.2 (THS 2.2), available commercially as IQOS: THS2.2/IQOS 
was assessed in 16 studies. According to the manufacturer, compared with THS 2.1, 
THS 2.2 has a slightly lower operating heating temperature of <350°C (326) compared 
with <400°C (327), higher ISO nicotine yield per tobacco stick (0.5 mg (326) compared 
with 0.3 mg (328, 329)) and ‘improved puff by puff consistency and improved sensory 
satisfaction’ (330).  
v. Other commercially available heated tobacco products: glo and Ploom/Ploom TECH 
were included alongside IQOS in two studies from Japan.  
 
Eight of the included studies were laboratory studies on heated tobacco product 
emissions (331-338). These compared IQOS emissions with emissions from factory-
made (331-333, 335-338) or hand-rolled (335) tobacco cigarettes, EC (332, 334-336) 
and a nicotine inhalator (334). Four were independently funded.  
 
Nine publications reported on six RCTs using a few different products (Table 24), one 
of them published in two parts, and two cross-over design experimental trials in human 
participants (total n = 796)(325, 326, 328, 329, 339-343). One of these studies was 
independently funded (339), the other eight were funded by the manufacturer and all 
published by the same set of authors. 
 
One publication was a case report (n = 1, (344)), one reported findings from a national 
cross-sectional survey from Japan (n = 8240, (155)); both independently funded. In 
addition to the studies identified from the literature, we included an independently 
funded update to the survey in Japan (345) that was not yet published at the time of the 
literature search but which the authors shared with us. 
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Table 24: Summary of included heated tobacco product studies  
 
Authors, year of 
publication Funder, country Study design 
Heated tobacco product and 
reference products 1 Main aim 
Mainstream emissions     
Auer, Concha-Lozano 
et al. 2017(331) 
Not reported, 
Switzerland 
Laboratory comparison study 
using smoking machines 
IQOS 
Cigarette 
To compare levels of HPHC in mainstream 
IQOS emissions with those in mainstream 
cigarette smoke 
Farsalinos, Yannovits et 
al. 2017(332) 
No funding, 
Greece 
Laboratory comparison study 
using smoking machines 
IQOS 
Cigarette 
EC: (i) Cigalike 
 (ii) eGo-style, 2nd generation 
 (pen-style tank) 
 (iii) variable wattage (tank) 
To compare levels of nicotine in mainstream 
IQOS emissions with nicotine in different type of 
EC aerosol and in mainstream cigarette smoke 
Schaller, Keller et al. 
2016(337) 
PMI, 
Switzerland 
Laboratory comparison study 
using smoking machines 
THS 2.2  
Cigarette 
To compare levels of HPHC in mainstream 
emissions and smoke 
Schaller, Pijnenburg et 
al. 2016(338) 
PMI, 
Switzerland 
Laboratory comparison study 
using smoking machines 
THS 2.2  
Cigarette 
To compare levels of HPHC in mainstream 
IQOS emissions from regular and menthol 
tobacco sticks with those in mainstream 
cigarette smoke 
Sidestream & 
environmental 
emissions 
    
Mitova, Campelos et al. 
2016(333) 
PMI, 
Switzerland 
Laboratory comparison study 
using smoking volunteers 
THS 2.2  
Cigarette 
To compare levels of environmental 
smoke/emissions 
O’Connell, Wilkinson et 
al. 2015(334) 
IT, 
United Kingdom 
Laboratory comparison study 
using smoking volunteers 
THS 2.2  
Nicorette inhalator 
EC (cigalike) 
To compare levels of sidestream emissions 
Protano, Manigrasso et 
al. 2016(335) 
Non-sponsored, 
Italy 
Laboratory comparison study 
using smoking volunteers 
THS 2.2  
Cigarette 
Hand-rolled cigarette 
EC (pen-style tank) 
To compare levels of environmental 
smoke/emissions  
Ruprecht, De Marco et 
al. 2017(336) 
National Cancer 
Institute Italy & 
University of 
Southern California, 
not reported 
Laboratory comparison study 
using smoking volunteers 
THS 2.2  
Cigarette 
EC (cartridge)  
To compare levels of environmental 
smoke/emissions  
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Authors, year of 
publication Funder, country Study design 
Heated tobacco product and 
reference products 1 Main aim 
Effects of use by 
humans     
Brossard, Weitkunat et 
al. 2017(341) 
PMI, 
Japan 
Randomised crossover 
experimental trial 
THS 2.2  
Cigarette 
Nicotine gum 
To compare nicotine delivery and effects on urge 
to smoke  
Haziza, de La 
Bourdonnaye, Merlet et 
al. 2016(328) 
PMI, 
Japan RCT 
THS 2.2  
Cigarette 
To compare exposure to HPHC during 5 days of 
use 
Haziza, de La 
Bourdonnaye, Skiada, 
et al. 2016 (329) 
PMI, 
Poland RCT 
THS 2.2  
Cigarette 
To compare exposure to HPHC during 5 days of 
use 
Kamada, Yamashita et 
al. 2016 (344) 
None reported, 
Japan Case report IQOS 
To report a case of acute eosinophilic 
pneumonia following use 
Lopez, Hiler et al. 2016 
(339) 
National Institutes of 
Health & FDA, 
United States 
Randomised crossover 
experimental trial 
Pax LLTV 
Cigarette 
eGo EC (pen-style tank) 
To compare nicotine delivery, expired air CO 
and abstinence symptom suppression 
Ludicke, Baker et al. 
2017 (326) 
PMI, 
Poland RCT 
THS 2.1 
Cigarette 
To compare exposure to HPHC during 5 days of 
use in confinement 
Ludicke, Haziza et al. 
2016 (325) 
PMI, 
Poland RCT 
CHTP 
Cigarettes 
To compare exposure to HPHC during 5 days of 
use in confinement 
Ludicke, Picavet et al. 
2017c (343) 
PMI, 
Japan RCT 
THS 2.2  
Cigarette 
To compare exposure to HPHC during 5 days of 
use in confinement and further 85 days of use in 
an ambulatory setting 2 
Ludicke, Picavet et al. 
2017b (342)  
PMI, 
Japan RCT 
THS 2.2  
Cigarette 
To compare effect on biologically and clinically 
relevant risk markers during 90 days of use  
Picavet, Haziza et al. 
2016 (340) 
PMI, 
United Kingdom RCT 
THS 2.1 
Cigarette 
To compare nicotine delivery and effects on urge 
to smoke  
Epidemiology     
Tabuchi, Kiyohara et al. 
2016 (155) 
Ministry of Health, 
Labour and Welfare 
Japan 
Cross-sectional survey, 
nationally representative 
sample 
IQOS, Ploom/Ploom TECH, glo To report awareness and use of heated tobacco products in a nationally representative sample 
Tabuchi, Gallus et al. 
2017 (345) 
Ministry of Health, 
Labour and Welfare 
& Society for the 
Promotion of 
Science, 
Japan 
Follow-up survey of 
participants in Tabuchi et al, 
2016 (155) 
IQOS, Ploom/Ploom TECH, glo 
To assess population interest, rate of use, 
predictors of use, and perceived effects of 
second-hand aerosol 
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1 Labels as provided by study authors, additional EC categories in brackets 
 
2 Confinement means that participant stayed in a controlled environment and were not given access to other products. Ambulatory refers to a period of use outside of that controlled 
environment. 
 
Abbreviations: CHTP: carbon heated tobacco product; Cigarette: Factory-made cigarette; HPHC: harmful and potentially harmful compounds; IT: Imperial Tobacco (now Imperial Brands); 
LLTV: loose-leaf tobacco vaporiser; PMI: Philip Morris International; THS 2.1: tobacco heating system 2.1.; THS 2.2: tobacco heating system 2.2 (commercially available as IQOS) 
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Heated tobacco product nicotine and emissions 
Nicotine levels in tobacco sticks 
An independent study (332) reported that a regular IQOS tobacco stick contained 
15.2 ± 1.1 mg of nicotine per gram of tobacco and a menthol tobacco stick contained 
15.6 ± 1.7 mg of nicotine per gram of tobacco. Based on the reported average weight of 
a tobacco stick of 320 mg (327), this equates to 4.9–5 mg of nicotine in each IQOS 
tobacco stick. For comparison, commercially available cigarettes have around 10–
14 mg nicotine per gram of tobacco (346) and the mean amount per cigarette has been 
reported as 8.7 mg (347) or 10–15 mg (348). However, the content of products before 
use is less relevant than what is inhaled by the user and those around them. Smokers 
usually take in about 1-2mg nicotine per cigarette (348).  
 
Emissions 
For cigarettes, emissions can be categorised into mainstream, sidestream and 
environmental (or second-hand) tobacco smoke. Mainstream tobacco smoke is usually 
defined as the smoke that the user draws in (349). Laboratory studies use machines to 
measure the mainstream that would be inhaled by a smoker. Sidestream smoke is 
smoke that is emitted from the burning end of a cigarette or other tobacco product 
(349). Environmental tobacco smoke or second-hand smoke is the combination of 
exhaled mainstream smoke and sidestream smoke and ambient air (349). To 
categorise the studies in this section, we transfer this categorisation to heated tobacco 
products as mainstream, sidestream and environmental emissions. All eight studies 
that focused on heated tobacco product emissions (Table 24) assessed IQOS 
products; we present the results based on the studies’ key focus on i) mainstream 
emissions, ii) sidestream and environmental heated tobacco product emissions. 
 
Mainstream emissions 
Nicotine levels 
 
The available evidence suggests that nicotine levels in mainstream heated tobacco 
product aerosol are lower than those in cigarette smoke. Two independent (331, 332) 
and two manufacturer-funded studies (337, 338) reported on nicotine levels in heated 
tobacco product aerosol. The studies used different reference cigarettes and different 
machine smoking regimes, either the ISO regime (ISO; 35 mL puff volume, 30 s 
intervals between puffs, 14 puffs on average during 5–6 minutes) or the Health Canada 
Intense regime (HCI; 55 mL puff volume, 2 s puff duration, 30 s intervals between puffs, 
14 puffs on average during 5–6 minutes). Generally, for cigarettes, the HCI regime 
yields higher levels of Harmful and Potentially Harmful Compounds (HPHC) (350) than 
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the ISO regime but neither are representative of human smoking behaviour and 
exposure (351). These regimes were also used for the heated tobacco products and 
EC, sometimes with adaptations.  
 
One independent study (331) followed the ISO puffing regime and used BAT’s Lucky 
Strike Blue Lights (7 mg tar, 0.6 mg nicotine) as a reference cigarette, another 
independent study (332) used the HCI regime and PMI’s Marlboro Regular reference 
cigarette (10 mg tar, 0.8 mg nicotine). The two studies funded by the manufacturer 
(337, 338) used the HCI regime and University of Kentucky 3R4F reference cigarette 
(9.4 mg tar, 0.7 mg nicotine). The independent study that used the ISO regime (331) 
reported an average yield of 0.3 mg of nicotine in the aerosol from a single tobacco 
stick. The other three studies (332, 337, 338) used the HCI puffing regime and reported 
nicotine levels in the aerosol which were similar across studies. For regular tobacco 
sticks, they found a mean and SD of 1.40 ± 0.16 mg (332), 1.38 ± 0.2 mg (338) and 
1.32 ± 0.16 mg nicotine (337) and for menthol sticks they reported 1.38 ± 0.11 mg (332) 
and 1.21 ± 0.09 mg (337) nicotine. Across the four studies, the relative level of nicotine 
in the heated tobacco product aerosol compared with nicotine in cigarette smoke was 
reported at 84% (331), 73% (338), 72% (332) and 70% (337). 
 
One study (332) compared nicotine levels in heated tobacco product aerosol with 
nicotine in aerosol from EC using the HCI puffing regime with increased 4 seconds 
puffing duration. The heated tobacco product delivered more nicotine than a cigalike 
EC (0.86 ±0.08 mg, p<0.001), but less than an ‘eGo-style’ (pen-style tank) EC (1.73 
± 0.09 mg, p<0.001) or a variable wattage tank style EC (1.84 ± 0.11 mg, p<0.001). 
 
Harmful and potentially harmful compounds  
 
One independent (331) and two manufacturer-funded studies (337, 338) reported 
levels of HPHC in mainstream heated tobacco product aerosol compared with cigarette 
smoke. Different machine puffing regimes and reference cigarettes were used across 
studies, so results cannot be directly compared. The three studies reported proportions 
of HPHC in aerosol from regular tobacco sticks for the heated tobacco product 
compared with HPHC levels in smoke from reference cigarettes; for some, they found 
similar proportions, others differ widely (Table 25). 
 
When comparing levels of polycyclic aromatic hydrocarbons in heated tobacco product 
aerosol and cigarette smoke, the independent study (331) used reference data from 50 
US cigarette brands (350). However, as a critique from PMI noted (352), Auer and 
colleagues (331) had inadvertently used incorrect reference values for these 
constituents (data obtained under HCI instead of ISO regimes). Therefore, for the 
purposes of this chapter, we recalculated the ratios and provide both the originally 
published and the recalculated ratios in the comparison of relative levels of three 
polycyclic aromatic hydrocarbons across the three studies (Table 25). 
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Auer and colleagues also assessed further constituents and reported a much higher 
concentration of the polycyclic aromatic hydrocarbon acenaphthene for the heated 
tobacco product relative to cigarettes (295% reported in the publication; 580% if using 
ISO reference values). Acenaphthene was not included in the manufacturer studies; 
the manufacturer commented that the compound is not included in any regulatory lists 
and that Auer’s method may have been faulty, and that they ‘could not detect it 
[acenaphthene] in the IQOS aerosol’ (352). 
 
Table 25: Level of constituents in mainstream heated tobacco product (IQOS) aerosol 
relative to mainstream cigarette smoke (only showing constituents measured in all three 
studies) 
 
Schaller, 
Pijnenburg et al. 
2016 (338) 
Schaller, Keller et al.  
2016 (337) 
Auer, Concha-
Lozano et al. 
2017 (331) 
Tobacco stick Regular Regular Menthol Regular 
Reference cigarette 3R4F 3R4F 3R4F Lucky Strike Blue 
Puffing regimen HCI HCI HCI ISO 
Levels relative to 
cigarette     
Nicotine (mg/stick) 73% 70% 64% 84% 
Gases     
Nitric oxide (µg/stick) 3% 3% 3% 6% 
Carbonyls     
Acetaldehyde 12% 14% 13% 22% 
Propionaldehyde 12% 12% 11% 26% 
Formaldehyde 11% 10% 8% 74% 
Acrolein 7% 7% 6% 82% 
Crotonaldehyde <6% 6% 5% 4% 
Acetone 5% 6% 5% 13% 
Polycyclic aromatic 
hydrocarbons     
Benzo[a]pyrene 
(ng/stick) 7% 9% 8% 4%*/ 8%** 
Benz [a]anthracene 
(ng/stick) 10% 5% 9% 6%*/ 11%** 
Pyrene (ng/stick) 10% <6% 10% 7%*/ 15%** 
 
* Originally reported proportions 
 
** We calculated these proportions based on mean values of polycyclic aromatic hydrocarbons in mainstream smoke of 50 
commercial US cigarettes measured by the ISO smoking regimen as reported by (Vu, Taylor et al. 2015) 
 
Sidestream and environmental emissions 
Published evidence disagrees on the extent to which heated tobacco products produce 
environmental emissions and the composition of these emissions.  
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Four studies, two independent (335, 336), one manufacturer-funded (333) and one 
funded by a competing tobacco company (334), compared environmental heated 
tobacco product emissions with environmental tobacco smoke from factory-made (333, 
335, 336) or hand-rolled (335) tobacco cigarettes, or aerosol from a nicotine inhalator 
(334) and different EC (334-336). The studies were heterogeneous in the methods 
used and in the reporting of results, therefore only key findings are summarised here. 
 
Two studies (334, 335) reported few measurements of individual compounds and only 
provided some general conclusions about environmental heated tobacco product 
emissions. The independent study (335) reported that the tested EC and heated 
tobacco product generated four times lower levels of submicronic particles, an indicator 
of second-hand smoking, compared with environmental tobacco smoke from regular or 
hand-rolled cigarettes. Despite low levels of emissions, the study authors concluded 
that the tested EC and heated tobacco products still posed health risks to users and 
bystanders (335). The study funded by the competing tobacco company (334) reported 
that IQOS produced a significantly greater level of sidestream emissions than a 
nicotine inhalator or an EC: the heated tobacco product emissions were detectable 
when the device was activated but not used, which contradict the manufacturer’s 
claims that IQOS ‘does not emit a true sidestream aerosol’ (333). 
 
The second independent study (336) reported levels of particulate matter of different 
sizes (>1.0 µm, >0.3 µm, and 10-1000 nm) and HPHC in environmental heated tobacco 
product emissions. In simulated indoors conditions with 1.54 air changes per hour 
levels of nano-sized (10-1000 nm) particulate matter in environmental heated tobacco 
product emissions reached up to 23.8% of the levels detected in environmental tobacco 
cigarette smoke; levels for other size particulate matter in environmental heated 
tobacco product emissions ranged from 0.7% to 7.3%. Regarding HPHC in 
environmental heated tobacco product emissions, acrolein concentration reached 
1.8%-2.3% of levels detected in environmental cigarette smoke, acetaldehyde reached 
5.0%-5.9%, and formaldehyde 6.9%-7.1%. For EC, these were not detectable, with the 
exception of nano-sized particles (5.7%-7.0% of cigarettes), acetaldehyde (0.2%-0.3%) 
and formaldehyde (3.1%-3.7%). The study concluded that environmental emissions 
from heated tobacco products were substantially higher than from EC but significantly 
lower than those detected in environmental tobacco smoke from a cigarette. The study 
authors also noted the presence of carbonyls in environmental heated tobacco product 
emissions as a concern that heated tobacco product use might affect bystanders (336). 
 
In contrast to other three studies, the manufacturer-funded study (333) concluded that 
the tested heated tobacco product did not produce particulate matter and also reported 
lower levels of environmental heated tobacco product emissions compared with 
environmental tobacco smoke from a cigarette. In simulated indoors condition with 1.2 
air changes per hour, no change in particulate matter markers was detected and levels 
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of HPHC in air after heated tobacco product use ranged from 5.8% for benzene to 
40.5% for formaldehyde compared with cigarette smoke. 
 
Heated tobacco product use by human participants and effects of use 
We summarise nine articles that compared levels of exposure to biomarkers of HPHC, 
nicotine delivery characteristics, human puffing topography, effect on urges to smoke 
and subjective satisfaction with heated tobacco products. The six RCTs (one of them 
reported in two papers) and two studies with a crossover design are presented by the 
type of heated tobacco product they assessed. 
 
Loose-leaf tobacco vaporiser 
One independent study (339) used a crossover design (so that each of the 15 
participants went through all three conditions) to compare the loose-leaf tobacco 
heated tobacco product Pax, cigarettes and pen-style EC. The study compared nicotine 
delivery, levels of expired air CO concentration and suppression of nicotine abstinence 
symptoms after short periods of use. The short period of use consisted of 10 puffs 
separated by 30 seconds and each period was separated by 60 minutes. The highest 
plasma nicotine levels were reported after cigarette use (24.4 ng/mL), lower levels were 
found after heated tobacco product use (14.3 ng/mL) and the lowest after EC use 
(9.5 ng/mL). Baseline expired air CO was around 5 parts per million for all conditions. 
After two periods of smoking a cigarette, this increased significantly (up to 16.9 parts 
per million, p<0.001), which contrasted with small but significant decreases after single 
periods of heated tobacco product and EC use (ps<0.05); no differences between the 
latter two were observed. Nicotine delivery was associated with suppression of nicotine 
abstinence symptoms; smoking a cigarette suppressed them most, use of the heated 
tobacco product was less effective, and use of the EC was least effective. Based on 
participants’ responses to a specifically modified version of Direct Effects of Product 
Scale questionnaire, the study authors concluded that the heated tobacco product and 
the EC were less satisfying than cigarettes. 
 
Carbon heated tobacco product 
One manufacturer-funded RCT (325) compared levels of exposure to HPHC between 
smokers who were randomised to using a CHTP (predecessor to TEEPS), to continue 
smoking, or to abstain from smoking, for five days in ‘confinement’, ie in a controlled 
environment without access to other products (n=112). After switching, smokers in the 
CHTP group were reported to demonstrate less exposure to HPHC than participants 
who continued smoking (Table 26). Smokers in the CHTP group altered their 
behaviour: they took more frequent and longer puffs, showed higher average and total 
puff volumes. On day five, product consumption by those randomised to the CHTP was 
reported to be 19.7 compared with 18.8 cigarettes among smokers randomised to 
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continued cigarette smoking. At the end of the five-day confinement period, nicotine 
equivalents measured in urine in the CHTP group was reported at 19.1 ng/mL 
compared with 17.2 ng/mL in the cigarette smoking group, plasma cotinine for the past 
24 hours was 319.8 mg versus 289.8 mg; these differences were not statistically 
significant. 
 
Tobacco heating system 2.1 (THS 2.1) 
Two manufacturer-funded RCTs (326, 340) reported findings on THS 2.1. One trial 
(340) compared the pharmacokinetic nicotine delivery profile of THS 2.1 with non-
menthol and smokers’ preferred cigarettes (n=28). After single use, THS 2.1 and 
cigarettes were reported to be similar in how fast plasma nicotine levels reached peak 
(median for both: 8 minutes), reduction of urges to smoke, and in the nicotine half-life 
length (2.6 hours for THS 2.1 and 2.5 hours for a cigarette). However, compared with 
cigarettes, THS 2.1 delivered lower peak levels of nicotine after single and a day’s ad 
libitum use (70% and 62%, respectively) and participants consumed fewer tobacco 
sticks than smokers smoked cigarettes during an ad libitum use day (10.9 tobacco 
sticks versus 16.7 CPD). THS 2.1 was perceived less rewarding in sensory and 
physical effects when used ad libitum; on the modified cigarette evaluation scores 
(353), THS 2.1 was rated significantly lower on four out of five subscales (Smoking 
satisfaction, Psychological rewards, Enjoyment of respiratory tract sensation and 
Craving reduction). The other trial (326) compared exposure levels to HPHC in 
smokers randomised to using THS 2.1 with smokers randomised to continued smoking; 
both groups were in confinement for five days (n=40). The exposure to HPHC was 
reported to be lower in the THS 2.1 group (Table 26). In contrast to the previous study 
findings that showed less use during one day, in this five-day study smokers in the THS 
2.1 group used up to 35% more tobacco sticks than the other group cigarettes (27.2 
and 20.1 respectively). Despite compensatory puffing (increased frequency, duration 
and volume), THS 2.1 users achieved only 85% and 88% of nicotine and cotinine of the 
cigarette group on the last confinement day. Modified cigarette evaluation scores were 
again significantly lower for THS 2.1 on the same four subscales. 
 
Tobacco heating system 2.2 (THS 2.2) 
The review identified a single case report related to use (344), one publication on a 
manufacturer randomised cross-over study and four publications reporting on three 
manufacturer-funded RCTs (328, 329, 341-343) using THS 2.2 which is equivalent to 
the commercially available IQOS.  
 
The case report (344) described a case of acute eosinophilic pneumonia in a 20-year-
old man from Japan who used 20 IQOS tobacco sticks per day for six months and 40 
IQOS tobacco sticks a day for two weeks before hospitalisation. Based on the 
relationship between cigarette smoking and this type of pneumonia, the case report 
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authors presumed that the rapid increase in the daily use of tobacco sticks had caused 
the onset of the acute eosinophilic pneumonia. 
 
The randomised cross-over study (341) was conducted in Japan and assessed 
pharmacokinetic nicotine delivery properties of regular and menthol THS 2.2 compared 
with cigarettes (n=44) and nicotine gum (n=18). The study authors concluded that the 
use of regular and menthol THS 2.2 delivered nicotine in a similar way as smoking 
regular and menthol cigarettes. In detail, compared with cigarettes, nicotine 
pharmacokinetics for regular and menthol tobacco sticks were similar to each other and 
similar to cigarettes: peak plasma concentrations for regular and menthol tobacco 
sticks and cigarettes were reached in six minutes, actual exposure to nicotine was 
comparable (ratio THS 2.2 : cigarettes: 96.3% for regular, 98.1% for menthol), as was 
nicotine half-life (93.1% and 102.3%). Peak nicotine concentration ratio for regular 
tobacco sticks versus cigarettes was 103.5% and 88.5% for menthol tobacco sticks 
versus cigarettes. Relative to nicotine gum, the results are less clear, probably due to 
the small sample. Regular tobacco sticks appeared to outperform menthol sticks for 
actual exposure to nicotine (127.2% and 55.9%) and peak nicotine concentration 
(240.2% and 101.6%); however, with only 18 participants, this may be due to chance. 
Relative to gum, nicotine half-life was 87.3% for regular and 92.1% for menthol tobacco 
sticks.  
 
Four papers reported on the three RCTs. Two manufacturer-funded RCTs, one 
conducted in Japan (328) and the other in Poland (329), compared the exposure to 
HPHC in smokers who were in confinement randomised to using regular THS 2.2 for 
five days, to continued smoking of their preferred non-menthol cigarette, or to smoking 
abstinence (both RCTs n=160). Two papers (342, 343) reported findings from one 
manufacturer-funded RCT comparing menthol THS 2.2 with menthol cigarettes 
conducted in Japan where exposure to HPHC and change in health risk markers were 
assessed after five days in confinement and a further 85 days in ambulatory setting. 
This RCT also had a third group of participants randomised to abstain from smoking. 
 
The three RCTs reported daily product use at the end of five days in confinement and 
provided contrasting results; in the trial in Japan (328), the THS 2.2 group used 
significantly fewer (on average 20%) tobacco sticks than the smoking group smoked 
cigarettes, while in the trial in Poland (329), the THS 2.2 group used significantly more 
(on average 25%) tobacco sticks than the other group cigarettes. In the menthol study 
(343), daily use of tobacco sticks and cigarettes did not differ.  
 
Publications on all three RCTs reported lower levels of exposure to biomarkers of 
HPHC in smokers who switched to using THS 2.2 compared with smokers who 
continued smoking (Table 26), (328, 329, 342). Across the three studies, the reduction 
in exposure to HPHC in the THS 2.2 groups approached that reported in the groups 
randomised to smoking abstinence. 
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The three RCTs also reported similar findings on puffing topography, the ability of THS 
2.2 to supress urges to smoke and modified cigarette evaluation scores. THS 2.2 users 
throughout all three studies demonstrated different puffing behaviours that may indicate 
compensatory puffing (increased puffing frequency, duration and number of puffs 
compared with the smoking group). THS 2.2 was reported to supress urges to smoke 
similarly to smoking cigarettes and was in all three studies rated lower on sensory and 
psychological satisfaction than cigarettes (significantly lower scores for THS 2.2 on four 
out of five modified Cigarette Evaluation Questionnaire (mCEQ) subscales in two 
studies (329, 343) and on one subscale in the other study (328). 
 
The RCT with a 90-day follow-up (342) additionally measured changes in a set of risk 
markers associated with CVD (eg endothelial functions, cholesterol metabolism, 
platelet functions, inflammation and oxidative stress). When compared with smokers 
who continued to smoke menthol cigarettes, smokers who had been randomised to 
using menthol THS 2.2 were reported to show improvements in risk markers associated 
with endothelial dysfunction, oxidative stress, inflammation, and high-density lipoprotein 
cholesterol counts, with the changes reportedly approaching those in the group 
randomised to complete abstinence. However, participants may have been non-
compliant with study conditions. Reportedly, 92.5% participants randomised to smoking 
abstinence and 89.7% randomised to exclusive heated tobacco product use were 
compliant throughout the 85 days of ambulatory use. However, compliance was 
defined as not having used more than two menthol CPD since the last visit and not 
more than half a cigarette per day on average. Consumption was assessed by self-
reported electronic diary entries, and while expired CO was measured, results were not 
reported, thereby not following standard practice (165) (354). This suggests that both 
‘abstinent’ participants and heated tobacco product participants may have been 
smoking. If heated tobacco product users had also smoked, any reduction in 
biomarkers relative to smokers would be conservative; however, comparison with the 
abstinence group should be treated with particular caution as the extent of abstinence 
is unclear. Study validity is further undermined because the study used a per-protocol 
approach instead of intention to treat analysis which compromises the validity of 
randomisation (355) and is in contravention to trial standards outlined eg in the 
CONSORT statement (356). 
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Table 26: Product use and level of exposure to HPHC in heated tobacco product users 
relative to cigarette smokers  
 
 
Ludicke, 
Haziza et al. 
2016 (325) 
Ludicke, 
Baker et al. 
2017 (326) 
Haziza, de La 
Bourdonnaye, 
Merlet, et al. 
2016 (328) 
Haziza, de La 
Bourdonnaye, 
Skiada, et al. 
2016 (329) 
Ludicke, 
Picavet et al. 
2017a; 2017b 
(342, 343) 
Heated tobacco 
product 
Carbon heated 
tobacco 
product 
THS 2.1, 0.3mg 
nicotine, 
5.0mg* glycerol 
Non-menthol 
THS 2.2, 0.5mg 
nicotine, 4.9mg 
glycerol 
Non-menthol 
THS 2.2, 0.5mg 
nicotine, 4.9mg 
glycerol 
Menthol THS 
2.2, 1.2mg 
nicotine, 3.9mg 
glycerol 
Reference product 
Non-menthol 
cigarette, 
preferred brand 
Non-menthol 
cigarette, 
preferred brand 
Non-menthol 
cigarette, 
preferred brand 
Non-menthol 
cigarette, 
preferred brand 
Menthol 
cigarette, 
preferred brand 
Mean (SD) product 
use (heated tobacco 
vs reference) 
19.7 (7.8) vs 
18.8 (4.4) 
27.2 (9.1) vs 
20.1 (3.2) 
9.9 (3.9) vs 
12.5 (3.5) 
20.7 (8.1) vs 
16.6 (3.8) 
13.9 (4.3) vs 
13.6 (4.7) 
Biomarkers for 
HPHC, Mean (95% 
CI if available) 
     
Carbon monoxide 
(CO) 39% 
23%  
(21%–26%) 
47%  
(44%–50%) 
24%  
(22%–25%) 45% 
Acrolein 26% 28% (23%–33%) 
53%  
(46%–61%) 
42%  
(38%–46%) 52% 
1,3-butadiene 10% 12%  (9%–16%) 
23%  
(18%–29%) 
8%  
(7%–10%) 13% 
Benzene 16% 7%  (5%–10%) 
16%  
(13%–19%) 
6%  
(5%–7%) 11% 
Nicotine-derived 
nitrosamine ketone 
(NNK) 
52% 33%  (25%–44%) 
49%  
(42%–57%) 
44%  
(39%–48%) 44% 
Pyrene 57% 43%  (36%–51%) 
46%  
(41%–52%) 
44%  
(40%–49%) 38% 
N-nitrosonornicotine 
(NNN) not reported 
12%  
(9%–16%) 
30%  
(24%–38%) 
24%  
(18%–33%) 29% 
4-Aminobiphenyl 16% 41%  (31%–53%) 
18%  
(15%–22%) 
15%  
(13%–17%) 21% 
1-aminonaphthalene not reported not reported 4%  (4%–5%) 
4%  
(3%–5%) 6% 
2-aminonaphthalene 19% 11%  (8%–14%) 
18%  
(15%–21%) 
12%  
(10%–13%) 14% 
o-toluidine 49% 58%  (48%–71%) 
51%  
(42%–60%) 
42%  
(36%–48%) 41% 
Acrylonitrile not reported 15%  (12%–18%) 
21%  
(18%–25%) 
13%  
(12%–15%) 18% 
Ethylene oxide not reported not reported 47%  (40%–55%) 
32%  
(27%–38%) 51% 
Crotonaldehyde not reported not reported 38%  (32%–45%) 
23%  
(20%–25%) 43% 
Benzo(a)pyrene not reported not reported 30%  (25%–36%) 
28%  
(23%–33%) 28% 
Nicotine equivalents 111% 87%  (76%–100%) 
105%  
(92%–120%)1/ 
99%2 
105%  
(92%–120%) 118% 
Nicotine not reported 85%  (62%–115%) 
113%  
(91%–140%)1/ 
90%2 
113%  
(91%–140%) not reported 
Cotinine 110% 88%  (75%–103%) 
96%  
(71%–131%) 
111%  
(91%–136%) not reported 
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All figures from fifth day of confinement (including only studies that used at least 5 days of confinement) 
 
* Reported as 50mg in publication, authors confirmed this was a typo and should be 5.0mg 
 
1 Originally reported proportions 
 
2 Proportions we calculated based on raw study figures 
 
Epidemiological studies on heated tobacco product use  
The literature search identified one independently-funded survey on awareness and 
use of heated tobacco products in Japan in 2015 (155), which was conducted about 
three months after the launch of IQOS and about a year after the launch of Ploom. EC 
are not generally available in Japan. Additionally, we report unpublished findings from a 
follow-up to that survey (357). 
 
The 2015 survey (155) provided evidence from a nationally representative sample of 
8,240 respondents aged 15 to 69 years. Survey questions did not distinguish between 
EC and heated tobacco products; almost half of Japan’s population (48%) were aware 
of EC and/or heated tobacco products, 6.6% had ever used these products, and 1.3% 
used them in the last 30 days. Data by product type were only reported for ever use 
which showed that 0.5% of the population had ever used Ploom and 0.6% had ever 
used IQOS. The as yet unpublished data on heated tobacco use in Japan in 2017 (357) 
are based on annual surveys following up the 2015 sample (follow-up rate 65.6% in 
2016 and 52.2% in 2017) and suggest growth in IQOS use. These data include past 30 
day use for different products for 2015 allowing comparisons over time; in 2015, 0.3% 
reported using IQOS in the last 30 days, this increased to 0.6% in 2016 and 3.6% in 
2017 (never smokers 1.3%, ex-smokers 2.1%, current smokers with intention to quit 
18.8%, current smokers without intention to quit 10.3%). Last 30-day use of other 
commercially available heated tobacco products in 2017 was reported at 1.2% for 
Ploom/ploom TECH and 0.8% for glo (the same respondent may have used more than 
one product). Smoking rates remained unchanged across survey waves (22.1% in 
2015, 22.0% in 2017). It is also reported that among the 7% of never-smokers who had 
been exposed to second-hand heated tobacco aerosol, nearly half reported at least 
one acute symptom, although these symptoms were not serious (357). 
 
Data and trends from Japan are not easily transferrable to the UK because in contrast 
to the UK, EC are not legal in Japan giving heated tobacco products a very different 
starting position. Nevertheless, data from Japan show rapid penetration of a non-
combustible tobacco product into the market. 
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Additional survey data from GB  
These data are unpublished and therefore not included in the preceding systematic 
review. The STS and ASH-A have introduced questions on heated tobacco products. In 
the ASH-A 2017, 9.3% reported awareness of heated tobacco products and 1.7% had 
tried or were using the products. Among those who had ever tried heated tobacco 
products, 38.7% had tried it once or twice and 12.7% had been using it daily. However, 
survey participants were asked about heated tobacco products prior to answering 
about EC, which is likely to have had led to overestimations of awareness and use of 
heated tobacco products (see Brose and colleagues (358) for more details). The 
hypothesis that the ASH-A represents an overestimation is strongly supported by data 
from the STS. Between January and July 2017, nearly 12,000 respondents were 
surveyed. The STS did not ask about awareness of the product, only about use. Last-
year smokers (n=2,185) were asked about use of heated tobacco products in recent 
quit attempts (n=4 reported use), to help cut down the amount smoked (n=6), in 
situations where not allowed to smoke (n=1) or for any other reason (n=0). Among 
never and long-term ex-smokers (n=9,777), n=5 said they were using heated tobacco 
products.  
 
Conclusions  
Key findings 
• In mid 2017 heated tobacco products were commercially available in 27 countries 
and further country launches were planned. Three tobacco manufacturers were 
promoting heated tobacco products: ‘IQOS’ was promoted by PMI, ‘glo’ by BAT, and 
‘Ploom TECH’ by Japan Tobacco International. 
• Out of 20 studies that were included in this review, 12 were funded by 
manufacturing companies so there is a lack of independent research.  
• There is a variety of heated tobacco products, including some that deliver via both 
vapour and combustion.  
• Most studies published at the time of the search for this review evaluated IQOS, 
none evaluated glo or Ploom TECH. An updated version of the review inlcuding 
later publications is in preparation to be published separately. 
• In Great Britain, in 2017, awareness and ever use of heated tobacco products were 
very rare. 
• Nicotine in mainstream aerosol from heated tobacco products reached 70%–84% of 
the nicotine detected in smoke from reference cigarettes. 
• The tested heated tobacco products delivered more nicotine in aerosol than a 
cigalike EC and less nicotine than tank style EC. 
• Pharmacokinetics and delivery of nicotine after single use of a heated tobacco 
product were generally comparable with smoking a cigarette. However, studies that 
compared ad libitum use of heated tobacco products with smoking cigarettes 
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consistently reported lower nicotine levels in heated tobacco product users 
compared with smokers. 
o Probably to compensate, smokers who were switched to using heated tobacco 
products adjusted their puffing behaviour. 
• Heated tobacco product use reduced urges to smoke, but smokers consistently 
reported heated tobacco product use to be less rewarding compared with smoking a 
cigarette. 
• Compared with cigarettes, heated tobacco products are likely to expose users and 
bystanders to lower levels of particulate matter and harmful and potentially harmful 
compounds (HPHC). The extent of the reduction found varies between studies.  
• The limited evidence on environmental emissions from use of heated tobacco 
products suggests that harmful exposure from heated tobacco products is higher 
than from EC, but further evidence is needed to be able to compare products. 
• Japan, where EC are not available, has the most diverse heated tobacco product 
market with three tobacco manufacturers participating. Past 30 day use for the most 
frequently used product increased from 0.3% in 2015 to 3.7% in 2017, suggesting 
rapid penetration of heated tobacco products.  
 
Implications 
Research 
• There is a need for more research that is independent of commercial interests. 
• Different types of heated tobacco products will have different characteristics and 
effects, presenting a challenge for research 
• Research is needed on relative risk of heated tobacco products to users and those 
around them compared with cigarettes and EC.  
• Evidence is needed on appeal of heated tobacco products to smokers and non-
smokers, particularly among youth. 
• Effects on smoking need to be researched, this includes whether they replace or 
complement cigarettes. Due to co-branding of some products with cigarettes and 
the more similar sensory profile, findings may be different than for EC.  
• Future studies, whether funded by manufacturers or independently should ensure 
conduct of studies in line with established guidelines such as definitions of 
abstinence from smoking, using intention-to-treat analysis and registering trial 
protocols prior to the start of participant recruitment.  
• The appropriateness of different methods for measuring emissions and their 
translation from cigarettes to heated tobacco products should be evaluated to be 
able to recommend a gold standard. 
• Prevalence and market share should be monitored, particularly in markets targeted 
by manufacturers.  
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o In line with recommendations for EC use (135), measures should go beyond 
lifetime use or past 30 day use to assess current use; uptake and use should be 
assessed by smoking status.  
o Monitoring should include transitions between smoking, EC use and heated 
tobacco product use.  
 
Policy and practice 
• The available evidence suggests that heated tobacco products may be considerably 
less harmful than tobacco cigarettes and more harmful than EC.  
• With a diverse and mature EC market in the UK, it is currently not clear whether 
heated tobacco products provide any advantage as an additional potential harm 
reduction product.  
• Depending on emerging evidence on their relative risk to combustible tobacco and 
EC, regulatory levers such as taxation and accessibility restrictions should be 
applied to favour the least harmful options alongside continued efforts to encourage 
and support complete cessation of tobacco use.  
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Appendices 
 
1  ASH-A unweighted base sizes 
1. By smoking status over time (age 18+) 
 
 
2012 2013 2014 2015 2016 2017 
Total 12,436 12,171 12,269 12,055 12,157 12,696 
Never-smokers 5,967 5,973 5,995 6,129 6,099 6,626 
Ex-smokers 4,132 4,303 4,498 3,889 4,354 4,438 
Smokers 2,337 1,895 1,776 2,037 1,704 1,632 
 
2. By EC use and smoking status, 2017 (age 18+) 
 
 
Never 
smokers Ex-smokers Smokers Total 
Never heard of them/don’t 
know 370 162 63 595 
Never tried 6,146 3,491 600 10,237 
Tried or used in the past 95 424 676 1,195 
Currently using 15 361 293 669 
Total 6,626 4,438 1,632 12,696 
 
3. By EC use and smoking status for those who have used EC more than once or twice,  
2017 (age 18+) 
 
 
Never smokers Ex-smokers Smokers Total 
Used in the past 45 253 405 703 
Currently using 15 361 293 669 
Total 60 614 698 1,372 
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cessation or reduction (chapter 7) 
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3  Non–UK case reports concerning injuries caused by EC explosion (Chapter 8) 
Author, 
publication 
year and 
location 
n of 
cases 
Gender Age Circumstance 
of EC 
explosion 
Nature of injury Treatment Details of EC 
Archambeau et 
al., 2016 (395) 
US 
1 Male 59 In mouth while 
vaping 
Fractures to skull and nose, black eye, laceration to lips.  
Pneumocephalus. 
Oral and maxillofacial 
surgery 
Bought it online 2 days previously, 
no modifications made 
Bauman et al., 
2017 (396) 
US 
 
 
 
3 Male 58 While in right 
trouser pocket  
7% TBSA combination of deep partial-thickness and full-
thickness burns to the back and side of left thigh 
Wound management. Skin 
graft 
Reported as unclear 
Male 20 While in right 
trouser pocket 
(with coins and 
keys) 
4% TBSA superficial, partial-thickness burn to the right 
thigh 
 
Wound management Immediately prior to the injury, the 
patient had changed the used 
battery  
Male 37 While in right 
trouser pocket 
11% TBSA deep partial-thickness to full-thickness burn 
to left thigh and buttock 
Wound management and 
skin graft 
The lithium battery in his EC was 
over 1-year old  
Bohr et al., 
2016 (397) 
Germany  
1 Male 24 While in right 
trouser pocket 
8% TBSA superficial and deep burn and soot-particle 
contamination to right leg 
Wound management Tank style EC  
Brooks et al., 
2017 (398) 
US 
1 Male 18 In mouth while 
vaping 
Loss of three teeth and damaged a further three. 
External/intra oral lacerations. Fracture to nose.  
Wound management and 
four teeth extracted 
Had been vaping for approx. an hour 
and occurred after refilling EC with 
e-liquid.  
Colaianni et al., 
2016 (399) 
US  
 
 
3 Male  In mouth while 
vaping 
Loss and fracture of several teeth. External/intra oral 
lacerations. 
Sutures and dental care Not reported 
Male  While in right 
trouser pocket 
Third-degree burn injuries to legs and second-degree 
burn injuries to genitalia and/or hands 
Skin graft Not reported 
Male  While in right 
trouser pocket 
Third-degree burn injuries to legs and second-degree 
burn injuries to genitalia and/or hands 
Skin graft Not reported 
Cason et al., 
2016 (400) 
US  
1 Male 23 In mouth while 
vaping 
Multiple fractures to hard palate (roof of mouth) and 
nose. Loss of teeth. Fractured finger. Corneal abrasion. 
Surgical repair of his hard 
palate 
Not reported 
Foran et al., 
2017 (401) 
US 
1 Male 30 While holding the 
EC 
First and second-degree burns to left hand. Material 
from EC device embedded deep in tissue from high 
pressure injection  
Wound management and 
surgery to finger 
immediately and 5 months 
later 
Not reported  
Harshman et 
al., 2017 (402) 
Canada 
2 Male 31 While in  
trouser pocket 
along with coins 
(EC battery 
10% TBSA mixed partial thickness and 
full-thickness burns to his right thigh, buttock and leg, 
and left inner thigh 
Wound management and 
skin graft 
Not reported 
Male  36 While in  
trouser pocket 
along with coins 
and keys (EC 
battery)  
3% TBSA deep partial and full thickness burns to his 
right thigh and superficial partial thickness burns to right 
hand 
Wound management and 
skin graft 
Not reported 
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Author, 
publication 
year and 
location 
n of 
cases 
Gender Age Circumstance 
of EC 
explosion 
Nature of injury Treatment Details of EC 
Harrison and 
Hicklin, 2016 
(403) 
US 
1 Male 28 In mouth while 
vaping 
Tooth loss and damage, burns to tongue, lips and gum  Teeth extraction, gum 
surgery and teeth implants 
EC had just been charged (with a 
charger purchased separately to EC) 
Jablow and 
Sexton, 2015 
(404) 
US 
1 Male 30 While in trouser 
pocket (lithium 
battery only) 
 
8% TBSA superficial partial-thickness burn to right leg Wound management  Not known 
Jiwani et al., 
2017 (405) 
US  
10  Male 26 While in trouser 
pocket 
5.5% Mixed partial and full thickness burn to left thigh 
and lower leg, groin and scrotal area 
Wound management Not reported  
  Male 46 While in his lap  4.4% TBSA partial thickness burn to left thigh  
 
Wound management Not reported  
  Male 19 Battery explosion 
(circumstance not 
reported) 
3.5% TBSA mixed partial and full thickness Left hand 
and forearm, left thigh 
Skin graft Not reported  
  Male 29 While in trouser 
pocket 
4.5% TBSA full-thickness burn to left thigh Skin graft Not reported  
  Male 19 Motorcycle crash 
inducing ignition of 
EC in trouser 
pocket 
2% TBSA mixed partial and full thickness burn to right 
thigh 
Wound management Not reported  
  Female 18 In mouth while 
vaping  
1% TBSA partial thickness burn to right hand, dental and 
face trauma  
Wound management Not reported  
  Male 38 While in trouser 
pocket 
5% TBSA mixed partial and full thickness to right thigh  Skin graft Not reported  
  Male 22 While in trouser 
pocket (with keys) 
3% TBSA burn to left thumb left thigh Wound management Not reported  
  Male 29 Vaporiser 
explosion 
(circumstances not 
reported) 
27.25% TBSA mixed deep partial and full thickness 
burns to Bilateral upper extremities, face, ear, anterior 
chest, abdomen 
Skin graft and elective 
contracture releases of his 
axillary region and both 
hands at later date 
Not reported  
  Male 22 While in trouser 
pocket 
3.25 TBSA mixed partial thickness burn to right thigh and 
right hand 
Wound management Not reported  
Khairudin et al., 
2016 (406) 
Malaysia 
1 Male 18 While modifying 
the EC 
Laceration to right eyelid and conjunctival. Traumatic 
mydriasis, anterior uveitis. Cataract. 
Irrigation and suturing of 
the eyelid and conjunctival 
laceration wounds 
Modifying the tank of the mechanical 
EC, changing the original coil to a 
homemade copper coil 
Kite et al., 2016 
(407) 
 
2 
 
Male 19 In mouth while 
vaping 
External/intra oral lacerations.  
Loss of three teeth, fractures to four teeth  
Oral and maxillofacial 
surgery 
Homemade vaporizer 
Male 24 While holding EC 3% TBSA deep partial thickness, second-degree burns 
to chest and left forearm. Full thickness skin and soft 
tissue loss to right palm and fingers.  
Metal and chemical deposits in soft tissue of the hand 
Surgery and eventually 
amputation of finger 
Lone Wulf Mechanical Mod 
cigarette.  
242 
Evidence review of e-cigarettes and heated tobacco products 2018: 
A report commissioned by Public Health England 
 
 
Author, 
publication 
year and 
location 
n of 
cases 
Gender Age Circumstance 
of EC 
explosion 
Nature of injury Treatment Details of EC 
Kumetz et al., 
2016 (408) 
US  
 
2 
 
Male 29 In mouth while 
vaping 
External/intra oral burns, lip lacerations and superficial 
burns. Loss and fracture of several teeth. Post-traumatic 
stress disorder. 
Oral and maxillofacial 
surgery 
 Refillable rechargeable device  
Female 23 While in  
trouser pocket 
4% TBSA partial and full thickness burn to the right 
thigh. Partial-thickness burns to palm and 3 fingers on 
right hand  
 Not reported 
Norii and Plate, 
2017 (409)  
US 
1 Male 27 In mouth while 
vaping 
Fractures of two vertebrae. Fractures to two teeth. 
Partial thickness burns to lips. Abrasion on tongue. 
Surgery to remove EC 
component from spine 
 Occurred after replacement of a 
new battery 
Paley et al., 
2016 (410)  
US 
 
2 Male 45 In mouth while 
vaping 
First-degree burns to face and right hand. Loss of two 
teeth. 
Lacerations to both corneas and irises. Damage to 
eyesight. 
Eye surgery  Not reported 
Male 16 While holding EC 
at chest level  
Burns to face, neck, and hands and both corneas 
 
Treatment for burns 
unspecified; irrigation and 
topical treatment to eyes. 
Vape pen  
Patterson et al., 
2016 (411) 
US  
2 
 
Male  46 While in trouser 
pocket  
1% TBSA partial thickness burns to left thigh, penis and 
two fingers of left hand 
An ‘operative intervention’ Not reported  
Male 41 In mouth while 
vaping  
0.5% TBSA burn to face, lip laceration, corneal abrasion Wound management Not reported  
Roger et al., 
2016 (412)  
US  
1 Male 18 In mouth while 
vaping 
Oral and abdominal burns (severity not specified), oral 
lacerations, tooth loss and fracture  
Reconstructive surgery 
and dental implants 
Not reported 
Shastry and 
Langdorf, 2016 
(413)  
US 
1 Male 26 In mouth while 
vaping 
Small area of second-degree burns. Foreign body 
penetration in abdomen and chest; small penetrating 
foreign bodies in thumb 
Wound care Patient was a paid tester for an EC 
company. Was using an 
experimental customizable, device 
with a lithium-ion battery 
Sheckter et al., 
2016 (414) 
US  
 
3 
 
Male 34 While in  
trouser pocket 
15 % TBSA1; deep partial-thickness and full-thickness 
burn of the right leg 
Skin graft  Not reported 
Male 19 While in trouser 
pocket  
7 % TBSA mixed partial- and full-thickness burn to the 
thigh and calf 
Skin graft Not reported 
Male 35 While in trouser 
pocket  
2 % TBSA partial- and full-thickness burn to right 
thigh  
Wound management Not reported 
Treitl et al., 
2017 (415) 
US  
3 
 
Male 25 While in trouser 
pocket (lithium 
battery only)  
6% TBSA partial thickness burns to the left thigh and 
knee 
Wound management Not reported  
Male  43 While in trouser 
pocket (battery 
only)  
3–4% TBSA partial and full thickness burns to his right 
thigh, scrotum, and penis. < 1% TBSA partial thickness 
burns to hands. Neuropathic pain 4 months post event. 
Wound management and 
transferred to burn centre 
Not reported  
Male 30 While in trouser 
pocket (battery 
only)  
10% TBSA, partial thickness burns, as well as 2–3% 
TBSA full-thickness burns to his left calf 
Wound management and 
transferred to a burn 
centre for skin graft 
Not reported  
 
 
1 TBSA = total body surface area 
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